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Summary  
The incidence of cardiovascular disease (CVD) is lower in premenopausal women, 
compared to postmenopausal women and age-matched men. This suggests an 
association between estrogen levels and vascular protection. This notion is 
supported by findings of epidemiological studies and by the fact that postmenopausal 
women taking hormone replacement therapy within 5 years after the onset of 
menopause have a reduced risk of vaso-occlusive disorders. Indeed, estradiol (E2) 
inhibits the pathological vascular remodeling processes leading to atherosclerosis 
and vaso-occlusion. It improves the endothelial integrity and stimulates its recovery/ 
regeneration following damage or dysfunction. Moreover, E2 inhibits the abnormal 
proliferation and migration of vascular Smooth Muscle Cells (SMCs), thus preventing 
intimal thickening. The beneficial action of E2 in the vascular system has been 
intensively studied; nevertheless the molecular mechanisms remain unclear. Recent 
findings provide evidence that microRNAs (miRNAs) regulate the physiology and 
pathophysiology of vascular cells and are involved in estrogen signaling. However, 
their role in mediating the differential effects of E2 in vascular Endothelial Cells (ECs) 
and vascular SMCs remains undefined.   
Hence, in this study we investigated the role of E2-regulated miRNAs in mediating 
the beneficial actions of E2 in the vasculature. We identified two miRNAs, miR-193a 
and miR-221, which are down-regulated by E2 in ECs and vascular SMCs. Since 
endothelial dysfunction and abnormal growth of vascular SMCs contribute to the 
development of vascular pathologies, we investigated the role of miR-193a and miR-
221 in modulating EC and vascular SMC function and the underlying mechanisms. 
Using synthetic miRNA mimics and miRNA antimirs to respectively up-regulate or 
inhibit the expression of the identified miRNAs, we demonstrate that they inhibit 
proliferation, migration and vasculogenesis in Human Umbilical Vein Endothelial 
Cells (HUVECs). Moreover, we show that these effects are mediated via the 
inhibition of two key pathways for vasculogenesis, i.e. PI3K/ Akt/ VEGF and ALK1/ 
SMAD1/5/8/ Id1 signaling. Further, we demonstrate that miR-193a and miR-221 
induce proliferation and migration of Human Coronary Artery Smooth Muscle Cells 
(HCASMCs) and that the increased growth is due to the stimulation of G1 to S phase 
progression of the cell cycle. Importantly, we provide evidence that the inhibition of 
miR-193a and miR-221 by E2 contributes to its beneficial effects in vascular cells and 
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may explain its differential actions in ECs and vascular SMCs. In addition, we provide 
evidence that down-regulation of miR-193a and miR-221 requires estrogen receptor 
(ER)-α and that E2 potentially inhibits the maturation process of these miRNAs, 
rather than having an effect on the transcription of their precursor molecules. 
In summary, our findings demonstrate that miR-193a and miR-221 mediate the 
differential actions of E2 on vascular ECs and SMCs and that their down-regulation 
by E2 may prevent vascular remodeling associated with vaso-occlusive disorders in 
CVD. In conclusion, we postulate that miR-193a and miR-221 may be exciting novel 
therapeutic targets to treat CVD in postmenopausal women and in men, as miRNA 
therapeutics may overcome the feminizing and carcinogenic actions of E2. 
 
Riassunto 
 
11 
 
Riassunto 
La minore frequenza di malattie cardiovascolari in donne giovani rispetto a donne in 
menopausa o uomini della medesima età, suggerisce un’associazione tra estrogeni e 
protezione vascolare. Questa teoria è sostenuta da studi epidemiologici e dal fatto 
che le donne in menopausa, soggette a terapia ormonale sostitutiva entro 5 anni  
dall’inizio della menopausa, hanno un rischio minore di disturbi vasoocclusivi. Infatti, 
l’estradiolo (E2) inibisce il rimodellamento vascolare patologico che porta alla 
formazione di aterosclerosi e la conseguente ostruzione dei vasi sanguigni. L’E2 
migliora l’integrità dell’endotelio e stimola la sua rigenerazione in seguito a danni o 
malfunzionamento. Inoltre l’E2 inibisce la proliferazione e migrazione delle Cellule 
Muscolari Lisce (CML) vascolari, pertanto impedendo l’ispessimento intimale dei vasi 
sanguigni. Gli effetti benefici dell’E2 sul sistema vascolare sono stati studiati 
intensamente; ciò nonostante i meccanismi molecolari restano poco chiari. Recenti 
scoperte dimostrano che i microRNA (miRNA) regolano la fisiologia e patologia delle 
cellule vascolari. Inoltre diversi studi attestano che i miRNA sono coinvolti nella 
trasmissione intracellulare degli estrogeni. Tuttavia rimane incerto il ruolo dei miRNA 
nella mediazione degli effetti differenziali dell’E2 nelle Cellule Endoteliali (CE) e CML 
vascolari. 
Lo scopo di questa ricerca è di studiare il ruolo dei miRNA regolati dall’E2 nel 
mediare gli effetti benefici dell’E2 nel sistema vascolare. Abbiamo identificato due 
miRNA, miR-193a e miR-221, la cui espressione è ridotta dall’E2 sia nelle CE sia 
nelle CML. Considerando che sia il danneggiamento dell’endotelio che la crescita 
anormale delle CML contribuiscono allo sviluppo di patologie vascolari, abbiamo 
esaminato il ruolo svolto da miR-193a e miR-221 in queste cellule. Utilizzando 
miRNA mimi e antagonisti per aumentare e rispettivamente diminuire l’espressione 
dei miRNA endogeni, abbiamo dimostrato che miR-193a e miR-221 bloccano la 
proliferazione, migrazione e formazione di vasi sanguigni nelle CE derivate della 
vena ombelicale umana (HUVEC). Inoltre abbiamo osservato che questi effetti sono 
dovuti all’inibizione di due vie di trasmissione intracellulare chiave per la formazione 
dei vasi sanguigni, più precisamente PI3K/ Akt/ VEGF e ALK1/ SMAD1/5/8/ Id1. 
Abbiamo ulteriormente dimostrato che miR-193a e miR-221 inducono la 
proliferazione e migrazione delle CML derivate da arterie coronarie umane 
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(HCASMC) e che l’aumento della crescita è dovuto alla stimolazione della transizione 
dalla fase G1 a S del ciclo cellulare. La regolazione dei livelli di espressione di miR-
193a e miR-221 da parte dell’E2 contribuisce ai suoi effetti benefici nelle cellule 
vascolari. Questa azione può spiegare la differente regolazione della crescita di CE e 
CML in seguito a trattamento con E2. Inoltre, comproviamo che l’E2 necessita del 
ricettore estrogeno ERα per ridurre l’espressione di miR-193a e miR-221. Infine 
comproviamo che l’E2, in concomitanza con ERα, blocca il processo di maturazione 
di entrambi i miRNA, piuttosto che ostacolarne la trascrizione dal DNA.  
Riassumendo, i nostri risultati dimostrano che miR-193a e miR-221 mediano l’azione 
differenziale dell’E2 nelle CE e CML vascolari e indicano che la riduzione dei loro 
livelli di espressione dovuta all’E2 impedisce il rimodellamento vascolare 
comunemente associato alle affezioni ostruttive delle malattie cardiovascolari. In 
conclusione ipotizziamo che miR-193a e miR-221 potrebbero rappresentare ottimi 
bersagli per nuove terapie contro le malattie cardiovascolari, sia nelle donne in 
menopausa sia negli uomini. Infatti, una terapia basata sui miRNA potrebbe revocare 
gli effetti indesiderati causati dall’E2, come la femminilizzazione dei soggetti maschili 
e l’aumento del rischio di cancro nei soggetti femminili.  
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Abbreviations 
2ME 2-Methoxyestradiol 
2OHE  2-Hydroxyestradiol  
A Antimir 
A193a miR-193a Antimir 
A221 miR-221 Antimir 
AC Control Antimir 
AGO Argonaute  
Akt Protein kinase B 
ALK1 Activin Receptor-like Kinase 1 
ALK1Fc ALK1 neutralizing antibody 
BrdU 5’-Bromo-2`-deoxyuridine 
Ca2+ Calcium 
cAMP 3',5'-cyclic Adenosine Monophosphate  
CDK Cyclin-Dependent Kinase 
cGMP  3',5'-cyclic Guanosine Monophosphate 
COMT Catechol-O-methyltransferase 
CVD Cardiovascular Disease 
CYP450 Cytochrome P450 enzyme 
DGCR8 DiGeorge Syndrome Critical Region 8 
DMSO  Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
DPN Diaryl-Proprio-Nitrile, ERβ specific agonist 
E1 Estrone 
E2 17-β Estradiol 
E3 Estriol 
EC Endothelial Cell 
ELISA Enzyme-Linked Immunoassay 
eNOS endothelial Nitric Oxide Synthase 
EPC Endothelial Progenitor Cell 
ER Estrogen Receptor 
ERE Estrogen Response Element 
ERK1/ 2  Extracellular Signal-Regulated Kinases 1/ 2 
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EtOH Ethanol 
FGF Fibroblast Growth Factor  
G0 Cell cycle phase Gap 0 
G1 Cell cycle phase Gap 1 
G1 GPER specific agonist 
G2 Cell cycle phase Gap 2 
GPCR G-protein Coupled Receptor 
GPER G-protein Coupled Estrogen Receptor 
GTP Guanosine Tri-Phosphate 
HCASMC Human Coronary Artery Smooth Muscle Cell 
HERS Heart and Estrogen/ Progestin Replacement Study 
hr hours 
HRT Hormone Replacement Therapy 
HSD Hydroxysteroid Dehydrogenase 
HUVEC Human Umbilical Vein Endothelial Cell 
ICI ICI 182-780, fulvestrant, ER unspecific antagonist 
Id1 Inhibitor of Differentiation 1 
LDL Low-density Lipoprotein 
LY LY294002, PI3K-inhibitor 
M Mimic 
M193a miR-193a Mimic 
M221 miR-221 Mimic 
MC Control Mimic 
MCF-7 Hormone-responsive breast cancer cell line 
Mg2+ Magnesium 
miRNA microRNA 
MPP Methyl-Piperidino-Pyrazole, ERα unspecific antagonist 
mRNA messenger Ribonucleic Acid 
MTT Thiazol Blue Tetrazolium Bromide 
NO Nitric Oxide 
p27 p27 (Kip1), cyclin dependent kinase inhibitor 
PDGF Platelet-derived Growth Factor 
PI Propidium Iodide 
PI3K  Phosphoinositide 3 Kinase 
Abbreviations 
 
15 
 
PPT Propy Pyrazole Triol, ERα specific agonist 
pRB  hyperphosphorylated Retinoblastoma protein 
Pre-miRNA precursor microRNA 
Pri-miRNA primary microRNA 
RB Retinoblastoma protein 
RISC RNA-induced silencing complex 
RNA Ribonucleic acid 
rpm rounds per minute  
RT-qPCR Real Time quantitative Polymerase Chain Reaction 
S Cell cycle phase Synthesis 
Ser Serine 
Skp2 S-phase kinase associated protein 2 
SMC Smooth Muscle Cell 
TGFβ Transforming Growth Factor Beta  
Thr Threonine 
Tyr Tyrosine 
UTR Untranslated Region 
VEGF Vascular Endothelial Growth Factor 
VEGFAb VEGF neutralizing antibody 
WHI Women`s Health Initiative  
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1 Introduction 
1.1 Estrogen(s) biology and pharmacology 
Estrogen is the generic term for the primary female sex hormones, which include the 
endogenous forms Estrone (E1), 17-β-Estradiol (E2) and Estriol (E3). Among these, 
E2 is functionally the most relevant as it is predominant in women of reproductive 
age. E1 is the weaker form of estrogen and the only one produced after menopause. 
E3 is only produced in significant quantities during pregnancy [1]. 
1.1.1 Biological effects 
Estrogens are important for the growth and function of the female reproductive 
system. They promote the development of secondary sex characteristic, regulate the 
menstrual cycle and influence the fertilization process and maintenance of 
pregnancy. In addition to these classical functions, estrogens play a critical role in 
regulating the physiology of many other tissues (Figure 1).  
 
Figure 1: A simple model of the positive (green) and negative (red) effects of estrogens in 
the female body. 
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Among the potential positive effects, estrogens have neuroprotective effects in the 
brain and may prevent Alzheimer`s disease, stroke and Parkinson’s disease [2, 3]. In 
the vascular system they improve vascular function and protect against 
cardiovascular diseases (CVDs). Additionally, estrogens ameliorate cholesterol 
metabolism by the liver, increase bone density thereby protecting against 
osteoporosis, improve skin aging, and reduce the risk of colon cancer [4, 5]. On the 
other hand the deleterious effects of estrogens include increased carcinogenesis in 
the uterus and in the breast tissue [6]. Interestingly, even though estrogens are 
considered to be the female hormones, they influence the reproductive system and 
the fertility in male too [7].  
1.1.2 Estrogen synthesis 
The ovaries are the main location for estrogen production [8], but other tissues are 
also capable of estrogen synthesis, for example brain, liver, adipose tissue, skin, 
muscle, breast, vaginal mucosa and endometrium.  
Estrogens, as well as the other endogenous steroid hormones are synthesized from 
cholesterol [9] as described in Figure 2. First, cholesterol is taken up into 
steroidogenic cells, in which it is converted to pregnenolone by specific Cytochrome 
P450 (CYP450s) enzymes. Then pregnenolone is enzymatically processed to 
testosterone via two different mechanisms: either through production of progesterone 
by the enzyme 3-β-Hydroxysteroid Dehydrogenase (HSD) and conversion of 
progesterone to androstenedione, or through hydroxylation at the 17-α position by 
the enzyme 17-α-hydroxylase to form 17-α-pregnenolone, which is further converted 
to dehydroepiandosterone by the enzyme 17,20 lyase and finally converted into 
testosterone by the 17-β-HSD. Finally, testosterone is converted to 17-β-estradiol 
(E2) by the enzyme aromatase.  
The ovarian granulosa cells express the highest levels of aromatase in 
premenopausal women, but it is also expressed by a large number of other tissues, 
for example adipose tissue, skin, vaginal mucosa, endometrium, breast, liver and 
vascular cells [10].  
Following synthesis, E2 is released into the circulation, where 2-3% of the total 
amount can be found in a free form and the majority is bound to albumin or sex-
hormone binding globulin. Circulating E2 concentrations range from 0.36 nM in the 
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follicular phase to 2.8 nM during ovulation. The highest levels of circulating E2 are 
during pregnancy, reaching up to 70 nM, whereas they drop to 0.02 nM following 
menopause and are comparable to estrogen concentrations in men [11]. 
 
Figure 2: Estrogen synthesis from cholesterol. Depicted from Cignarella et al. [9]. 
1.1.3 Estrogen metabolism 
Estrogen elimination is facilitated through its conversion to water-soluble metabolites, 
which can be excreted via urine or feces, via conjugation to sulfates, glucuronides or 
fatty acids esters. In addition, E2 can be metabolized into oxidative biologically active 
products as described in Figure 3. CYP450 oxidizes E2 to Catecholestradiols (for 
example 2-Hydroxyestradiol), which are further metabolized to Methoxyestradiols by 
Catechol-O-Methyl-Transferase (COMT) [12].  
E2 is largely metabolized in the liver, although the enzymes responsible for E2 
metabolism (CYP450 and COMT) also occur in other tissues, like vasculature, 
kidneys, gastrointestinal tract, spleen, brain and pancreas. Though the majority of the 
E2 metabolites are excreted, there is increasing evidence that they have significant 
growth regulatory properties in several tissues. In fact, 4-Hydroxyestradiol has 
carcinogenic effects, whereas 2-Hydroxyestradiol (2OHE) and 2-Methoxyestradiol 
(2ME) have been shown to inhibit tumor growth [13]. Further, 2ME has been reported 
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to play a role in vascular cells, since it reduces neovascularization and prevents 
neointima formation by inhibition of vascular Smooth Muscle Cell (SMC) proliferation 
[14, 15].  
 
Figure 3: 17-β-estradiol conversion into the biologically active metabolites 2OHE and 2ME. 
CYP, Cytochrome P450; 2OHE, 2-Hydroxyestradiol; COMT, Catechol-O-Methyl-Transferase; 
2ME, 2-Methoxyestradiol. Depicted and modified from Dubey et al. [16]. 
1.1.4 Estrogen Receptors 
The biological effects of estrogens are largely mediated via Estrogen Receptors 
(ERs). To date, three ERs have been identified: the classical nuclear receptors ERα 
and ERβ and the membrane bound G-protein Coupled ER (GPER).  
1.1.4.1 Estrogen Receptor α and Estrogen Receptor β 
ERα was discovered in 1960 and cloned for the first time in 1986 [17], while ERβ was 
detected later in 1996 [18]. The receptors are encoded by genes, which are located 
on different chromosomes (6 and 14, respectively) and encode for proteins 
containing 595 and 530 amino acids, respectively [19]. 
ERα and ERβ belong to the superfamily of nuclear receptors, with 95% located in the 
cell nucleus and the remaining 5% in the cytoplasm [20]. They are composed of 6 
conserved domains A-F, as shown in Figure 4. The N-terminal A/B and the C-
terminal F domain contain the transactivation function (AF-1 and AF-2 respectively), 
which interact with co-repressors and co-activators to regulate transcription. The 
highly conserved C domain is the DNA-binding domain. The D domain is a hinge 
region that connects the C and E domains. Finally, the E region contains the ligand-
binding domain, which confers ligand specificity to the receptor [21]. Although the 
DNA-binding domains of the two receptor subtypes are very similar (97%), the overall 
homology is low. Nevertheless, the binding affinity to the major ligand E2 is very 
similar (Kd=0.6 nM) [18]. 
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Beside the differences in structure and ligand-binding specificity, the tissue 
distribution of the two classical ERs is also different. For example, ERα expression 
prevails in the endometrium, breast cancer cells and ovary, whereas ERβ is 
predominantly expressed in the kidney, intestinal mucosa, lungs, bone and prostate 
[4]. Moreover, the ERs show a specific cell type dependent distribution and knock-out 
studies for ERα and ERβ provide evidence for differential functions for the two 
receptors [22]. These findings indicate that the final effect of ER-ligands depends on 
ER regulation within a cell type, which is influenced by extracellular signals. In this 
regard, E2 has been shown to regulate the expression of the ERs in many cell types, 
such as human breast cancer cells [23], retinal pigment epithelial cells [24] and 
osteoclasts [25]. 
 
Figure 4: Structure of estrogen receptor. Adapted from Aranda and Pascual [26]. 
1.1.4.2 G-protein Coupled Estrogen Receptor 
The G-protein Coupled ER (GPER) was first discovered between 1996 and 1998 and 
named GPR30, due to its similarities to the classical seven-transmembrane G-
Protein Coupled Receptors (GPRs). Its relation to estrogens was unknown, until in 
2000 Filardo et al. discovered that GPR30 is necessary for estrogen-mediated 
stimulation of ERK1/2 [27]. Only in 2005, the affinity of estrogen to GPR30 was 
demonstrated by Revankar et al. [28] and Thomas et al. [29] and E2 was identified as 
the endogenous ligand for this receptor, which nomenclature was finally changed in 
2007 to GPER [30]. 
The GPER gene is located on chromosome 7 and its protein entails 375 amino acids 
[31]. Although the exact structure of GPER is still unknown, it is divided into three 
parts similar to the GPRs: the extracellular region (N-terminus and three extracellular 
loops ECL1-ECL3), the transmembrane region consisting of seven α helices (TM1-
TM7) and the intracellular region (three intracellular loops ICL1-ICL3, an amphipathic 
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helix H8 and the C-terminus). The cellular location of GPER is under debate: it was 
found to be a membrane receptor in some studies [29, 32], while others suggest its 
intracellular location within the Endoplasmatic Reticulum [28, 33].  
Recent studies have demonstrated the expression and functions of GPER in the 
reproductive, endocrine, urinary, nervous, immune, musculoskeletal and 
cardiovascular system [34].  
1.1.5 Pathways of estrogen action 
Estrogen actions can be exerted via genomic pathways, resulting in changes in gene 
expression either through direct activation of the ERs as transcription factors 
(classical pathway), via association with other transcription factors (indirect, ERE-
independent pathway) or without the involvement of estrogens (ligand-independent 
pathway). Additionally, there is evidence that E2 induces its biological effects also via 
non-genomic mechanisms [35].   
1.1.5.1 Genomic pathways 
Classical (direct) pathway  
In the classical pathways of E2 action, the lipophilic E2 diffuses into the cells through 
the membrane and binds to the intracellular ERs. Upon E2 binding to the receptor, a 
conformational change takes place and the ER dissociates from the heat shock 
proteins (chaperones), which stabilize the receptor and mask the DNA-binding site in 
the absence of ligand binding. Homo- or heterodimerization of ERα and ERβ allows 
the E2-ER complex to diffuse into the nucleus, where it binds to the DNA at specific 
Estrogen Response Elements (EREs), located within the regulatory regions of target 
genes. Finally, inhibition or induction of the target genes is regulated by the 
association of the E2-ER complex with several co-repressors and co-activators via 
the AF-1 and AF-2 domains [36] (Figure 5A). 
ERE-independent pathways 
Several studies provide evidence that E2-ER complexes are able to control 
expression of genes lacking the ERE sequence in their regulatory regions. In this 
case, after ligand activation ERs interact with other transcription factors, such as Fos, 
Jun and Sp1, thereby affecting target regulation by indirect DNA binding [37]. Some 
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examples are the genes encoding Epidermal Growth Factor (EGF), EGF receptor 
and cyclin D1 [38] (Figure 5B).  
Ligand-independent pathways 
Activation of ERs is also possible through other signaling pathways without the 
binding of a ligand. In this case, growth factor activated kinases phosphorylate ERs, 
stimulating them to dimerize and directly regulate gene expression [39] (Figure 5D). 
1.1.5.2 Non-genomic pathway 
The non-genomic pathway is not as well understood as the genomic mechanisms, 
even though it has been detected in many tissues. For example, the effects of 
estrogens are observed within seconds to minutes following stimulation and are not 
explainable by mechanisms involving genomic changes, which require hours to days. 
The ligand binds and activates a receptor at the membrane, potentially involving 
GPER [29, 32], which initiates signaling cascades, including involvement of second 
messengers (Figure 5C). Examples of rapid physiological response of E2 include the 
modulation of the activity of Mitogen-Activated Protein Kinases (MAPKs) ERK1 and 
ERK2 [40], increase in Nitric Oxide (NO) synthesis via stimulation of endothelial Nitric 
Oxide Synthase (eNOS) [41], activation of cAMP formation by Protein Kinase A 
(PKA) and Protein Kinase C (PKC) activation and increase in cellular Ca2+ [42].  
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Figure 5: Model representing the mechanistically distinct molecular pathways used in the 
regulatory actions of ERs. Panel A: The classic (direct) pathway includes ligand activation 
and a direct DNA binding to ERE before modulation of gene regulation. Panel B: The 
tethered ERE-independent pathway includes protein-protein interaction with other TFs after 
ligand activation, and thereby gene regulation is affected by indirect DNA binding. Panel C: 
Non-genomic pathway. The ligand activates a receptor and signaling cascades are initiated 
via SMs ultimately leading to a rapid physiological response without involving gene 
regulation. Panel D: The ligand-independent pathway includes activation through other 
signaling pathways, like growth factor signaling. In this case, activated kinases phosphorylate 
ERs and thereby activate them to dimerize, bind DNA, and regulate genes. ER, Estrogen 
Receptor; ERE, Estrogen Response Element; TF, Transcription Factor; SM, Second 
Messenger; NO, Nitric Oxide. Depicted from Heldring et al. [43]. 
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1.2 MicroRNA biology and pathophysiology 
1.2.1 MicroRNAs 
RNA molecules perform many critical tasks in the cell apart from the classical 
function as intermediate carriers of genetic information. MicroRNAs (miRNAs), small 
untranslated RNA molecules containing around 22 nucleotides, are part of these non-
coding RNAs and play a widespread role in regulating gene expression at the post-
transcriptional level. To the present day, over 1000 miRNAs have been found to be 
encoded in the human genome [44] and they appear to target at least 60% of all 
human and mammalian protein-coding genes, thus being involved in many clinically 
relevant biological and pathophysiological processes [45, 46].  
The first miRNA (cel-lin-4) was discovered independently by two research groups 
studying the development of C.elegans in 1993 [47, 48] and followed by a second 
miRNA (cel-let-7) in 2000 [49]. Only in 2001, small RNAs were recognized as a 
distinct class of biological regulators and nominated miRNAs [50]. Since then, the 
number of studies addressing the biology, function and pathophysiology of miRNAs 
has increased exponentially.  
1.2.2 MicroRNA Biogenesis 
miRNAs are transcribed by RNA polymerase II (RNAPII) either from individual 
miRNA genes (intergenic), from introns of protein-coding genes (intronic) or from 
units encoding multiple miRNAs (polycistronic) [51]. Most of the miRNAs are 
intergenic and have their own promoter, thus likely to be transcribed as independent 
units [52], while the intronic miRNAs are usually transcribed together with their host 
genes [53]. As shown in Figure 6, following synthesis, the resulting primary miRNA 
precursor (pri-miRNA) is capped, polyadenylated and processed, first by the 
Microprocessor Complex (MC) in the nucleus and subsequently by the endonuclease 
Dicer, following its export to the cytoplasm [54, 55]. The MC is minimally composed 
of one Drosha protein and two DGCR8 (DiGeorge Syndrome Critical Region 8) 
proteins [56], which recognize the pri-miRNAs and direct the RNase domain of 
Drosha to cleave them into 70 to 100 nucleotides long hairpin-shaped precursors 
(pre-miRNA) [57]. In addition to the minimal MC components, other cofactors may 
also associate with the complex to mediate the activity of Drosha [58, 59]. 
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Figure 6: A schematic representation of miRNA biogenesis and their mode of action. Pri-
miRNA, primary miRNA; pre-miRNA, precursor miRNA; MC, Microprocessor Complex; RISC, 
RNA-Induced Silencing Complex; ORF, Open Reading Frame. Adapted from van Rooij [60]. 
Some pre-miRNAs, called Mirtrons, are spliced directly out of very short intronic 
regions, thus bypassing Drosha-mediated processing [61]. Pre-miRNAs are exported 
from the nucleus to the cytoplasm by exportin-5 in complex with Ran-GTP [62]. In the 
cytoplasm, miRNA maturation is continued by the RNase Dicer. Dicer cleaves the 
pre-miRNA hairpin to form a miRNA:miRNA* duplex of about 20 to 22 nucleotides in 
length. Even though both strands of the duplex potentially act as a functional miRNA, 
usually only one, the functional guide strand, is incorporated into the RNA-Induced 
Silencing Complex (RISC), while the other, the passenger strand, is subsequently 
degraded [63]. The RISC finds the target mRNAs by searching for complementary 
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nucleotide sequences, which is considerably eased by the Argonaute 2 protein 
(AGO2), a component of RISC, which positions the miRNA optimally for base-pairing 
to other RNA molecule [64]. 
1.2.3 Cellular function and mode of action 
The main function of miRNA is gene regulation, through base-pairing to mRNAs. 
Upon binding of miRNA and mRNA, silencing occurs either by translational 
repression or induction of mRNA degradation, depending on the level of sequence 
complementarity between the miRNA and the target mRNA. Complete base-pairing, 
which is unusual in humans but common in many plants, leads to direct cleavage of 
the mRNA by the AGO2 protein (“slicing”), which results in degradation of the mRNA 
and release of the miRNA-RISC complex. In case of partial complementarity, 
silencing is slicer-independent and achieved through translational repression, which 
is likely to be caused by the disruption of translation initiation [65]. Moreover, recent 
evidence indicates that P-bodies are essential for miRNA-mediated gene silencing 
and may contribute to the complexity of its mechanisms, including the reversibility of 
mRNA silencing [66].  
The extent of base-pairing for partial complementarity is typically at least 7 
nucleotides, it is called seed sequence in the miRNA and most often occurs in the 3’ 
untranslated region (UTR) of the target mRNA. Interestingly, a single miRNA can 
regulate a whole set of different mRNAs, given that they have at least partial 
complementarity to the miRNA seed sequence in their UTRs. Furthermore, regulation 
by miRNA can be combinatorial as different miRNAs can bind to the same target 
mRNA to further reduce its translation [67].   
1.2.3.1 Activation of translation 
Down-regulation of the target mRNA is the common mechanism of miRNA-mediated 
gene regulation; however, there is increasing evidence indicating that miRNA action 
includes both repression and stimulation, as a result to particular cellular conditions, 
cell type and context and that both up- and down-regulation can vary from fine tuning 
to extensive deregulation of gene expression [68, 69]. For instance, miR-145 inhibits 
ROCK1 expression in osteosarcoma [70], yet mediating myocardin up-regulation 
during muscle differentiation [71]. Further, KLF-4 is up-regulated by miR-206 in 
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confluent and non-tumor cells, whereas it is down-regulated by miR-344 in 
proliferating and normal cells [72].   
1.2.4 Analysis of microRNA function 
Through the regulation of gene expression, miRNAs are able to modulate most, if not 
all, of the biological processes which take place in the cells and tissues. Accordingly, 
the most common strategy to probe miRNA functions are by gain- and loss-of-
function approaches as shown in Figure 7.  
 
Figure 7: The various methods to artificially modulate miRNA expression or activity.  
Endogenous miRNAs are depicted in red, miRNA Mimic is green, Antimir is shown in grey, 
the target mask is blue and the miRNA sponge is the transcript with multiple miRNA seed 
sequences. Depicted from Small and Olson [73]. 
The expression and activity of a specific miRNA is artificially increased by the 
delivery of a miRNA Mimic, a chemically modified and stabilized ribonucleotide 
duplex, which imitates the action of the endogenous miRNA and further down-
regulates target gene expression. In contrast, miRNA loss-of-function can be 
achieved via three different methods. The widely used antisense oligonucleotides 
complementary to an endogenous miRNA (Antimirs) prevent the miRNA from binding 
to the seed sequence of the target transcripts, de-repressing the expression of all 
target mRNAs. In a second approach overexpression of an exogenous mRNA 
containing multiple copies of the specific miRNA seed sequence (miRNA sponge) 
competes for miRNA binding and prevents it from base-pairing with the target 
mRNAs. The third strategy rescues one particular mRNA from miRNA-mediated 
repression through the delivery of an antisense oligonucleotide able to associate with 
the miRNA target sequence (target mask) [73]. 
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1.2.5 Association with diseases 
MiRNAs play an important role in regulating gene expression in normally functioning 
cells, hence influencing numerous cellular and developmental processes in many cell 
types, as for example cell differentiation, proliferation, migration and apoptosis. 
Accordingly, deregulation or abnormal function of miRNAs is linked to abnormal 
function of the biological processes they regulate and is therefore associated with 
pathologies [74]. The first human disease associated with deregulated miRNAs was 
chronic lymphocytic leukemia in 2002 [75], which was followed by many other cancer 
types, inflammatory diseases, CVDs, kidney diseases, nervous system and metabolic 
disorders [76], suggesting that miRNAs could serve as therapeutic targets [77]. 
Indeed, the dysregulated miRNAs can be potentially restored to their original 
expression levels by miRNA replacement or inhibition strategies.  
 
Figure 8: Overview of miRNAs therapeutics development status. Depicted from Christopher 
et al. [78].  
Consequently, a small number of miRNAs have entered the preclinical and clinical 
stage (Figure 8) and might be soon available in the market [78]. Furthermore, thanks 
to their differential expression pattern in diseases and their presence and stability in 
extracellular fluids such as human plasma and serum, aberrantly expressed miRNAs 
are also potential diagnostic and prognostic markers [79]. Some examples are the 
cardiac-specific miR-208a, which is elevated in plasma of acute myocardial infarction 
patients within 4 h of the onset of the symptoms [80], the 5 specific miRNAs (miR-21, 
-92, -93, -126 and -29a) overexpressed in the serum from ovarian cancer patients 
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[81] and the miR-34a, which has been identified as a prognostic marker in non-small-
cell lung cancer patients and correlated with relapse and overall survival [82]. 
1.2.6 Association with estrogens 
Association between miRNA expression and estrogens was first reported in 2005 
[83]. Subsequently the first evidence demonstrating miRNA regulation by E2 was 
published two years later demonstrating that E2 suppresses mR-206 in MCF-7 
human breast cancer cells [84]. To date, over 200 E2-regulated miRNA have been 
identified, mostly using microarray [85-88]. Several reports provide evidence that E2 
suppresses or stimulates miRNA expression in different human cell lines and tissues 
[89]. Moreover, changes in expression of E2-regulated miRNAs are linked with 
estrogen-dependent cellular responses. For instance, in MCF-7 cells E2 significantly 
induced the expression of the cell proliferation and survival genes bcl-2, cyclin D1 
and survivin by suppressing the levels of miR-16, miR-143, miR-203 [90]. 
Furthermore, a broad set of miRNAs, including miR-21, miR-26a, miR-181a, miR-
193a, miR-203, miR-23a, miR-221 and miR-222, decreased in MCF-7 cells treated 
with E2 [91, 92]. Moreover, enforced overexpression of several of the repressed 
miRNAs reduces E2-dependent cell growth [93]. Since E2-regulated miRNAs actively 
participate in E2 mediated responses, miRNAs are postulated to play a critical role 
mediating the regulation of gene expression by E2 and mediating its biological 
actions [88]. Although estrogenic miRNA regulation has been mainly studied in 
traditional estrogen target tissues, such as breast and breast cancer cells, 
endometrial cells and uterus, evidence of E2-regulated miRNAs in other systems, 
including the vascular system, are emerging. Indeed, E2 induces miR-203, which 
mediates the inhibitory effects of E2 on vascular SMC proliferation [94]. 
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1.3 Cardiovascular disease 
1.3.1 Atherosclerosis and cardiovascular disease etiology 
The leading cause of death and disability in the Western civilization is cardiovascular 
disease (CVD) [95]. CVD includes numerous pathologies, for instance coronary 
artery disease, myocardial infarction, heart disease, thrombosis and stroke; however, 
most of the vascular problems are related to atherosclerosis. The processes leading 
to atherosclerosis are triggered by the disruption of the functionally active 
endothelium [96]. Injured Endothelial Cells (ECs) secrete cytokines and express 
adhesion molecules, thus triggering the inflammatory responses and recruiting 
monocytes to the vessel wall. These monocytes migrate into the subendothelial 
space, where they differentiate into macrophages, which ingest low density 
lipoproteins (LDL) resulting in the formation of foam cells. In addition, damage or 
dysfunction of the ECs activates secretion of growth factors by platelets, such as 
Platelet Derived Growth Factor (PDGF)-BB and Transforming Growth Factor (TGF)-
β. These mitogens, together with autocrine/paracrine factors produced by foam cell 
and ECs, stimulate vascular SMC proliferation, cell migration into the damaged area 
and production of extracellular matrix rich in collagen [97]. Moreover, plaque 
development is enhanced by macrophage proliferation and cytokine production, 
which further increases the inflammatory response and thickening of the vessel wall. 
Finally, the evolution of atherosclerosis depends on many factors, thought it can be 
summarized by two scenarios as described in Figure 9: the vessel occlusion can be 
steady, in case of stabilized or healed ruptured plaques, or plaque rupture leads to 
thrombotic complications, including ischemic stroke, myocardial infarction and death 
[98].  
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Figure 9: Schematic representation of the evolution of atherosclerosis. Depicted from Libby 
[98]. 
1.3.2 The role of vascular cells in vascular remodeling 
Atherosclerosis develops from a set of many different factors, yet the main 
participants are ECs and vascular SMCs, as they are directly involved in vascular 
remodeling processes.  
1.3.2.1 Endothelial cells 
As described in the previous chapter, atherosclerosis originates from damage or 
dysfunction of the endothelium, thus highlighting that EC function is imperative for 
vascular health. Therefore, accelerated recovery or substitution of injured cells might 
prevent the progression of atherosclerosis [96]. The processes that characterize EC 
function are viability, proliferation, migration and the ability to form new vessels via 
vasculogenesis and/ or angiogenesis, in order to supply the tissues with the 
necessary oxygen and nutrients [99]. Angiogenesis is the formation of new blood 
vessels from pre-existing vessels, while vasculogenesis designates the de novo 
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production of vessels [100-102]. Angiogenesis occurs both during embryonic 
development and in adults, whereas post-natal vasculogenesis is recognized only 
since 1997, once circulating Endothelial Progenitor Cells (EPCs) were first isolated 
and described [103]. Importantly, both angiogenesis and vasculogenesis contribute 
to cardiovascular regeneration, as both processes promote wound healing and 
neovascularization of injured tissues. Accordingly, the widespread model to assess 
EC function is through vasculogenesis assays using Human Umbilical Vein ECs 
(HUVECs) [104].  
1.3.2.2 Smooth muscle cells 
The second cell type involved in vascular remodeling are vascular SMCs, which 
promote the development of atherosclerosis through abnormal proliferation, migration 
and differentiation, stimulating plaque formation and neointimal thickening [105]. 
Moreover, vascular SMC growth plays a key role in the development of restenosis 
following balloon angioplasty [106]. Vascular SMC proliferation and migration are 
mainly triggered by cytokines and growth factors released from injured ECs. This 
highlights the importance of a healthy and functional endothelium to maintain 
vascular SMCs quiescent [99]. Lastly, a controlled and balanced cross-talk between 
ECs and vascular SMCs is critical for the preservation of functional blood vessels 
[107].  
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1.4 The effects of Estrogens on the cardiovascular system 
There are several risk factors for CVD: hypertension, diabetes, high cholesterol, 
obesity, inappropriate lifestyle, high age and male gender. Epidemiologic studies 
provide evidence that the incidence of CVD is generally higher in men, compared to 
age-matched women [108, 109], and in postmenopausal compared to 
premonopausal women. Indeed, compared to premenopausal women, increased 
intimal thickening and plaque formation is documented in postmenopausal women 
[110]. These findings, and the fact that upon menopause (around the age of 55) the 
ovaries become dysfunctional leading to a drop in endogenous estrogen synthesis, 
suggest that decreased estrogen levels are associated with increased development 
of CVDs [111].  
The association between vascular pathology and estrogen deficiency is further 
supported by the fact that postmenopausal women taking hormone replacement 
therapy (HRT) present a reduced risk of coronary disease [112, 113] and all-cause 
mortality [114, 115]. Even though several observational studies in humans and 
experimental studies in animals and isolated cells support the protective role of HRT 
in the cardiovascular system [115-117], the Women’s Health Initiative (WHI) trial and 
the Heart and Estrogen/ Progestin Replacement Study (HERS) contradicted these 
findings [118, 119]. The reasons for the controversial role of HRT in the vascular 
system are not known, however, re-evaluation of the data from these studies 
revealed that the participant age and condition of the vessels might be critical. 
Indeed, HRT was effective in younger healthy women, as opposed to older 
participants with established vascular pathologies [120], suggesting that timing of 
HRT initiation is crucial for vaso-protection by estrogens [121, 122]. 
1.4.1 Beneficial actions of estradiol on vascular cells 
In vivo studies provide strong evidence for the beneficial effects of E2, which has 
been shown to prevent pathological processes associated with the development of 
hypertension, thrombosis, restenosis, cardiomyophathy, atherosclerosis and other 
CVDs. Indeed, there is abundant evidence for an inhibitory role of E2 in vascular 
remodeling processes like neointimal thickening, cholesterol-induced atherosclerosis, 
injury-induced neointima formation and allograft-induced dysplasia [123-127]. 
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Figure 10: Summary of the principal beneficial actions of E2 in the vascular system. Adapted 
from Menazza and Murphy [35]. EPC, Endothelial Progenitor Cells. 
The anti-occlusive effects of E2 are mediated via multiple mechanisms. Both indirect 
systemic actions and direct regulation of vascular cell function [128, 129] are 
summarized in Figure 10. The main systemic actions include induction of 
vasodilation, through promotion of endothelial NO release and prostaglandin 
synthesis. Additionally, E2 reduces the production of vasoconstrictors such as 
angiotensin II, endothelin-1 and catecholamine [116]. Among the recognized effects 
of E2 on vascular cells, E2 promotes physiological functions in ECs by different 
mechanisms. First, it induces proliferation and migration of ECs in vitro [130] and 
promotes endothelial regeneration in vivo [131, 132]. Second, it contributes to the 
repair of the endothelium through the mobilization of EPC, inflammatory immune cells 
and platelets [133, 134]. Third, it stimulates angiogenesis by secreting important pro-
angiogenic factors such as fibroblast growth factor (FGF), vascular endothelial 
growth factor (VEGF) and nitric oxide (NO) [135, 136]. Since EC health is essential 
for vascular SMC quiescence, improvement of endothelial integrity can additionally 
contribute to the beneficial effects of E2. Endothelial damage or dysfunction results in 
SMC proliferation and migration and E2 has been proven to inhibit both these 
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processes in vitro as well as in vivo [124-127]. Anti-mitogenic effects of E2 result from 
the release of growth inhibitory molecules such as NO, cGMP and cAMP [137, 138]. 
The recognized effects of estrogens go beyond the mechanisms elucidated here and 
encompass multiple pathways and cell types contributing to the pathophysiology of 
CVD. [139] However, the key mechanisms to understand the protective actions of 
estrogens in the vascular system still need to be elucidated. 
1.4.2 Molecular mechanisms of estradiol-mediated vascular protection 
1.4.2.1 Endothelial cells  
E2 induces regeneration and repair of the endothelium principally by stimulating 
vasculogenesis via different intracellular signaling pathways, including the PI3K/ Akt 
and VEGF pathway and the TGFβ signaling pathway ALK1/ SMAD1/5/8.  
PI3K/ Akt and VEGF 
The PI3K/ Akt pathway regulates multiple cellular functions including metabolism, 
growth, proliferation, migration, survival, transcription, protein synthesis and 
angiogenesis [140, 141]. This pathway is activated by growth factors such as VEGF, 
and several studies support its importance in tube formation and other processes 
associated with angiogenesis [142, 143] (Figure 11A). An important target of PI3K/ 
Akt signaling is eNOS, which generates NO upon phosphorylation, thus contributing 
to EC-induced vasodilation. NO in turn induces VEGF expression hence, NO and 
VEGF stimulate each other in a feedback circle until the PI3K signaling is terminated 
[144-146]. 
The role of VEGF in angiogenesis has been intensively studied and established 
[147]. VEGF is important in embryogenesis, as inactivation of one VEGF allele 
results in defective vascularization and embryonic lethality in mice [148, 149]. VEGF 
production is regulated in response to external stimuli by numerous cytokines and 
growth factors, which modulate VEGF expression to exert pro- or anti-angiogenic 
effects. As already described, among the molecules that up-regulate VEGF 
expression is NO, which contributes to VEGF-stimulated vasodilation [150]. 
Moreover, NO production is induced by VEGF through the PI3K/ Akt pathway, 
indicating that a positive feedback loop exists between these two factors. 
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Several studies provide evidence that estrogens activate PI3K/ Akt signaling and that 
this pathway mediates the stimulatory actions of E2 on EC proliferation migration and 
tube formation [136, 151-153]. Moreover, there is evidence that E2 stimulates VEGF 
and NO [154], which mediate its angiogenic effects [135]. Since VEGF is both a 
ligand and a downstream product in the PI3K/ Akt pathway, it is not clear whether E2 
activates the pathway by directly stimulating PI3K or via increased VEGF expression. 
However, these results indicate that PI3K/ Akt signaling and VEGF are important 
mediators of estrogen stimulated angiogenesis in ECs.  
ALK1/ SMAD1/5/8 
A second important pathway in the regulation of EC function is the ALK1/ SMAD1/5/8 
pathway (Figure 11B). ALK1 is a receptor for some members of TGFβ superfamily. 
This family includes TGFβ, Bone Morphogenetic Proteins (BMPs), growth 
differentiation factors (GDFs), activins, inhibins and myostatins. The TGFβ signaling 
pathway plays an essential role in the regulation of multiple cellular functions such as 
growth, adhesion, migration, apoptosis and differentiation [155]. TGFβ signaling is 
complex, since it encompasses numerous ligands, receptors and their various 
combinations depending on the cell type and cellular context.  
ALK1 is highly expressed in ECs and exerts its function via the activation of 
SMAD1/5/8. SMADs transduce extracellular signals from TGFβ ligands to the 
nucleus where they activate downstream gene transcription. Briefly, upon binding to 
the ligand a TGFβ type II receptor complexes with the type I receptors ALK1 or ALK5 
and phosphorylates them. ALK1 phsophorylation leads to the recruitment and 
phosphorylation of SMAD1/5/8, which complexes with SMAD4 to translocate to the 
nucleus [156], where it induces the expression of Inhibitor of Differentiation (Id1), 
leading to increased migration, proliferation and tube formation of ECs [157-159]. 
Although ALK1 expression has been shown to correlate with increased proliferation, 
migration and tube formation [160-163], its role in ECs is controversial, since other 
studies have found inhibitory effects on the same processes [164, 165]. These 
opposing results might be due to the complexity of TGFβ signaling and differences in 
cell type and context [166]. The importance of ALK1/ SMAD1/5/8/ Id1 for EC 
functions is further supported by the fact that mutations in ALK1 and in SMAD genes 
lead to severe defects in embryogenesis and early lethality due to vascular 
abnormalities in murine embryos [167, 168]. There is evidence that estrogens 
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regulate TGFβ signaling. Indeed, E2 inhibits the TGFβ pathway in MCF-7 breast 
cancer cells [169]. Moreover, previous studies from our laboratory demonstrate that 
E2 mediates vasculogenesis and endothelial growth via stimulation of ALK1/ 
SMAD1/5/8 signaling [170, 171].  
 
Figure 11: Simplified schematic representation of the pro-vasculogenesis pathways PI3K/ 
Akt/ VEGF (Panel A) and ALK1/ SMAD1/5/8/ Id1 (Panel B) and their regulation by E2. PI3K, 
Phosphoinositide 3 Kinase; Akt, Protein Kinase B; VEGF, Vascular Endothelial Growth 
Factor; eNOS, endothelial Nitric Oxide Synthase; NO, Nitric Oxide; ALK1, Activin Receptor-
Like Kinase 1; TGFβ, Transforming Growth Factor β; BMP, Bone Morphogenetic Protein; 
TβR, TGFβ Receptor; Id1, Inhibitor of differentiation. Panel B adapted from Plutino [172].  
1.4.2.2 Vascular smooth muscle cells 
Abnormal growth of vascular SMCs significantly contributes to intimal thickening in 
atherosclerosis and is initiated by growth factors such as PDGF-BB, which are 
released as a result of vascular injury. Although the molecular mechanisms 
underlying the anti-mitogenic actions of estrogens in vascular SMC are far from clear, 
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current evidence indicates that they might regulate several key molecules required 
for S phase entry and cell cycle progression (Figure 12).  
Upon stimulation, quiescent vascular SMCs begin to proliferate by entering the cell 
cycle in G1-phase and activating genes required for transition from G0 to G1 phase 
[173-175]. The accumulation of G1 cyclins (cyclins D) and their association with 
Cyclin-Dependent Kinase (CDK)-4 and CDK6 leads to the hyperphosphorylation of 
Retinoblastoma protein (pRB). The activation of pRB is central in the G1 to S phase 
transition of the cell cycle. In quiescent cells pRB is bound to and inhibits the 
transcription factor E2F. However, upon pRB phosphorylation by cyclin-CDK 
complexes, E2F is released and activates the transcription of genes necessary for 
G1/S transition, such as the genes encoding cyclin E and CDK2, and proteins 
required for DNA synthesis in S-phase, including the Proliferating Cell Nuclear 
Antigen (PCNA) and the DNA-polymerase [176, 177]. After replication of the genomic 
material, the cells proceed into G2 phase and undergo cellular division. Estrogens 
have been shown to inhibit PDGF-BB-induced [3H]-thymidine incorporation [178, 179] 
and to reduce pRB phosphorylation and cyclin D1 expression in vascular SMCs 
[180]. Moreover, there is evidence that E2 prevents degradation of the CDK inhibitor 
p27 in pulmonary artery SMCs [181], indicating that its anti-mitogenic actions are in 
part due to the regulation of G1/S-phase cell cycle proteins.  
PDGF-BB and other growth factors regulate cellular activities ranging from gene 
expression, proliferation, migration, metabolism and apoptosis, through the activation 
of various signaling cascades. The Raf/ MEK/ ERK1/2 pathway has been shown to 
be stimulated after arterial injury [182, 183], and to play a role in vascular SMC 
proliferation [184] and migration [185]. A second pathway activated by vascular injury 
is the PI3K/ Akt pathway [186, 187], which is also implicated in promoting cell cycle 
progression [188]. PI3K is required for mitogen-induced cyclin D1 expression and 
p27 reduction and delays G1/S exit [189]. Moreover, there is evidence for Akt 
regulation of Raf, suggesting a crosstalk between the PI3K/ Akt and the MAPK 
pathways [190]. E2 inhibits ERK1/2 activity [178] and has been associated to PI3K 
signaling [191], indicating that estrogens not only inhibit cell cycle progression, but 
also play a role in the regulation of upstream signaling cascade.  
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Figure 12: Simplified schematic representation of the cell cycle in vascular SMCs and its 
regulation by E2. G0, quiescence; G1, Gap 1; S, Synthesis; G2, Gap 2; M, Mitosis; PDGF-BB, 
Platelet-Derived Growth Factor BB; MAPK, Mitogen Activated Protein Kinase; PI3K, 
Phosphoinositide 3-Kinase; CDK, Cyclin-Dependent Kinase; RB, Retinoblastoma protein; 
PCNA, Proliferating Cell Nuclear Antigen; MPF, Mitosis Promoting Factor. Adapted from 
Barchiesi [192]. 
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1.5 MicroRNAs in cardiovascular biology and disease 
The importance of miRNAs in many clinically relevant biological and 
pathophysiological processes, including those of the cardiovascular system, has 
been demonstrated in multiple experimental and clinical studies [193-195]. General 
ablation of miRNAs in the cardiovascular system through tissue-specific deletion of 
Drosha, DGCR8, AGO2 or Dicer provided evidence for their critical roles in 
cardiovascular development and function [196, 197]. For instance, miRNAs are 
involved in the regulation of embryonic heart development [198, 199] and 
cardiomyocyte differentiation [200-202]. Further, several miRNAs have been reported 
to be essential in hematopoiesis [203] and angiogenesis [204] and there is evidence 
about miRNAs necessary for vascular SMC growth and differentiation [205], implying 
that miRNAs play a crucial role for the physiological function of both ECs and 
vascular SMCs.  
 
Figure 13: Role of miRNAs in healthy and diseased vasculature. Left: examples of miRNAs 
important for hematopoiesis and angiogenesis. Center: cell type specific miRNAs in vascular 
SMCs and ECs. Left: examples of miRNAs aberrantly expressed after pathological changes. 
Depicted from Hata [193]. 
Given the importance of miRNAs in the vascular system, it is not surprising that their 
dysregulation is associated with pathological conditions such as heart disease, 
ischemia, tumor angiogenesis, atherosclerosis and restenosis [206]. Moreover, many 
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in vitro and in vivo studies provide evidence that vascular remodeling, the underlying 
mechanisms for atherosclerosis and most of the vascular diseases, develops as a 
result from aberrant expression of miRNAs in ECs and vascular SMCs [207] (Figure 
13). 
1.5.1 MicroRNAs in endothelial cells 
EC proliferation, migration and angiogenesis are important biological processes for 
the recovery of injured or dysfunctional endothelium, the primary process of vascular 
remodeling. Genetic deletion of Dicer in mice resulted in abnormal blood vessel 
formation and embryonic lethality [204], and siRNA-mediated knock-down of Dicer in 
ECs resulted in a failure of capillary sprouting and tube formation [208, 209], 
revealing a role for miRNAs in the regulation of EC function. Individual miRNAs have 
since been shown to play positive and negative regulatory roles in angiogenesis.  
Among the positive regulators of EC function, the cell specific miR-126 promotes 
angiogenesis and vascular integrity by repressing negative regulators of the VEGF 
signaling pathway [210], and its deletion leads to vascular abnormalities and 
endothelial leakage [211]. Another example of a miRNA regulating EC function is the 
hypoxia-induced miR-210, which stimulates EC proliferation and migration, thus 
enhancing angiogenesis in response to low oxygen levels [212, 213]. Members of the 
miR-17-92 cluster, which includes miR-17, -18a, -19a/b, -20a, and miR-92a, have 
been shown to influence angiogenesis in either positive or negative ways, depending 
on the cellular context. A negative regulator of vessel growth is miR-92a, which is up-
regulated after ischemia. Knock-down of miR-92a in vivo improved recovery from 
ischemic damage due to enhanced angiogenesis [214]. Moreover, studies using 
HUVECs demonstrated that miR-221 and miR-222 decrease cell survival, migration 
and endothelial tube formation [215].  
1.5.2 MicroRNAs in smooth muscle cells 
In healthy normal blood vessels, vascular SMCs are differentiated cells with a 
contractile phenotype. However, damage of the vascular system triggers vascular 
SMC state alteration to a synthetic pro-proliferative state. They then migrate into the 
subendothelial space, leading to neointimal thickening and potential vessel occlusion. 
Several studies provide evidence for the role of miRNAs in vascular SMC phenotypic 
modulation. The vascular SMC specific miR-143/miR-145 cluster is necessary for 
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SMC contractility and the maintenance of a quiescent cell phenotype [71, 216]. 
Vessels of knock-out mice are thin and distended and display a decreased vascular 
tone [217]. In addition, the abrogation of miR-143/miR-145 in vitro reduced actin 
stress fiber formation, resulting in de-differentiation and acquirement of a pro-
proliferative phenotype [218]. Further, expression of miR-143/miR-145 gene cluster is 
down-regulated in the carotid artery after mechanical injury and its overexpression 
blunted the change in phenotype and reduced injury-induced neointima formation 
[219].  In contrast, miR-21, which is increased after injury, promoted vascular SMC 
proliferation in vitro and induced neointima formation in response to balloon 
angioplasty of the carotid artery in vivo [220]. Another miRNA positively regulating the 
switch to a less contractile phenotype of vascular SMCs is the PDGF-BB-induced 
miR-221, which has been demonstrated to mediate the pro-mitogenic effects of 
PDGF-BB by blocking the expression of contractile genes and stimulating cell de-
differentiation, proliferation and migration [221]. Knock-down of miR-221 reduced 
vascular SMC proliferation in vitro and inhibited injury-induced neointima formation in 
rat carotid artery [222]. Besides, miR-221 was reported to be up-regulated in 
quiescent cells in response to vascular injury and in proliferative vascular SMCs 
[223].  
1.5.3 MicroRNA cell-specific effects 
Recent studies in cancer cells provide evidence of miRNA cell specific effects, for 
instance miR-21 increased HeLa cell apoptosis, meanwhile inhibiting glioblastoma 
cell apoptosis [224, 225]. These cell specific roles of miRNAs appear to also be 
relevant in the vascular system, where miRNAs have been demonstrated to 
differentially regulate EC and SMC functions.  
A first example is miR-21, which was previously described to be a pro-proliferative 
miRNA in vascular SMCs [220]. In contrast, miR-21 was demonstrated to reduce EC 
and EPC proliferation and was anti-angiogenic in ECs [226, 227]. Another miRNA 
with a biphasic effect in vascular cells is miR-26a. Evidence indicates that miR-26a 
inhibits EC function [228], although it suppresses vascular SMC differentiation and 
promotes cell growth [229]. Lastly, the cell specific effects of miR-221 were compared 
in one study showing that miR-221 actively contributes to pathological vascular 
remodeling by reducing EC survival, growth and tube formation ability, while 
promoting SMC proliferation and migration [230].  
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2 General Hypothesis and Objectives 
CVD is the leading cause of mortality in women, and endogenous estrogens as well 
as estrogen replacement therapy have shown to induce cardiovascular protection. 
Experimental observations from animal studies provide evidence for the vaso-
protective actions of estrogens [109, 111-114]. These are further supported by 
clinical studies in women in early menopause receiving estrogen therapy [118-122]. 
Although estrogens are known to protect against vaso-occlusive disorders, the 
mechanism(s) by which they induce their protective effects are still unclear. 
Endothelial dysfunction and damage are key processes, which contribute to 
abnormal vasodilation and growth of SMCs resulting in vaso-occlusive disorders. 
Treatment with E2 has been shown to improve endothelial dependent relaxation and 
promote endothelial regeneration by inducing EC growth, recruitment of EPCs and 
stimulation of angiogenesis [131, 132, 135, 136]. Furthermore, E2 inhibits SMC 
proliferation and migration, thus preventing vascular remodeling processes leading to 
vascular occlusion [125-127]. Recent studies suggest that the differential effects of 
E2 on ECs and SMCs are potentially mediated via mechanisms linked to the 
estrogen receptors ERα, ERβ and GPER [35-37] or to ER-independent pathways 
involving downstream metabolites of E2 [14, 15]. Recent studies provide evidence 
that miRNAs mediate the effects of growth factors. However, the role and contribution 
of non-coding miRNAs in mediating the growth effects of estrogen on vascular cells 
remain largely undefined. Since miRNAs actively participate in the processes 
associated with vascular remodeling [193-195] and are known to mediate the biologic 
actions of E2 in several cancer cells [88], it is feasible that the protective actions of 
E2 on the vascular system are potentially mediated via the modulation of miRNA 
expression. Indeed, up-regulation of miR-203 by E2 is reported to contribute to the 
anti-mitogenic effects in vascular SMCs [94]. Moreover, cell specific effects of 
miRNAs have been observed in many tissues including the vascular system. For 
example, miR-221 actively contributes to injury-induced neointima formation by 
inhibiting EC growth and promoting SMC growth [222]. This biphasic effect of miR-
221 mimics the differential actions of E2 on vascular cells, which specifically 
promotes EC repair/ recovery and inhibit SMC growth. Hence, it is feasible that the 
beneficial effects of E2 on the cardiovascular system are due to the modulation of cell 
specific miRNAs, such as miR-221.  
General Hypothesis and Objectives 
 
46 
 
Based on the above findings, we hypothesize that E2-regulated miRNAs 
participate in mediating the protective actions of E2 on the vascular system 
and are responsible for the differential effects on EC and vascular SMC growth.  
The first aim of this study was to identify E2-regulated miRNAs in ECs and SMCs. 
To achieve this, we used data from preliminary small miRNA sequencing in EPCs to 
screen for differentially expressed miRNAs after E2 treatment and subsequently 
validated the candidate miRNAs by RT-qPCR in HUVECs and HCASMCs.  
The second aim was to investigate the role of the selected miRNAs on both 
HUVEC and HCASMC cell function. To accomplish this objective, we assessed 
proliferation, migration, vasculogenesis and viability of HUVECs as well as 
proliferation, migration and viability of HCASMCs in response to miRNA modulation 
with specific miRNA mimics and antimirs. Moreover, we examined the response of 
miRNA modulation after E2 treatment, to assess whether the selected miRNAs 
mediate the differential effects of E2 in these cells. 
The third aim was to examine the potential intracellular mechanisms of miRNA-
mediated vasculogenesis and proliferation in HUVECs and in HCASMCs, 
respectively. Hence we investigated and identified molecular mechanisms, which 
are either involved in E2-induced vasculogenesis in HUVECs or participate in the 
anti-mitogenic action of E2 in HCASMCs. E2 has been shown to stimulate 
vasculogenesis via the PI3K/ Akt pathway [152] and via stimulation of VEGF-A [231]. 
Additionally, the ALK1/ SMAD1/5/8 pathway plays a key role in embryonic 
angiogenesis [167, 168, 232]. Therefore, we investigated the role of the selected 
miRNA on the PI3K/ Akt pathway, the ALK1/ SMAD1/5/8 /Id1 pathway and 
VEGF-A in HUVECs. E2 inhibits SMC proliferation partly via the prevention of cell 
cycle progression from G1 to S phase. Therefore, we studied the role of the 
selected miRNAs on the regulation of several early cell cycle proteins in 
HCASMCs.  
The role of the classic estrogen receptors, ERα, ERβ, and the recently discovered 
GPER, in mediating the beneficial effects of E2 in vascular cells is well established 
[233]. Therefore, our forth aim was to identify the receptor involved in the 
modulation of the E2-regulated miRNAs. To accomplish this, we assessed the 
expression levels of the miRNAs in response to specific ER agonists and antagonist.  
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The regulation of mature miRNA expression potentially occurs at the transcriptional 
level or during processing of pri-miRNAs and pre-miRNAs to functionally active 
mature miRNAs [86]. Since ERs are transcription factors and regulate gene 
expression, the fifth aim was to elucidate whether E2 regulates the transcription 
of the selected miRNAs. To assess this, we analyzed the expression level of pri-
miRNA following E2 treatment.  
Overall, the main goal of this study was to investigate the role of miRNAs in 
mediating the growth effects of E2 in vascular ECs and SMCs. The results will 
help to improve our understanding about the mechanism(s) by which E2 
regulates growth and function of vascular cells that actively participate in 
vascular remodeling processes. Moreover, these findings would help to 
develop better (miRNA-based) therapy for menopause associated CVD.  
 
Figure 14: Schematic representation of hypotheses and objectives. The main purpose 
of the study was to identify E2-regulated miRNAs, which contribute to the differential actions 
of E2 in vascular cells. Panel A: We used HUVECs to assess the role of the selected 
miRNAs in EC function and on the possible molecular mechanisms involved. Panel B: We 
used HCASMCs to assess the role of the selected miRNAs in vascular SMC growth and on 
the possible molecular mechanisms involved. HUVEC, Human Umbilical Vein Endothelial 
Cell; HCASMC, Human Coronary Artery Smooth Muscle Cell; E2, 17β-estradiol; ER, 
Estrogen Receptor; ALK1, Activin Receptor-Like Kinase 1; Id1, Inhibitor of Differentiation; 
PI3K, Phosphoinositide 3 Kinase; Akt, Protein Kinase B; VEGF, Vascular Endothelial Growth 
Factor; G1, Gap1; S, Synthesis. 
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3 Materials 
3.1 Cell culture 
EPC Lonza, MD, USA (00189423) 
HCASMC  Life Technologies, CA, USA (C-017-5C) 
HUVEC  Lonza, MD, USA (CC-2517) 
2-Propanol Kantonsapotheke, Zürich, CH 
Antibioticum-Antimycotium (AA)  Life Technologies, CA, USA (15240-096) 
Bovine Serum Albumin (BSA)  Sigma-Aldrich, MO, USA (T-9647) 
Collagen, Rat Tail Roche, Mannheim, DE (11179179001) 
Dulbecco’s Modified Eagle Medium (DMEM)-F12   
 Sigma-Aldrich, MO, USA  (D-6434) 
Endothelial Basal Medium (EBM)-2  Lonza, MD, USA (CC-3156) 
EGM-2 SingleQuots  Lonza, MD, USA (CC-4176) 
Fetal Calf Serum (FCS) Thermoscientific, MA, USA (SH30070) 
FCS Charcoal Stripped Thermoscientific, MA, USA (SH3006803) 
Hank`s Buffered Salt Solution (HBSS) Biocencept, Allschwill, CH (3-02K34-I) 
L-Glutamine Life Technologies, CA, USA (25030-024) 
Low Serum Growth Supplements (LSGS) Life Technologies, CA, USA (S003-10) 
M231 media  Life Technologies, CA, USA (M-231-500) 
Phosphate Buffered Saline (PBS) Life Technologies, CA, USA (18912-014) 
Smooth Muscle Growth Supplements (SMGS)  
 Life Technologies, CA, USA (S-007-25) 
Trypsin Sigma-Aldrich, MO, USA (T-3924) 
3.2 Chemicals and buffers 
Acetic acid Merck, Darmstadt, DE (100063) 
ALK1 Fc Chimera, Human Recombinant  R&D Systems, MN, USA (370-AL-100) 
Ammonium Persulfate (APS)  Sigma-Aldrich, MO, USA (A-3678) 
Aprotinin Sigma-Aldrich, MO, USA (A-1153) 
Bichinonic Assay (BCA) Protein Assay Kit   Pierce, USA (23227) 
Bovine Serum Albumin (BSA)  Sigma-Aldrich, MO, USA (A-3059) 
Cell Lysis Buffer Cell Signaling, Danvers, USA (9803) 
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Cell proliferation ELISA, BrdU Roche, Basel, CH (11669915001) 
Chloroform Sigma-Aldrich, MO, USA (C-2432) 
Coulter Clenz cleaning agent Kantonsapotheke, Zürich, CH 
Coulter Isoton II diluent Kantonsapotheke, Zürich, CH 
Diethylpyrocarbonate (DEPC)-treated water  Life Technologies, CA, USA (AM9916) 
DNA Gel loading dye (6x) Thermoscientific, MA, USA (R0611) 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, MO, USA (D-2650) 
Dithiotheritol (DTT) Fermentas, MD, USA (R-0891) 
DPN Tocris, Bristol, UK (1494) 
E2 Steraloids, RI, USA (E950) 
Ethanol (EtOH), abs Kantonsapotheke Zurich, CH 
Fibrinogen Type I Sigma-Aldrich, MO, USA (F-0895) 
G1 Calbiochem, Darmstadt, DE (371705) 
Glucose Sigma-Aldrich, St.Louis, USA (G-6152) 
Guava EasyCheck Kit Millipore, Darmstadt, DE (4500-0025) 
Guava Instrument Clean Fluid Millipore, Darmstadt, DE (4200-0140) 
Hoechst33342 Life Technologies, CA, USA (H3570) 
Hydrochloric acid (HCl)  Merck, Darmstadt, DE (109973) 
Hyperfilm ECL  Amersham, CH (RPN2103K) 
ICI 182-780 Tocris, Bristol, UK(1047) 
Laemmli Sample Buffer Biorad, Reinach CH (161-0747) 
Lipofectamine2000 Life Technologies, CA, USA (11668019) 
LY0294002 Merck, Darmstadt, DE (440202) 
Magnesium Chloride (MgCl2) Sigma-Aldrich, MO, USA (M-2393) 
Matrigel BD Biosciences, NJ, USA (356237) 
Methanol  Sigma-Aldrich, MO, USA (32213) 
miRNeasy Mini Kit Qiagen, CA, USA (217184) 
MPP Tocris, Bristol, UK (1991) 
NewBlot Nitro Stripping buffer  LI-COR, NE, USA (928-40030) 
Nonfat dry milk COOP, CH 
PBS tablets Life Technologies, CA, USA (18912-014) 
PDGF-BB Sigma-Aldrich, MO, USA (P-3201) 
Phenyl-Methyl-Sulfonyl Fluoride (PMSF) Sigma-Aldrich, MO, USA (P-7626) 
Ponceau S Solution (2%)  Sigma-Aldrich, MO, USA (P-7767) 
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Potassium Chloride (KCl) Sigma-Aldrich, MO, USA (P-5405) 
PPT Tocris, Bristol, UK (1426) 
Precision Plus Dual Color Standard  Biorad, Reinach CH (161-0374) 
Propidium Iodide (PI) Sigma-Aldrich, MO, USA (P-4170) 
Quick-RNA MiniPrep Kit Zymo Research, USA (R1055)  
RNase A Roche, Basel, CH (10109142001) 
RNase Zap Life Technologies, CA, USA (AM9782) 
Rotiphorese Gel 30  Carl Roth GmbH, Karlsruhe, DE (3029.1) 
Sodium Chloride (NaCl)  Sigma-Aldrich, MO, USA (71381) 
Sodium Dodecyl Sulfate (SDS)  Sigma-Aldrich, MO, USA (L-5750) 
Sodium Hydroxide (NaOH)  Sigma-Aldrich, MO, USA (S-8045) 
SuperSignal West Dura  Pierce, Rockford, USA (34076) 
SuperSignal West Pico  Pierce, Rockford, USA (34077) 
TaqMan Fast Advanced Master mix Life Technologies, CA, USA (4444964) 
TaqMan High-Capacity cDNA Reverse Transcription Kit  
 Life Technologies, CA, USA (4368814) 
TaqMan miRNA Reverse Transcription Kit Life Technologies, CA, USA (4366597) 
Temed  Sigma-Aldrich, MO, USA (T-9281) 
TGFβ1, Human Recombinant  R&D Systems, MN, USA (240-B) 
Thiazol Blue Tetrazolium Bromide (MTT) Sigma-Aldrich, MO, USA (M-5655) 
Tris/Boric Acid/EDTA Buffer (TBE, 10x) Bio-Rad, Reinach, CH (161-0770) 
Tris/Glycine Buffer (TG, 10x) Bio-Rad, Reinach, CH (161-0771) 
Tris/Glycine/SDS Buffer (TGS, 10x) Bio-Rad, Reinach, CH (161-0772) 
Tris/HCl, 0.5M, pH 6.8  Biorad, Reinach, CH (161-0799) 
Tris/HCl, 1.5M, pH 8.8  Biorad, Reinach, CH (161-0799) 
Tween 20  Sigma-Aldrich, MO, USA (P-7949) 
VEGF antibody, human R&D Systems, MN, USA (MAB293) 
VEGF Sigma-Aldrich, MO, USA (V-7295) 
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3.3 MicroRNA sequences and primers 
3.3.1 Mature microRNA Sequences 
hsa-miR-100   5’ -  AACCCGUAGAUCCGAACUUGUG - 3’ 
hsa-miR-146a   5’ -  UGAGAACUGAAUUCCAUGGGUU - 3’ 
hsa-miR-193a-3p  5’ -  AACUGGCCUACAAAGUCCCAGU - 3’ 
hsa-miR-203  5’ -  GUGAAAUGUUUAGGACCACUAG - 3’ 
hsa-miR-221-3p  5’ -  AGCUACAUUGUCUGCUGGGUUUC - 3’ 
hsa-miR-222  5’ -  AGCUACAUCUGGCUACUGGGU - 3’ 
hsa-miR-638  5’ -  AGGGAUCGCGGGCGGGUGGCGGCCU - 3’ 
RNU48 5’ -  GATGACCCCAGGTAACTCTGAGTGTGTCG 
       CTGATGCCATCACCGCAGCGCTCTGACC - 3’ 
RNU49  5’ -  CACTAATAGGAAGTGCCGTCAGAAGCGA 
     TAACTGACGAAGACTACTCCTGTCTGATT - 3’ 
3.3.2 Mimics and Antimirs 
AccuTarget Human miRNA Antimirs Bioneer, CA. USA (SMI-001) 
AccuTarget Human miRNA Mimics Bioneer, CA. USA (SMM-001) 
AccuTarget miRNA Antimir Negative Control #1 Bioneer, CA. USA (SMC-2101) 
AccuTarget miRNA Mimic Negative Control #1 Bioneer, CA, USA (SMC-2001) 
AccuTarget miRNA Mimic Positive Control Bioneer, CA, USA (SMC-1001) 
miRIDIAN miRNA Antimir Control with Dy547   
 Dharmacon, CO, USA (IP-004500-01-05) 
miRIDIAN miRNA Mimic Control with Dy547   
 Dharmacon, CO, USA (CP-004500-01-05) 
3.3.3  RT-qPCR primers 
TaqMan miRNA assays Life Technologies, CA, USA (4427975) 
 hsa-miR-100  Assay ID 000437 
 hsa-miR-146a   Assay ID 000468 
 hsa-miR-193a-3p  Assay ID 002250 
 hsa-miR-203  Assay ID 000507 
 hsa-miR-221-3p  Assay ID 000524 
 hsa-miR-222  Assay ID 002276 
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 hsa-miR-638  Assay ID 001582 
 RNU48  Assay ID 001006 
 RNU49  Assay ID 001005 
TaqMan Pri-miRNA Assays Life Technologies, CA, USA (4427012) 
 hsa-pri-miR-193a  Assay ID Hs03303307_pri 
 hsa-pri-miR-221  Assay ID Hs03303007_pri 
TaqMan Gene Expression Assays  Life Technologies, CA, USA (4331182) 
 GAPDH  Assay ID Hs99999905_m1 
 hPRT1  Assay ID Hs99999909_m1 
3.4 Antibodies 
3.4.1 Primary antibodies 
Anti-β-Actin  Sigma-Aldrich, MO, USA (A-5441) 
Anti-Akt Cell Signaling Tech., MA, USA (9272) 
Anti-phospho-Akt (Ser473) Cell Signaling Tech., MA, USA (9271) 
Anti-ALK1 Santa Cruz, TX, USA (sc-28976) 
Anti-CDK4  Millipore, CA, USA (07-659) 
Anti-Cyclin D1 Millipore, CA, USA (06-137) 
Anti-Cyclin E Cell Signaling Tech., MA, USA (4129) 
Anti-GAPDH Abcam, Cambrige, UK (ab9484) 
Anti-Id1 Santa Cruz, TX, USA (sc-488) 
Anti-p27 Millipore, CA, USA (04-240) 
Anti-PCNA Millipore, CA, USA (CBL407) 
Anti-pRB  BD Biosciences, NJ, USA (554136) 
Anti-VEGF A Santa Cruz, TX, USA (sc-152) 
3.4.2 Secondary antibodies 
IGF-Peroxidase Conj. Goat anti-Mouse Pierce, Rockford, USA (31430) 
IGF-Peroxidase Conj. Goat anti-Rabbit Pierce, Rockford, USA (31460) 
IRDye 680 Conj. Goat anti-Mouse IgG  LI-COR, NE, USA (926-32220) 
IRDye 800 Conj. Goat anti-Rabbit IgG  LI-COR, NE, USA (926-32211) 
IRDye 680 Conj. Goat anti-Rabbit IgG  LI-COR, NE, USA (926-68021) 
IRDye 800 Conj. Goat anti-Mouse IgG  LI-COR, NE, USA (926-68020) 
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3.5 Plastic material 
µ-slides  ibidi, Planegg-Martinsried, DE (81506) 
25-gauge needle Terumo, Somerset, NJ, USA 
Cell culture dishes, multiwell plates Falcon by Beckton Dickinson 
Cell culture flask TPP, Trasadingen, CH 
Cell lifter Corninc Inc., NY, USA 
Cryotubes Nalge Nunc International, USA (377224) 
Freezing container, Mr.Frosty Nalgene Nunc International, USA 
Nitrocellulose membrane Whatman GmbH, Dassel, DE 
Reaction tubes (15, 50 ml) Falcon by Beckton Dickinson 
Tips, Combitips Eppendorf, Hamburg, DE 
Reaction tubes (0.5, 1.5 ml) Eppendorf, Hamburg, DE 
PCR plates Biorad, Reinach, CH  
3.6 Instruments and software 
3.6.1 Western blot apparatus 
Mini-PROTEAN 3 Electrophoresis Cell  Biorad, Reinach, CH 
Mini-Trans-Blot Electrophoretic Transfer Cell  Biorad, Reinach, CH 
Power Pac 200, Power Supplier  Biorad, Reinach, CH 
X-ray cassette 13x18 Universitätsspital Zürich, CH 
3.6.2  Instruments 
5417R Centrifuge Eppendorf,Hamburg, DE 
CFX Real-Time PCR Detection System Biorad, Reinach, CH 
Coulter Z1, Cell Counter  Coulter Electronics, Luton, UK 
GUAVA easyCyte HT Flow Cytometer Millipore, Darmstadt, DE 
H54AR Precision balance Mettler-Toledo, USA 
Hera Cell 150, Cell incubator Thermoscientific, MA, USA  
Odyssey 3.0 Infrared Imaging System  LI-COR, NE, USA 
C-DiGit Blot Scanner LI-COR, NE, USA 
Microtiter Centrifuge Hettich, Bäch, CH 
NanoDrop 1000 Thermoscientific, MA, USA  
Olympus BX61 Microscope, Bright field Olympus, Volketswil, CH 
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Olympus IX81 Microscope, Fluorescence Olympus, Volketswil, CH 
Rotina 46R Centrifuge Hettich, Bäch, CH 
Sonicator Bandelin electronics, Berlin, DE 
Tecan Infinite series M200 microplate reader Tecan, Salzburg, AU 
Tecan Infinite series M200 NanoQuant Tecan, Salzburg, AU 
X-ray Film developer 
3.6.3 Software 
Xcellence pro Olympus, Volketswil, CH 
Image Studio Lite LI-COR, NE, USA 
Magellan 6 and iControl Tecan, Salzburg, AU  
StatView, Version 5.0.1  SAS Institute, Cary, USA 
GuavaSoft and InCyte Merck Millipore, Darmstadt, DE 
NanoDrop 1000  Thermoscientific, MA, USA 
CFX Manager Biorad, Reinach, CH 
ImageJ  
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4 Methods 
4.1 Cell culture 
HCASMCs: Human Coronary Artery Smooth Muscle Cells between 4-8th passage 
were cultured in 75 cm2 flasks under standard tissue culture conditions (37°C, 5% 
CO2) in complete growing media: M231 culture medium supplemented with  
antibiotic-antimycotic (AA; 100 μg/ml streptomycin, 100 μg/ml penicillin and 0.025 
μg/ml amphotericin B) and SMGS (5% v/v FCS, 2 ng/ml human basic Fibroblast 
Growth Factor, 0.5 ng/ml human Epidermal Growth Factor, 5 ng/ml Heparin, 5 µg/ml 
insulin and 0.2 µg/ml BSA). Medium was changed every two days until 
subconfluency. To split the culture, the cells were washed twice with HBSS (w/o Ca2+ 
and Mg2+) and detached through trypsinization with 0.25% trypsin diluted in HBSS 
(w/o Ca2+ and Mg2+). After 3 minutes incubation, an equal volume of growing medium 
was added and the cells were either diluted 4 times in 75 cm2 flasks or plated on 
culture dishes or well plates. For experiments, HCASMCs were starved overnight and 
treated in HCASMCs starving media (M231, supplemented with AA). 
HUVECs: Human Umbilical Vein Endothelial Cells between 4-12th passage were 
cultured in 75 cm2 flasks under standard tissue culture conditions in complete 
growing media: DMEM-F12 supplemented with L-Glutamine, AA (100 μg/ml 
streptomycin, 100 μg/ml penicillin and 0.025 μg/ml amphotericin B), LSGS (2% v/v 
FCS, 1 µg/ml hydrocortisone, 10 ng/ml human Epidermal Growth Factor, 3ng/ml 
human basic Fibroblast Growth Factor, 10 µg/ml heparin) and 10% FCS. Medium 
was changed every two days an when the cells reached subconfluency they were 
washed twice with HBSS (w/o Ca2+ and Mg2+) and trypsinized in 0.25% trypsin. After 
2 minutes, double volume of growing medium was added to stop the detaching 
reaction. The cells were pelleted by centrifugation (5 minutes, 1200 rpm, room 
temperature) and the supernatant discarded prior resuspension of the cells in 
growing media and seeding 1:4 in 75 cm2 flasks, culture dishes or well plates. For 
experiments, HUVECs were starved overnight and treated in HUVEC starving media 
(DMEM-F12, supplemented with L-Glutamine, AA and 1% BSA).  
EPCs: Endothelial Progenitor cells between 4-8th passage were cultured under 
standard tissue culture conditions (5% CO2 at 37°C). Prior cell seeding, 75 cm2 
flasks were coated with collagen (50 μg/ml in 0.02 N acetic acid). After 1 hr 
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incubation at room temperature, collagen was removed, the surface washed with 
PBS and the cells seeded in complete growing medium: EBM-2, supplemented with 
EGM-2 SingleQuots (containing human Epidermal Growth Factor, Hydrocortisone, 
human basic Fibroblast Growth Factor, VEGF, Insulin-like Growth Factor, Ascorbic 
Acid, Heparin and FCS), AA and 10% FCS.  Medium was renewed every two days 
and upon confluency the cells were washed with HBSS (w/o Ca2+ and Mg2+), 
trypsinized 2 minutes, neutralized in double volume of complete medium, centrifuged 
(5 minute, 1200 rpm, room temperature) and re-plated at 1:4 in tissue culture flasks, 
dishes or well-plates.  
4.1.1 Cryopreservation of cells 
Subconfluent cells were dislodged as described above. After trypsinization, fresh 
growing medium was added and the cells were centrifuged at 1200 rpm for 10 min at 
room temperature. The pellet was resuspended in ice-cold growing medium (4ml/ 75 
cm2 flask) containing 10% DMSO as cryoprotective agent. Aliquots of 1ml were 
gradually frozen to –70 °C in cryotubes in a Mr. Frosty box (freezing container filled 
with 2-propanol). For long-term storage the cells were kept in liquid nitrogen (-
196°C).  
4.1.2 Cell defrosting 
Frozen cells in cryotubes were taken from liquid nitrogen and rapidly thawed under 
warm water. After disinfection of the vial, the content was slowly transferred to a 75 
cm2 culture flasks with 10 ml of the respective growing medium. The cells were 
incubated under standard tissue culture conditions (5% CO2 at 37°C) and the media 
was replaced after 24 hr.  
4.2 MicroRNA sequencing  
EPCs were seeded in 6 cm dishes and grown in complete media to 60% confluency 
prior 36 hr treatment with or without 10 nM E2 in triplicates in EBM-2 without phenol 
red and growth factors, supplemented with 2.5% steroid-free Charcoal Stripped FCS. 
RNA was extracted using the miRNeasy Mini Kit. First cell membranes and content 
were dissolved in 350 μl lysis buffer. The collected lysates were passed through the 
columns to filter cell debris and the resulting solutions were mixed with 70% ethanol 
and transferred to RNA-binding columns. DNA was digested using DNases and 
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several washing steps were performed prior RNA elution with RNase-free water. The 
obtained RNA was stored at -80°C and handled over to the Functional Genomic 
Center Zürich for RNA quality and quantity assessment and the following 
sequencing. For the quality assessment Agilent Tape Station/ Bioanalyzer and Qubit 
fluorometer were used. For the sequencing, the libraries were prepared using 
Illumina’s TruSeq Small RNA Library Prep Kit and sequenced on an Illumina 
HiSeq2000. The raw reads were first cleaned by removing adapter sequences using 
Trimmamatic [234]. Sequence alignment, quantification and quality control were 
performed using ncPRO (version 1.5.1) [235]. Bowtie was used for the mapping with 
ncPRO (with the following options '-e 50 -a -m 50 --best --strata --nomaqround') and  
hg19 was used as genome reference for the mapping. The miRNA annotation is 
based on miRBase version 20. The detection of differentially expressed miRNAs was 
done using EdgeR [236].  
4.3 Transfection with microRNA Mimics and Antimirs 
HCASMCs and HUVECs were plated in the respective growth medium and allowed 
to recover at least for 24 hr. Before transfection, as described in Table 1, the 
appropriate amount of lipofectamine2000 was diluted in serum and antibiotic free 
DMEM-F12 in one tube (solution A). MiRNA Mimics or Antimirs (at a final 
concentration of 25 nM) were also diluted in serum and antibiotic free DMEM-F12 in 
a different tube (solution B). Both solutions were incubated 5 minutes at room 
temperature before being equally mixed (A+B) and incubated 20 minutes at room 
temperature to allow the miRNA olignonucleotides:lipofectamine2000 complexes to 
form. The cells were rinsed with serum and antibiotic free DMEM-F12 and the miRNA 
oligonucleotides:Lipofectamine2000 complexes added to each well.  
  
6 cm dish 
6-well plate 
3.5 cm dish 
12-/ 24-well 
plate 
96-well plate 
A Lipofectamine 2000 3 μl 2 μl 1 μl 0.25 μl 
 
Media 147 μl 98 μl 49 μl 25 μl 
B Mimic / Antimir 0.9 μl 0.6 μl 0.3 μl 0.075 μl 
 
Media 99.1 μl 99.4 μl 49.7 μl 25 μl 
 
Media on cells 1.5 ml 1 ml 0.5 ml 0.1 ml 
Table 1: Transfection guideline for final 25 nM miRNA Mimics or Antimirs. The ratio of 
lipofectamine2000 and RNA were scaled for the different sizes of dishes or well plates.  
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After 5-6 hr the transfection media was removed and replaced by the regular growing 
media or respective starving media in presence or absence of the test agents. Mock 
transfection was carried out as described above but with the omission of the miRNA 
oligonucleotides.  
4.3.1 Transfection efficiency 
HCASMCs and HUVECs were transfected with a Dy547-labeled Mimic or Antimir 
and kept in the respective growing media for 24 hr before the transfection efficiency 
was assessed using fluorescence microscopy and flow cytometry. For the former, the 
cell nuclei were stained with Hoechst33342 (0.5 μg/ml) and incubated 30 minutes 
before microscope images were taken. For flow cytometry, the cells were detached 
by trypsinization, centrifuged and resupsended in 300 μl sample buffer (1 g/L glucose 
in PBS) before the percentage of fluorescent signal was measured by a GUAVA 
easyCyte Flow Cytometer. Cells transfected with miRNA negative Control Mimic or 
Antimir without a fluorescent tag were used as negative controls.  
Efficient transfection with the Mimics was further proved using a positive Control 
Mimic specifically targeting GAPDH. Expression of GAPDH protein was assessed by 
Western blotting of samples at 24, 48 and 72 hr after transfection.  
4.4 Cell proliferation studies 
4.4.1 Cell counts 
Cells were plated in 12-well plates and growth arrested in starving media for 24 hr, 
before stimulation with 10 nM E2 (HUVEC) or PDGF-BB (20 ng/ml) in presence or 
absence of E2 (HCASMC). Before transfection with Mimics and Antimirs, the cells 
were starved overnight and treated 5-6 hr post-transfection with or without PDGF-BB 
and E2. After 3 days, cells were dislodged by trypsinization, transferred into cuvettes 
and counted in a Coulter Counter.  
4.4.2 DNA synthesis  
HCASMC proliferation was additionally determined by a chemiluminescent BrdU 
incorporation ELISA kit (Roche). Cells were plated on a 96-well plate (5’000 cells per 
well) and allowed to attach overnight. The next day the cells were washed with PBS 
and incubated with or without PDGF-BB and E2 in starving media or transfected with 
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Mimics and Antimirs prior treatment. BrdU (10 μM) was added after 24 hr and 
allowed to incorporate into the cells for further 24 hr. Cells were fixed and anti BrdU-
antibody was added as described in the kit and the luminescent signal was measured 
using a Tecan Spectrofluorometer reader. 
4.5 Migration studies 
Cell migration was determined using a Scratch/ Wound Closure Assay. HCASMCs in 
6-well plates and HUVECs in 12-well plates were grown to confluency before a 
scratch was made using a yellow pipet tip. The cells were then washed twice with 
PBS to remove cell debris and treated in presence or absence of the test agents. 
Cells transfected with miRNA Mimics and Antimirs were allowed to grow to 
confluency 48 hr post-transfection, before the scratch was made and the treatment 
added. Several images of the scratch were taken using the Olympus inverted 
microscope right after treatment (T0) and after 24 hr of incubation (T24). Wound 
closure was determined using Olympus Xcellence Pro software and calculated 
accordingly: (area T0- area T24)/ area T0. 
4.6 Microvessel formation assay 
HUVECs cultured in regular conditions and cells transfected with miRNA Mimics and 
Antimirs, kept 24 hr in growing media post-transfection, were collected by 
trypsinization, counted and resuspended in 1 ml per each treatment in DMEM-F12 
supplemented with L-Glutamine, AA and 0.4% BSA at a density of 80’000 cells/ml in 
15 ml falcon tubes. The cells were incubated with experimental agents 30 minutes 
prior transfer of 50 μl (4’000 cells) to each well of the angiogenesis μ-slide, previously 
coated with 10 μl matrigel. The cells were allowed to form microvessels overnight 
and imaged with an Olympus inverted microscope. Five pictures were taken for each 
well at a 10x magnification. Microvessel length was determined using Olympus 
Xcellence Pro software.  
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4.7 Viability studies 
4.7.1 MTT test 
HUVECs and HCASMCs were plated in a 24 well plate and allowed to attach. After 
transfection the cells were kept in culture media or growth arrested for 48 hr. 
Subsequently the medium was replaced with fresh medium containing 0.5 mg/ml 
MTT. After additional incubation for 1 hr, the medium was aspirated and the cells 
lysed by the addition of 100 l DMSO. The absorbance was quantitated at 540 nm 
using a Tecan Spectrofluorometer reader.     
4.7.2 PI staining 
HUVECs and HCASMCs were plated in 6 cm dishes and allowed to attach. After 
transfection, the cells were kept in culture media for 24 hr prior collection through 
trypsinization followed by centrifugation (5 minutes, 1200 rpm, room temperature). 
The cells were than stained with PI (0.2 μg/ml), incubated in the dark for 5 minutes 
and analyzed on a GUAVA easyCyte Flow Cytometer.  
4.8 Protein expression analysis 
HCASMCs were serum-starved overnight and treated 48 hr in presence or absence 
of PDGF-BB (20 ng/ml) and E2 (10-100 nM). Mimic and Antimir transfected cells 
were treated for 48 hr with the test agents post-transfection. HUVECs were serum-
starved overnight and stimulated 45 minutes with 10 nM E2. Mimic and Antimir 
transfected cells were kept in growing media 48 hr post-transfection and stimulated 
45 minutes with or without 10 nM E2. Cells were washed twice with HBSS and lysed 
by the addition of 60 μl cell lysis buffer (containing 20 mM Tris pH7.5, 1% Triton X-
100, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 2.5 mM sodium phosphate, 1 mM β-
glycerophosphate, 1 mM sodium vanadate, 0.5 PMSF and 0.2% SDS) followed by 
scraping. The samples were homogenized 2-10 seconds by sonication and stored at 
-20°C. The protein concentration was determined with the BCA Assay Kit according 
to the manufacturer’s protocol. The absorbance was measured with the Tecan Infinite 
series M200 microplate reader.  
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4.8.1 Western blot  
Western blot analysis was performed on whole-cell lysates. Equivalent amounts of 
proteins (10-30 µg per lane) were diluted with 4x Laemmli Sample Buffer (containing 
77.8 mM Tris-Hcl, pH 6.8, 4.4% w/v glycerol, 0.02% bromophenol blue) and 0.1 M 
DTT. After denaturation at 95°C for 5 minutes, the samples were loaded and 
separated onto 8-12.5% SDS-polyacrylamide gels at 90-120V. Precision Plus dual 
color Standard was used as protein standard. After separation on the gel, the 
proteins were transferred to a nitrocellulose membrane at 0.35A during 60 minutes. 
Successful transfer was visualized by Ponceau S staining. The red Ponceau S 
staining was washed out through washing with PBS and the membrane was blocked 
in 5% nonfat dry milk or 5% BSA in PBS/ 0.2% Tween 20 at room temperature for 1 
hr. After blocking, the membrane was incubated with the primary antibody over night 
at 4°C (antibody diluted in 5% BSA in PBS/ 0.2% Tween 20). To remove unbound 
primary antibodies, the membrane was washed 3x 10 minutes with 1% nonfat dry 
milk in PBS/ 0.2% Tween 20. Incubation with secondary antibodies was performed at 
room temperature for 1 hr (antibody dissolved in 1% nonfat dry milk in PBS/ 0.2% 
Tween 20). The membrane was washed 3x 10 minutes with PBS/ 0.2% Tween 20 
before detection of the protein. For peroxidase-conjugated secondary antibodies, 
peroxidase activity was detected using ECL and the membranes were exposed to X-
OMAT LS films or measured with the LI-COR C-DiGit Blot Scanner. For IRDye680 
and 800 conjugated antibodies, the membranes were analyzed with the Odyssey LI-
COR system.  
For successive detection of additional proteins, the membrane was washed with 
PBS/ 0.2% Tween 20 after analysis of the first protein, incubated for 30 minutes with 
the stripping buffer 1 (0.1 M glycine in PBS, pH 2-3) and subsequently shortly 
washed in stripping buffer 2 (1 M NaCl in PBS). Subsequently the membranes were 
washed three times with PBS and the protein detection procedure restarted from 
blocking process.  
4.9 MicroRNA and pri-microRNA expression analysis 
For the analysis of miRNA expression levels, HUVECs were stimulated 24 hr by 10 
nM E2 in starving media whereas HCASMCs were induced by PDGF-BB (20 ng/ml) 
for 24 hr in the presence or absence of E2 (10-100 nM) in starving media. The role of 
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estrogen receptors (ERs) on miRNA expression was studied using ER agonists PPT, 
DPN and G1 (100 nM). ER antagonists MPP (500 nM) and ICI (1 μg) were added 1 
hr prior to E2 or the ER-agonists. Controls of both cell types were treated with vehicle 
(maximal 0.1% DMSO). Additionally, expression of miR-221 and miR-193a was 
assessed at 24, 48 and 72 hr after transfection with Mimics and Antimirs, and their 
respective controls, to confirm overexpression by the Mimics and silencing by the 
Antimir.  
For pri-miRNA expression analysis, HUVECs were stimulated 24 hr by 10 nM E2 in 
starving media whereas HCASMCs were induced by PDGF-BB (20 ng/ml) for 24 hr in 
the presence or absence of E2 (10-100 nM) in starving media. 
4.9.1 RNA extraction and quantification 
Total RNA, including small RNAs, was extracted from the treated cells using the 
Quick-RNA MiniPrep Kit (ZymoResearch) according to the manufacture’s protocol. 
Briefly, the cells were lysed directly in the culture dish by removing the culture media, 
adding RNA lysis buffer and collecting the lysate. Samples homogenized in lysis 
buffer can be stored frozen and processed at a later time. All centrifugation steps 
were performed at 10’000 x g. Lysates were cleared by centrifugation for 1 min 
before the supernatant was transferred into a Spin-Away Filter in a collection tube 
and centrifuged again to remove gDNA. The flow-through was saved for RNA 
purification. The same volume of ethanol (95-100%) was added to the sample and 
the solution was mixed well. The mixture was transferred to a Zymo-Spin IIICG 
Column in a collection tube and centrifuged 30 seconds. The flow through was 
discharged. For the optional In-column DNase I treatment, the column was 
prewashed with 400 μl RNA Wash Buffer, centrifuged 30 seconds and flow-through 
discarded, before 80 μl DNase I reaction mix (5 μl DNase I and 75 μl DNA digestion 
buffer) was added directly to the column matrix and incubated for 15 minutes at room 
temperature. The following washing steps were followed by 30 seconds 
centrifugation and discharge of flow-through. The column was washed by 400 μl RNA 
Prep Buffer, 700 μl RNA Wash Buffer and finally by 400 μl RNA Wash Buffer, 
followed by 2 minutes of centrifugation. The RNA was eluted from the column by 50 
μl DNase/ RNase-free water, through 30 seconds of centrifugation and placed 
immediately on ice. The purified RNA could be stored at -80°C or directly processes 
to the reverse transcription, as described below.  
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The concentration of the total RNA was quantified by the absorbance at 260 nm 
using a NanoDrop system or Infinite 200 NanoQuant (Tecan). The overall quality of 
the RNA preparation purified with the Quick-RNA MiniPrep Kit was assessed on 
electrophoresis on a 1% denaturing agarose gel. Further RNA purity was considered 
by the ratios A260/ A280 > 1.8 and A260/ A230 > 1.8.  
4.9.2 MicroRNA RT-qPCR 
RT-qPCR for miRNAs was performed using the TaqMan miRNA assays (Life 
Technologies) which provides miRNA-specific RT primers as well as primers and 
probes for amplification and detection of the miRNA. Briefly, single-stranded 
complementary DNA (cDNA) was synthetized from 10 ng total RNA in 15 μl reaction 
volume with the TaqMan miRNA Reverse Transcription Kit. Each 15 μl reaction 
contained 1 mM deoxynucleotide (dNTP) mix, 50 U MultiScribe Reverse 
Transcriptase, 1x Reverse Transcription Buffer, 0.3 U RNase Inhibitor and 1x 
miRNA-specific RT primers. The reaction was incubated at 16°C for 30 minutes 
followed by 30 minutes at 42°C and inactivation at 85°C for 5 minutes. Samples were 
chilled on ice and diluted by addition of 75 μl DEPC treated water. cDNA was stored 
at -20°C.  
Amplification and detection of the specific products were performed on a Bio-Rad 
CFX Real-Time PCR Detection System. PCR reaction included 5 μl 2x TaqMan Fast 
Advanced Master mix, 0.5 μl each 20x TaqMan miRNA Assay mix, 0.5 μl DEPC 
treated water and 4 μl cDNA. The PCR reaction plate was run as following: 2 minutes 
at 50°C and 20 seconds at 95°C, followed by 40 cycles of 95°C for 3 seconds and 
60°C for 30 seconds.  
As an internal control, RNU48 and RNU49 were used for miRNA template 
normalization. The relative gene expression was determined using the 2-ΔΔCt Method.  
4.9.3 Pri-microRNA RT-qPCR 
The TaqMan High-Capacity cDNA Reverse Transcription Kit (Life Technologies) was 
used to synthetize single-stranded cDNA from the extracted RNA. Briefly, 20 μl 
reaction contained 1x Reverse Transcription Buffer, 1x RT Random Primers, 4 mM 
deoxynucleotide (dNTP) Mix, 50 U MultiScribe Reverse Transcriptase, nuclease-free 
water and 10ul of 20 μg/μl RNA. The reaction was incubated at 25°C for 10 minutes 
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followed by 120 minutes at 37°C and inactivation at 85°C for 5 minutes. cDNA was 
stored at -20°C or placed on ice for immediate procession with qPCR. 
Amplification and detection of the specific products were performed on a Bio-Rad 
CFX Real-Time PCR Detection System. PCR reaction included 5 μl 2x TaqMan Fast 
Advanced Master mix, 0.5 μl each 20x TaqMan pri-miRNA Assay mix, 2.5 μl DEPC 
treated water and 2 μl cDNA. The PCR reaction plate was run as following: 2 minutes 
at 50°C and 20 seconds at 95°C, followed by 40 cycles of 95°C for 3 seconds and 
60°C for 30 seconds.  
As an internal control, GAPDH and hPRT1 genes were used for pri-miRNA template 
normalization. The relative gene expression was determined using the 2-ΔΔCt Method.  
4.10 Statistical analysis 
All experiments were repeated a minimum of 3 times. Data are presented as mean ± 
standard error. Unless stated differently, for statistical evaluation Student’s t tests and 
ANOVA were used and statistical significance (p<0.05) was calculated using Fisher’s 
Least Significant Difference test. 
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5 Results and Discussion 
5.1 E2 regulates miRNAs in ECs 
Objective 
The beneficial effects of E2 on the endothelium are well known; however, the role of 
miRNAs in mediating these effects remains unclear. Hence, under this specific aim, 
we screened for E2-regulated miRNAs in ECs.   
Introduction 
The beneficial effects of E2 on endothelial growth and function are well established. 
For example, E2 promotes the recovery of injured or dysfunctional endothelium by 
stimulating EC proliferation, migration and capillary formation [130-132, 135, 136] 
and improving endothelial-dependent vascular relaxation [116]. Multiple intracellular 
signaling mechanism(s) have been identified in inducing the protective actions of E2 
on ECs; however, the role of miRNAs in mediating these effects remains unclear.  
Since miRNAs actively regulate ECs [208, 209] and are postulated to mediate 
estrogenic actions in cancer cells [88], we hypothesize that the protective actions of 
E2 on the vascular system are potentially mediated via regulation of miRNAs. To test 
our hypothesis, we screened for miRNAs that were regulated by E2 in ECs. To 
achieve this goal, we analyzed the data from a preliminary small RNA sequencing 
experiment in EPCs, searched the literature for interesting miRNAs and subsequently 
validated the selected miRNA candidates by RT-qPCR in HUVECs.  
5.1.1 E2 alters miRNA expression in EPCs  
To investigate the role of miRNAs in mediating the protective actions of E2 in the 
vascular system, we first identified miRNAs that were differentially expressed in 
EPCs in response to E2. In this context, the cells were treated for 36 hr with or 
without 10 nM E2 and the RNA extracted. Subsequently a small RNA sequencing 
was preformed using Illumina HiSeq2000 and the data analysed in collaboration with 
the Functional Genomic Center Zürich. Indeed, we found 10 miRNAs significantly 
regulated by E2 (Figure 15) - 7 down-regulated (miR-193a.3p, miR-335.5p, miR-494, 
miR-340.5p and miR-30b.5p, miR-30c.5p and miR-30c.5p.1) and 3 up-regulated 
(miR-146a.5p, miR-146b.5p and miR-3074.5p). 
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Figure 15: Treatment with E2 alters miRNA expression in EPCs. EPCs were seeded and 
grown to 60% confluency in complete media prior to 36 hr treatment with or without 10 nM 
E2 in triplicates. RNA was extracted and handled over to the Functional Genomic Center 
Zürich for RNA quality and quantity assessment and the following miRNA sequencing and 
data analysis. Panel A: Volcano plot of sequenced miRNAs. The miRNAs with single counts 
<100 (grey) were not analyzed for differential expression. Significantly regulated miRNAs are 
depicted in red. Panel B and C: Differentially expressed (p<0.05) miRNAs. 
5.1.2 E2 down-regulates miR-193a in HUVECs 
From the 10 differentially expressed miRNAs after treatment with E2 in EPCs, we 
picked out the two highly regulated, miR-193a.3p (log2 Ratio = -0.5839) and miR-
146a.5p (log2 Ratio = 0.4556), to be validated by RT-qPCR in HUVECs.  
We found that treatment with 10 nM E2 reduced the levels of miR-193a.3p by 27±6% 
(p<0.05), while it had no significant effect on miR-146a.5p (Figure 16), suggesting 
that E2 regulates only miR-193a.3p in HUVECs under our experimental conditions.  
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Figure 16: Validation of E2-regulated miRNAs in HUVECs. Cells were grown to 60% 
confluency in complete media prior to 24 hr treatment with or without 10 nM E2. Total RNA 
was extracted and the relative miRNA expression levels were determined by RT-qPCR using 
TaqMan miRNA assays. The results were normalized to U48 and U49. n=3, *p<0.05 
compared to the respective control. 
5.1.3 E2 down-regulates miR-221 expression in HUVECs 
In addition to the miRNAs chosen from the EPC sequencing results, we tested the 
effect of E2 on miRNA-100 and miRNA-221, two miRNAs known to play a role in EC 
and vascular SMC function. It was demonstrated that miR-100 modulates 
proliferation, tube formation, and sprouting activity of ECs and migration of vascular 
SMCs [237]. Similarly, miR-221 decreases cell survival, migration and endothelial 
tube formation in HUVECs [215], whereas it induces growth of SMCs [230], which 
recalls the differential actions of E2 on EC and SMC growth.  
In this study, we found that 10 nM E2 had no effect on miR-100 expression, while it 
inhibited the expression of miR-221 by 26±5% (p<0.05; Figure 17), suggesting that 
in HUVECs miR-221, but not miR-100, is an estrogen responsive miRNA.  
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Figure 17: E2 effect on miRNAs involved in EC regulation. The miRNAs were chosen 
based on a literature search. HUVECs were grown to 60% confluency in complete media 
prior to 24 hr treatment with or without 10 nM E2. Total RNA was extracted and relative 
miRNA expression levels were determined by RT-qPCR using TaqMan miRNA assays. The 
results were normalized to U48 and U49. n=3, *p<0.05 compared to the respective control. 
5.1.4 Discussion 
The protective effects of estrogens in the cardiovascular system are well established 
and include the promotion of endothelial repair and regeneration; however, the 
mechanisms involved remain unclear. The role of miRNAs in the vasculature has 
been extensively studied [193-195]. Recently, estrogens have been associated with 
alterations in miRNA expression [83, 84] and several studies have shown that E2-
regulated miRNAs mediate the actions of E2 in different tissues, including the 
vascular system [90-93]. Hence, to assess the role of miRNAs in mediating the 
protective effects of E2 in ECs, we screened for miRNAs regulated by E2 in EPCs by 
performing a small RNA sequencing experiment, plus through literature research, 
and validated the differential expression in HUVECs, our model to investigate EC 
functions.  
Analysing the data from the small RNA sequencing, we identified 10 miRNAs 
significantly regulated by E2 in EPCs: 7 down-regulated (miR-193a.3p, miR-335.5p, 
miR-494, miR-340.5p and miR-30b.5p, miR-30c.5p and miR-30c.5p.1) and 3 up-
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regulated (miR-3074.5p, miR-146b.5p and miR-146a.5p). Of the 10 identified miRNA, 
we decided to validate only the two most strongly regulated miRNAs by RT-qPCR in 
HUVECs: miR-193a.3p and miR-146a.5p. 
Although no study has elucidated the role of miR-193a in vascular cells until now, few 
studies revealed that miR-193a modulates cancer cell growth, i.e. miR-193a 
regulates proliferation and apoptosis in epithelial ovarian cancer cells [238]. In 
addition, numerous studies have reported that miR-193a suppresses tumor 
development in different types of cancers [239-245]. Moreover, miR-193a 
overexpression inhibited tumor cell migration and invasion capabilities [246, 247]. In 
contrast, miR-146a has been shown to regulate vascular proliferation and 
angiogenesis. Overexpression of miR-146a enhanced angiogenic activity in HUVECs 
through the promotion of the pro-angiogenic factor FGF [248] and knock-down of 
miR-146a significantly reduced LPS-induced EC migration and angiogenesis [249].  
Based on the above findings, both miRNAs are interesting targets, since it is 
conceivable that the stimulatory effects of E2 on EC growth and motility are 
potentially mediated via down-regulation of the anti-proliferative miR-193a and/ or 
induction of the pro-angiogenic miR-146a. However, validation of the two miRNAs in 
HUVECs confirmed only down-regulation of miR-193a by E2, while miR-146a was 
not altered. The controversial finding about miR-146a might be due to false positive 
results in the small RNA sequencing, or more likely caused by the phenotypic 
differences of cells i.e. EPCs and ECs.  
In addition to the miRNAs chosen from the EPC sequencing results, we tested the 
effect of E2 on miRNA-100 and miRNA-221 expression in HUVECs, two miRNAs 
described to negatively influence EC function [215, 237]. We discovered that E2 
altered miR-221 expression, while miR-100 was unaffected, suggesting that only 
miR-221 might mediate the protective actions of E2 in ECs. Since miR-221 adversely 
affects EC proliferation, migration and tube formation, it is very well possible that the 
stimulatory effects of E2 on EC function are mediated via the down-regulation of this 
miRNA.  
The alterations in miRNA expression are generally rather small, both in the 
sequencing and in the RT-qPCR results. However, even relatively small changes in 
miRNA expression may be biologically significant, as the capability of miRNAs to 
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regulate multiple targets within the same pathway amplifies their biological effect 
[250, 251]. 
Taken together, we identified two E2-regulated miRNAs miR-193a and miR-221 in 
HUVECs. Moreover, we postulate that the beneficial effects of E2 on the endothelium 
and consequently on the vascular system are in part mediated via down-regulation of 
these miRNAs and abrogation of their potentially disruptive impact in ECs.  
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5.2 The role of miR-193a and miR-221 in ECs 
Objective 
We identified two miRNAs that were regulated by E2 in HUVECs: miR-193a and miR-
221. Hence, under this specific aim we investigated the effects of miR-193a and miR-
221 on EC function and their role in mediating the beneficial effects of E2. 
Introduction 
The function of miR-221 in the vascular endothelium has been elucidated by several 
studies. It has been shown to inhibit pro-angiogenic activation, proliferation and 
migration of ECs. Expression of miR-221 is increased at the onset of atherosclerosis 
and is possibly involved in maladaptive vascular remodeling as it increases EC 
dysfunction and apoptosis [215, 221]. Compared to miR-221, the impact of miR-193a 
on the vascular system is not known. However, it has been shown to be associated 
with the inhibition of proliferation and motility of different cancer cells [238-247]. 
Based on the above findings, we postulate that in ECs miR-193a may have similar 
physiological effects as miR-221. Moreover, their actions would be opposite to the 
actions of E2. Furthermore, we hypothesize that the stimulatory effects of E2 on ECs 
are, at least in part, due to the down-regulation of miR-193a and miR-221. To study 
this, we first confirmed the role of miR-221 and examined the effects of miR-193a on 
HUVEC vasculogenesis, migration and proliferation using synthetic Mimics and 
Antimirs to specifically modulate the expression of miRNAs. Second, we compared 
the effects of miRNA inhibition with the effects of E2. Finally we investigated the 
effects of miR-193a and miR-221 overexpression after treatment of E2.  
5.2.1 Mimics and Antimirs dysregulate the expression of miRNAs 
To determine the role of miR-193a and miR-221 in HUVECs, the cellular levels of 
these miRNAs were increased using miRNA Mimics (small double-stranded RNA 
molecule with the same sequence as the respective miRNA, thus able to “mimic” 
native miRNAs). Inhibition of both miRNAs was achieved using the respective miRNA 
Antimirs (single stranded RNA molecules designed to specifically bind endogenous 
miRNA molecules and prevent their activity). Both Mimics and Antimirs can be 
introduced into cells using transfection and enable detailed study of miRNA biological 
effects.  
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Transfection success was assessed using Dy547-labelled controls and quantified 
using flow cytometry. Transfection efficiency was 91±3.1% for the Dy547-labelled 
Control Mimic and 88±4.6% for the Dy547-labelled Control Antimir in HUVECs 
(Figure 18A). Representative images were taken with a fluorescence microscope to 
visualize the transfection efficiency (Figure 18B).  
 
Figure 18: Transfection efficiency of miRNA Mimics and Antimirs. Cells were 
transfected with 25 nM of Dy547-labelled Control Mimic (MC-Dy547) or 25 nM of Dy547-
labelled Control Antimir (AC-Dy547) using Lipofectamine 2000 for 6 hr in the absence of 
antibiotics and serum. Panel A: The percentage of Dy547-positive cells was measured using 
flow cytometry. Panel B: Representative images were taken using bright field and 
fluorescence microscopy (Red = Dy547-labeled Mimic or Antimir; blue = Hoechst33342 
stain). n=3. 
We further confirmed optimal transfection conditions by means of a Positive Control 
Mimic specifically targeting GAPDH. Protein expression of GAPDH was reduced by 
~40% (n.s.) 24 hr post-transfection and by ~75% (p<0.05) at 48 hr and 72 hr after 
transfection with the positive Control Mimic (Figure 19). 
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Figure 19: Confirmation of optimal Mimic transfection conditions. HUVECs transfected 
with 25 nM GAPDH-targeting Positive Control Mimic (MC+), Negative Control (MC-) or mock 
transfected (C) were kept in growing media for 24 hr, 48 hr and 72 hr prior to cell lysis and 
analysis of GAPDH protein expression using Western blot. β-Actin was used as a loading 
control. n=3, *p<0.05 compared to MC-. 
In order to confirm the alterations in miRNA levels by the Mimics and Antimirs, we 
isolated RNA from transfected cells and determined miR-193a as well as miR-221 
levels by RT-qPCR (Figure 20). Both miR-193a and miR-221 Mimics (M193a and 
M221, respectively) substantially increased the levels of the respective miRNA after 
24 hr, 48 hr and 72 hr. Transfection with the Antimir of miR-193a resulted in a time 
dependent reduction in miR-193a levels, which was significant after 72 hr (32±9.78% 
reduction, p<0.05). In case of miR-221, its levels were inhibited by ~50% (p<0.05) at 
each tested time point by its Antimir.  
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Figure 20: Transfection with Mimics and Antimirs changes the level of the respective 
miRNA. HUVECs were transfected either with 25 nM miR-193a Mimic (M193a) or miR-193a 
Antimir (A193a; Panel A) or 25 nM miR-221 Mimic (M221) or miR-221 Antimir (A221; Panel 
B) and the respective negative controls (MC, Mimic Control; AC, Antimir Control). The cells 
were kept in growing media 24 hr, 48 hr and 72 hr post-transfection before RNA was 
extracted and the miRNA levels determined by RT-qPCR using TaqMan miRNA assays. The 
results were normalized to U48 and U49. n=3, *p<0.05 compared to the respective control. 
5.2.2 miR-193a and miR-221 inhibit HUVEC function 
We first confirmed the inhibitory role of miR-221 on EC function. Transfection of 
HUVECs with miR-221 Mimic significantly reduced capillary formation in a matrigel-
based assay by 39±8% (Figure 21A). Moreover, increased levels of miR-221 
inhibited cell migration by 25±8% (p<0.05) as assessed by an in vitro wound closure 
assay (Figure 21B). Finally we found that HUVEC proliferation was reduced (from 
100±2% to 75±4%, p<0.05; Figure 21C).  
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Figure 21: miR-221 overexpression inhibits EC function. Prior to use in various assays, 
HUVECs were transfected with miR-221 Mimic (M221) or Control Mimic (MC). Panel A: 
Microvessel formation was investigated using matrigel-based assay. HUVECs were allowed 
to form tube-like structures for 16-18 hr, before tube length was measured. 
Photomicrographs depict representative images under each treatment condition. Panel B: 
Migration was investigated by a wound closure assay. Images represent scratch wounds at 
time 0 (T0) and after 24 hr (T24). Panel C: Proliferation was assessed by counting of the 
cells 3 days after transfection. n=3, *p<0.05 compared to the respective control. 
In parallel experiments, we investigated the role of miR-193a in ECs. Analogous to 
miR-221, miR-193a Mimic significantly inhibited the formation of capillaries in the 
matrigel-based assay by 25±6% (Figure 22A). Further M193a decreased HUVEC 
migration, as wound closure was reduced by 25±11% (p<0.05; Figure 22B), and 
reduced cell proliferation (from 100±2% to 74±4%, p<0.05; Figure 22C).   
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Figure 22: miR-193a overexpression inhibits EC function. Prior to use in various assays, 
HUVECs were transfected with miR-193a Mimic (M193a) or Control Mimic (MC). Panel A: 
Microvessel formation was investigated using matrigel-based assay. HUVECs were allowed 
to form tube-like structures for 16-18 hr and tube length was measured. Photomicrographs 
depict representative images under each treatment condition. Panel B: Migration was 
investigated by a wound closure assay. Images represent scratch wounds at time 0 (T0) and 
after 24 hr (T24). Panel C: Proliferation was assessed by counting of the cells 3 days after 
transfection. n=3, *p<0.05 compared to the respective control. 
Since inhibition of capillary formation, migration and proliferation could be a result of 
impaired cell viability, we verified whether overexpression of miR-221 or miR-193a 
increases cell death. Interestingly, neither of the two miRNAs affected cell viability, as 
assessed by MTT test and propidium iodide (PI) staining followed by flow cytometry 
analysis (Figure 23A and 23B). M221 showed only 6±2% (n.s.) and M193a 5±2% 
(n.s.) difference in MTT absorbance compared to the transfection of the cells with the 
Control Mimic. These results were confirmed by PI staining: MC displayed 7.7±0.4%, 
M221 had 6.1±0.7% and M193a showed 6.9±0.6% PI positive cells.  
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Figure 23: miR-221 and miR-193a overexpression does not affect EC survival. HUVECs 
were transfected with miR-221 Mimic (M221), miR-193a Mimic (M193a) or the Control Mimic 
(MC) and cultured in growing media for 24 hr after transfection. Panel A: For MTT assay the 
cells were incubated 1 hr with 0.5 mg/ml MTT prior to absorbance measurement. Panel B: 
For PI staining the cells were trypsinized, incubated for 5 minutes with 0.2 μg/ml PI and 
analyzed for viability with a flow cytometer. The percentage of dead cells is indicated. n=3.  
5.2.3 miR-193a and miR-221 Antimirs mimic the effects of E2  
As expected, down-regulation of the miRNAs by the Antimirs showed opposite 
outcomes in respect to the previously shown up-regulation by the Mimics. Capillary 
formation was significantly increased by A193a and A221, from 100±1% to 139±13% 
and 126±9%, respectively (Figure 24A and 24B). Moreover, neutralization of miR-
193a and miR-221 with the respective Antimirs stimulated wound closure/ cell 
migration by 47±9% and 51±15%, respectively (p<0.05; Figure 24C and 24D). 
Furthermore, the Antimirs significantly induced cell proliferation by 21±3% (A193a) 
and 25±2% (A221; Figure 24E and 24F).  
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Figure 24: miR-193a and miR-221 down-regulation stimulates vasculogenesis, 
migration and proliferation in HUVECs. Prior to being employed for various assays, 
HUVECs were transfected with miR-193a Antimir (A193a), miR-221 Antimir (A221) or the 
Control Antimir (AC). Panel A and B: Tube formation was investigated using matrigel-based 
assay. HUVECs were allowed to form tube-like structures for 16-18 hr and tube length was 
measured. Photomicrographs depict representative images for each condition. Panel C and 
D: Migration was investigated by a wound closure assay. Images represent scratch wounds 
at time 0 (T0) and after 24 hr (T24). Panel E and F: Proliferation was assessed by counting 
of the cells 3 days after transfection. n=3, *p<0.05 compared to the respective control. 
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As for the Mimics, we assessed the role of the Antimirs on cell viability using MTT 
assay and PI staining followed by flow cytometry analysis (Figure 25A and 25B). We 
found that silencing of miR-193a and miR-221 did not influence MTT absorbance or 
the profile of the PI-stained cells. The percent of non-viable cells in AC, A221 and 
A139a was 5.9±0.2%, 6.1±3% and 5.7±0.2%, respectively.  
 
Figure 25: miR-221 and miR-193a down-regulation does not affect EC survival. 
HUVECs were transfected with the Antimir for miR-221 (A221), miR-193a (A193a) or Control 
Antimir (AC) and cultured in growing media for 24 hr after transfection. Panel A: For MTT 
assay the cells were incubated 1 hr with 0.5 mg/ml MTT prior to absorbance measurement. 
Panel B: For PI staining the cells were trypsinized, incubated for 5 minutes with 0.2 μg/ml PI 
and analyzed for viability in a flow cytometer. The percentage of dead cells is indicated. n=3. 
Down-regulation of miR-221 and miR-193a in HUVECs had similar outcomes as 
treatment with E2, which is known to positively influence the endothelium through 
induction of EC recovery. Indeed, E2 stimulated capillary formation (from 100±9% to 
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137±9%, p<0.05) and induced wound closure (from 100±4 to 131±8%, p<0.05; 
Figure 26A and 26B). Further, E2 significantly induced cell proliferation by 73±10% 
(Figure 26C).  
 
Figure 26: E2 induces EC recovery. HUVECs were treated with 10 nM E2 or DMSO 
vehicle as a control (C) before being used in different assays. Panel A: Microvessel 
formation was investigated using matrigel-based assay. Cells were allowed to form tube-like 
structures for 16-18 hr. Tube length was measured microscopically. Photomicrographs depict 
representative images for each condition. Panel B: Migration was investigated by a wound 
closure assay. Images represent scratch wounds at time 0 (T0) and after 24 hr (T24). Panel 
C: Proliferation was assessed by counting of the cells on day 3 after treatment. n=3, *p<0.05 
compared to the respective control. 
5.2.4 miR-193a and miR-221 abrogate the protective actions of E2 
Based on our observations that E2 inhibits miR-193a and miR-221 expression and 
that down-regulation of both miRNAs mimics the effects of E2 on HUVECs, we 
hypothesized that modulation of miR-193a and miR-221 by E2 participates in 
mediating the protective effect of E2 in ECs. In order to verify this hypothesis, the 
effect of E2 was assessed and compared in HUVECs overexpressing miR-193a or 
miR-221. Indeed, the stimulatory effect of E2 on capillary formation was significantly 
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inhibited in HUVECs transfected with M193a (from 133±17% to 88±9%); Figure 27A) 
or M221 (from 137±9% to 85±13%; Figure 27B).  
 
Figure 27: miR-193a and miR-221 overexpression reduces the angiogenic actions of 
E2 in HUVECs. Cells were transfected with Control Mimic (MC), miR-193a Mimic (M193a; 
Panel A) or miR-221 Mimic (M221; Panel B) prior to analysis of microvessel formation. Cells 
were incubated for 30 minutes with and without 10 nM E2 in serum free media before plating 
on matrigel. Tube length was measured after 16-18 hr. Figures depict representative 
photomicrographs. n=3, *p<0.05 compared to the respective control, §p<0.05 as indicated. 
Likewise, the stimulatory effect of E2 on migration was significantly inhibited by up-
regulation of both miR-193a (from 132±7% to 75±16%; Figure 28A) and miR-221 
(from 125±5% to 82±12%; Figure 28B). 
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Figure 28: miR-193a and miR-221 overexpression abrogates the mitogenic actions of 
E2 in HUVECs. Cells were transfected with Control Mimic (MC), miR-193a Mimic (M193a; 
Panel A) or miR-221 Mimic (M221; Panel B) before assessing migration by wound closure 
assay. HUVECs were scratched before treatment with 10 nM E2 for 24 hr. Images represent 
scratch at time 0 (T0) and 24 hr later (T24). n=3, *p<0.05 compared to the respective control, 
§p<0.05 as indicated. 
Moreover, in support of our hypothesis that down-regulation of miR-193a and miR-
221 by E2 mediates the protective effect of E2 in HUVECs, we found that the 
angiogenic actions of E2 were not enhanced after down-regulation of the miRNAs 
with Antimirs. E2 induced tube formation from 100±2% to 133±15% (p<0.05) in cells 
transfected with Control Antimir, whereas in combination with A193a (Figure 29A) or 
A221 (Figure 29B) tube formation increased non-significantly from 133±15% to 
151±25% (n.s.) and to 143±14% (n.s.), respectively.  
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Figure 29: miR-193a and miR-221 down-regulation does not enhance the angiogenic 
actions of E2 in HUVECs. Cells were transfected with Control Antimir (AC), miR-193a 
Antimir (A193a; Panel A) or miR-221 Antimir (A221; Panel B) prior to analysis of microvessel 
formation. Cells were incubated for 30 minutes with and without 10 nM E2 in serum free 
media before plating on matrigel for 16-18 hr. Figures depict representative 
photomicrographs. n=3, *p<0.05 compared to the respective control. 
5.2.5 miR-193a and miR-221 do not have additive effects  
Since both miRNAs have a similar inhibitory role in HUVECs, we examined the effect 
of the joint overexpression of the two miRNAs on microvessel formation (Figure 30A) 
and wound closure (Figure 30B). We found that, similar to the individual Mimics, the 
combination of the Mimics significantly reduced both microvessel formation and 
wound closure by 37±5% or 20±3%, respectively. Importantly, there was no additive 
effect when compared to the individual Mimics M193a and M221, which inhibited 
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microvessel formation by 48±4% and 45±4%, respectively (p<0.05), and decreased 
wound closure by 18±5% and 19±7% respectively (p<0.05).  
 
Figure 30: Combined miR-193a and miR-221 overexpression has no additive effect. 
Cells were transfected with either 25 nM Control Mimic (MC), miR-221 Mimic (M221) or miR-
193a Mimic (M193a) or with a combination of M221 and M193a (12.5 nM each). Panel A: 
Microvessel formation. Panel B: wound closure. n=3, *p<0.05 compared to control. 
5.2.6 Discussion 
The first aim of this part of the study was to confirm the inhibitory role of miR-221 on 
HUVEC vasculogenesis, migration and proliferation and to investigate the effect of 
miR-193a on EC function. Based on the evidence of an anti-proliferative role of miR-
193a in several cancer cells [238-247], and the fact that E2 down-regulates the 
expression of both miR-193a and miR-221, we assumed that miR-193a has 
comparable physiological effects as miR-221 and that these are opposite to the 
actions of E2. We further hypothesized that down-regulation of miR-193a and miR-
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221 by E2 mediates its stimulatory effects on EC proliferation, migration and 
vasculogenesis.  
Indeed, we confirmed that miR-221 increases EC dysfunction and provide the first 
evidence for a role of miR-193a in vascular cells. Similar to miR-221 overexpression, 
the up-regulation of miR-193a by the specific Mimic impaired HUVEC activity, 
reducing tube formation in the matrigel assay, wound closure and proliferation. The 
role of miR-193a and miR-221 in ECs is further supported by the contrasting results 
obtained following miRNA inhibition, including enhancement of tube formation, 
wound closure and proliferation. Moreover, down-regulation of both miRNAs 
promoted HUVEC activity similar to the treatment with E2. Finally, we demonstrate 
that overexpression of miR-193a and miR-221 abrogates E2-induced vasculogenesis 
and migration by HVUECs, suggesting that down-regulation of these miRNAs 
contributes to the protective effects of E2 in ECs.  
In order to study the physiological role of the miRNAs we employed miRNA Mimics or 
Antimirs. Although HUVECs are notoriously difficult to transfect and susceptible to 
the toxicity of transfection reagents, lipofection yielded very good transfection 
efficiency with little cell toxicity. Successful transfection of HUVECs was confirmed by 
the inhibition of GAPDH protein expression using a Positive Control miRNA Mimic 
specifically targeting GAPDH. These results show that the Mimic is efficiently 
incorporated into RISC, which is required for inhibiting the expression of the target 
genes, suggesting that all transfected miRNA mimics may be functionally active. We 
further used RT-qPCR to confirm the uptake of the Mimics and Antimirs and their 
maintenance in the cells for the time of the longest assay. The level of both miRNAs 
was dramatically increased by the Mimics; however, this might give a false 
impression about miRNA levels as location and functionality of the miRNA cannot be 
evaluated by RT-qPCR. Although RT-qPCR is widely used to test miRNA inhibition 
by the Antimirs, it might also be problematic, as the antisense can inhibit the qPCR 
reaction. Moreover, inhibition of miRNA activity has been shown to occur without 
degradation of the miRNA [252, 253]. We found that miR-221 was significantly 
reduced after transfection with the Antimir, while miR-193 was not. Nevertheless, 
miR-193a Antimir stimulated HUVEC function in the biological assays similar to miR-
221 Antimir, suggesting that miRNA activity is successfully inhibited though without 
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changes in miRNA levels. However, off-target effects of the miRNAs cannot be 
excluded. 
We demonstrated that miR-221 decreases tube formation, wound closure and 
proliferation in HVUECs. Moreover, we provided the first evidence that miR-193a is 
involved in the regulation of EC functions. Indeed, miR-193a overexpression inhibited 
vasculogenesis, migration and proliferation of HUVECs similar to miR-221. 
Accordingly, inhibition of both miRNAs using an Antimir stimulated HUVEC functions.  
miR-221 is highly expressed in HUVECs [254], suggesting a critical role of this 
miRNA in the regulation of EC function. Although most of the studies support our 
findings that miR-221 inhibits proliferation, migration and vasculogenesis of ECs 
[215, 221], the anti-angiogenic properties of miR-221 are restricted to mature human 
ECs. Indeed, in embryonic ECs miR-221 induces angiogenesis and promotes 
proliferation and migration of tip ECs in sprouting neovessels [255]. Moreover, in 
miR-221-deficient zebrafish embryos, proliferation of ECs is blocked [256], 
suggesting that the role of miR-221 greatly varies depending on the developmental 
stages and microenvironment. Since the function of miR-193a has never been 
investigated in association of vascular cells or angiogenesis, our findings that miR-
193a regulates EC functions, including tube formation, are novel and of potential 
clinical relevance.  
Proliferation, migration and vasculogenesis are all processes, which are influenced 
by cell viability, and their inhibition may result from increased apoptosis. Therefore, 
we further investigated the effect of miR-193a and miR-221 on HUVEC survival. The 
impact of miR-221 on EC survival is controversial. Previous research has 
demonstrated that miR-221/222 induces EC apoptosis. Liu et al. demonstrated that 
miR-221/222 inhibits proliferation, migration and cell survival in serum deprived 
condition [230]. Moreover, miR-221/222 has been reported to exert anti-angiogenic, 
anti-inflammatory and pro-apoptotic effects in HUVECs by direct targeting of several 
genes including c-Kit [215] and Ets-1 [257] and indirectly reducing eNOS expression 
[258]. In contrast, Qin et al. proposed an anti-apoptotic role for miR-221/222 in ECs. 
Indeed, they showed that miR-221/222 is significantly down-regulated in HUVECs 
exposed to ox-LDL [259] and that miR-221/222 overexpression decreases ox-LDL-
induced HUVEC apoptosis, while miR-221/222 inhibition increased it [260]. In support 
of these results, overexpression of miR-221/222 has been shown to be associated 
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with several human cancers, including glioblastoma, hepatocellular carcinoma, 
breast, prostate, pancreatic and gastric cancer. In tumor cells, miR-221/222 regulated 
cell survival by directly targeting cell cycle regulators, including p27 and p57, tumor 
suppressor genes, i.e. PTEN, transcription factors and several pro-apoptotic proteins 
such as Puma and Bim [261]. The role of miR-193a for EC survival has not yet been 
investigated; nevertheless, its pro-apoptotic functions are reported in several tumors, 
including melanoma, hepatocellular carcinoma, acute myeloid leukemia, breast and 
prostate cancer [245]. Overexpression of miR-193a and miR-193b induced activation 
of caspase 3/7 and resulted in apoptotic cell death of ovarian cancer cells [238, 262-
264]. In this study, we could not detect significant changes in cell viability after 
modulation of miR-193a or miR-221, suggesting that they do not affect apoptosis in 
ECs. However, we used indirect methods to study the effect of the miRNAs on cell 
survival and did not specifically measure apoptosis. Therefore, the analysis of 
apoptosis using a specific marker, such as Annexin V or TUNEL staining, might give 
a better answer on how miR-193a and miR-221 influence EC function. Finally, the 
incongruity about the role of miR-221 on cell viability indicates that the activity of 
miRNAs might strongly depend on the cell type and cellular environment, thus it is 
feasible that, under our specific condition, miR-221 and miR-193a do not affect cell 
survival. 
Endothelial damage and dysfunction are part of the underlying causes for 
atherosclerosis and CVD. E2 exerts its protective effects by promoting EC 
vasculogenesis, migration and proliferation, thus showing the same outcome as 
inhibition of miR-193a and miR-221. Indeed, re-expression of the miRNA after down-
regulation by E2 treatment abrogated E2-induced tube formation and promotion of 
wound closure. These findings suggest that down-regulation of miR-193a and miR-
221 by E2 participates in the E2-mediated stimulatory effects on HUVECs. Moreover, 
we observed no additive induction of tube formation after E2 stimulation and 
simultaneous inhibition of the miRNAs by the Antimirs. These findings support our 
hypothesis and indicate that the down-regulation of either miR-193a or miR-221 by 
E2 may be sufficient to abrogate the anti-angiogenic effects of these two miRNAs.  
The mechanisms by which E2 supports EC functions include several intracellular 
pathways. We postulate that miR-193a and miR-221 modulate molecules 
downstream of E2 and thus mediate its actions on ECs function. Since miRNAs 
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target numerous mRNAs in multiple pathways, it is possible that miR-193a and miR-
221 regulate EC function via the same or different pathways. To test this we 
overexpressed both miRNAs simultaneously and observed their effect in the matrigel 
tube formation assay and scratch wound closure assay. We found no additive 
inhibitory effect when the two Mimics were combined compared to the individual 
miRNAs, suggesting that miR-193a and miR-221 potentially target the same genes or 
different genes in the same pathway. However, the outcomes of these experiments 
should be interpreted with caution, as compared to cells treated with individual 
miRNAs Mimics, we did no assess their uptake and activity in cells following 
combined treatment. Several factors may be responsible for the lack of additive 
effectd observed and could and should be experimentally verified as follows. First, 
the possibility that only one miRNA is efficiently transfected into the cells can be 
easily tested using RT-qPCR analysis. Second, since we employed only 12.5 nM of 
each miRNA for the co-transfection, and 25 nM of each miRNA alone, it is possible 
that the additive effect on the stimulation of HUVEC tube formation and wound 
closure were masked. Therefore, the effects of 12.5 nM of each miRNA Mimics on 
the function of HVUECs needs to be examined to exclude concentration dependent 
effects. A third issue may be the competition between the co-administered miRNAs 
for the binding of AGO2, the limiting component of the RISC complex, which may be 
responsible for the absence of additive effects [265]. Hence, it is recommended to 
confirm the functional activation of both miR-193a and miR-221 Mimics. The activity 
of the miRNAs can be verified using luciferase or GFP reporters, designed with a 
3’UTR sequence, which are targeted by either one or the other miRNA, and 
comparing the output after transfection with negative control, miR-193a Mimic and 
miR-221 alone and the combination of both Mimics. Another experiment to 
demonstrate the presence of the miRNAs in the RISC complex would be to isolate 
the overall small RNAs bound to AGO2 using RNA binding immunoprecipitation 
(RIP), and examine the presence of miR-193a and miR-221 by RT-qPCR [60, 266]. 
In conclusion, we propose that miR-193a and miR-221 down-regulation by E2 
suppresses the inhibitory actions of miR-193a and miR-221 on proliferation, migration 
and vasculogenesis, thus imparting a promoting role for E2 on these same 
processes. Moreover, we speculate that miR-193a and miR-221 modulate mRNAs of 
genes within the same pathways, which are important for E2-mediated endothelial 
protection.  
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5.3 Intracellular mechanisms of E2-regulated miRNAs in ECs 
Objective 
Our findings in HUVECs provide evidence that down-regulation of miR-193a and 
miR-221 mediates the growth and vasculogenic effects of E2 and may contribute to 
its vaso-protective actions. Hence, our next aim was to investigate the underlying 
intracellular mechanisms potentially involved. The PI3K/ Akt pathway, VEGF-A and 
the ALK1/ SMAD1/5/8/ Id1 pathway are among important E2-regulated pathways in 
vasculogenesis; therefore, we assessed whether they are modulated by miR-193a 
and miR-221.  
Introduction 
In the previous section (5.2) we demonstrated that miR-193a and miR-221 inhibit 
proliferation, wound closure and tube formation in HUVECs. Moreover, 
overexpression of the individual miRNAs abolished the stimulatory effects of E2 on 
HUVEC function, suggesting that E2 induces vasculogenesis and migration of ECs 
by down-regulating the expression of miR-193a and miR-221. Furthermore, 
combined treatment with miR-193a and miR-221 Mimics did not enhance the 
inhibitory effects seen with the individual miRNAs on tube formation and wound 
closure, suggesting that they potentially target the same intracellular pathway.  
E2 stimulates EC proliferation, migration and tube formation via activation of PI3K/ 
Akt signaling [136, 151-153]. Moreover, E2-induced angiogenesis is dependent on 
VEGF [135, 154]. Another angiogenic pathway involved is the ALK1/ SMAD1/5/8/ Id1 
signaling pathway [170, 171]. Based on our findings that down-regulation of miR-
193a and miR-221 by E2 potentially mediates its vasculogenic actions in ECs, we 
postulate that they have an inhibitory role on one or more of these signaling 
pathways. We therefore investigated whether miR-193a and miR-221 modulate PI3K/ 
Akt signaling, VEGF and/ or ALK1/ SMAD1/5/8/ Id1 signaling and whether these 
pathways contribute to the modulatory actions of miR-193 and miR-221 on 
vasculogenesis. 
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5.3.1 The role of the PI3K/ Akt pathway in mediating the effects of E2 
and miR-193a and miR-221 in vasculogenesis 
The PI3K/ Akt pathway is a recognized pro-angiogenic pathway and plays a role in 
mediating several actions of E2 in different cell types, including ECs. We first 
confirmed that treatment of HUVECs with E2 (10 nM) increased Akt phosphorylation 
from 100±49% to 212±1% (p<0.05; Figure 31A). Next, we used the pharmacological 
PI3K inhibitor LY294002 (LY; 5 M) to assess the role of E2-induced Akt signaling in 
mediating vasculogenesis in HUVEC. Indeed, we found that LY significantly 
abrogated the stimulatory effect of E2 from 186±27% to 70±8% (Figure 31B), thus 
confirming that activation of the PI3K/ Akt pathway is important for E2-induced 
microvessel formation.  
 
Figure 31: E2 induces vasculogenesis via the PI3K/ Akt pathway. Panel A: 
Representative Western blots and bar graphs for Akt phosphorylation (pAkt, Ser473) after 
treatment with 10 nM E2 for 45 minutes. Total Akt and β-actin were used as loading controls. 
Panel B: The PI3K inhibitor LY294002 (LY, 5 M) abrogates the inducing effect of E2 on 
tube formation. HUVECs were pre-treated for 30 minutes with LY and subsequently for 30 
minutes with 10 nM E2 and plated on the matrigel. Tube length was measured after 16-18 hr. 
Photomicrographs show representative images for each treatment. n=3, *p<0.05 compared 
to the respective control, §p<0.05 as indicated. 
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To investigate the role of PI3K/ Akt in miR-221 and miR-193a mediated inhibition of 
tube formation, we examined whether their overexpression was able to produce 
changes in Akt phosphorylation. Indeed, we found that both miR-221 and miR-193a 
Mimics significantly reduced Akt phosphorylation from 100±6% to 59±8% and to 
75±8%, respectively (Figure 32A and 32B). To further confirm the contribution of 
PI3K/ Akt as part of the mechanism, we assessed the microvessel formation in the 
presence or absence of the PI3K inhibitor LY after down-regulation of the miRNAs by 
the respective Antimirs (Figure 32C and 32D). Interestingly, the stimulatory effect 
produced by A221 through down-regulation of the anti-angiogenic miR-221 is 
abrogated by treatment of the cells with LY: from 161±18% to 84±21% (p<0.05). We 
found similar results by combining transfection of the cells with Antimir A193a and LY 
treatment: microvessel formation was reduced form 146±22% to 81±17% (p<0.05). 
These results suggest a role for the PI3K/ Akt pathway in the regulation of 
vasculogenesis by miR-193a and miR-221. 
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Figure 32: miR-221 and miR-193a inhibit vasculogenesis via the PI3K/ Akt pathway. 
Panel A and B: Representative Western blots and bar graphs for Akt phosphorylation (pAkt, 
Ser473) after transfection with Control Mimic (MC), miR-221 Mimic (M221) or miR-193a 
Mimic (M193a). Total Akt and β-actin were used as loading controls. Panel C and D: The 
PI3K inhibitor LY294002 (LY, 5 M) abrogates the stimulatory effects of the Antimirs on tube 
formation. Cells were transfected with Control Antimir (AC) or Antimirs for miR-221 (A221) or 
miR-193a (A193a) and treated 30 minutes with LY prior to being plated on matrigel. Tube 
length was measured after 16-18 hr. Photomicrographs show representative images for each 
treatment. n=3, *p<0.05 compared to the respective control, §p<0.05 as indicated. 
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5.3.2 The role of VEGF-A in mediating the effects of E2 and miR-193a 
and miR-221 in vasculogenesis  
The pro-angiogenic properties of E2 are also due to induction of VEGF-A, whose 
expression was significantly increased following 45 minutes E2-treatment from 
100±4% to 179±45% (p<0.05; Figure 33A). Moreover, microvessel formation was 
abrogated when the cells where pre-treated with a neutralizing antibody for VEGF-A, 
from 147±19 to 99±8% (p<0.05; Figure 33B). As a positive control, HUVECs were 
treated with VEGF-A alone or in combination with its neutralizing antibody. VEGF-A 
significantly induced microvessel formation by from 100±10% to 142±8% and this 
stimulatory effect was inhibited by the VEGF-A neutralizing antibody (from 142±% to 
97±15%, p<0.05).  
 
Figure 33: E2 dependent vasculogenesis involves VEGF-A. Panel A: Representative 
Western blot and bar graph of VEGF-A protein expression after 45 minutes treatment with 10 
nM E2). β-Actin was used as loading control. Panel B: The VEGF-A specific neutralizing 
antibody (VEGFab, 500 ng/ml) abrogates the stimulatory effects of E2 and VEGF-A on tube 
formation. HUVECs were pre-treated for 30 minutes with VEGFab before a 30 minute 
treatment with E2 (10 nM) or VEGF-A (100 ng/ml). Cells were plated on matrigel, and tube 
length was measured after 16-18 hr. Photomicrographs show representative images for each 
treatment. n=3, *p<0.05 compared to the respective control, §p<0.05 as indicated. 
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To assess the role of VEGF-A in miR-221 and miR-193a mediated inhibition of 
microvessel formation, we examined the effect of miRNA Mimics on VEGF-A 
expression in HUVECs. Both miR-221 and miR-193a significantly reduced VEGF-A 
expression from 100±3% to 51±5% and 69±4%, respectively (p<0.05; Figure 34A 
and 34B). In agreement with these actions, treatment with the Antimirs induced tube 
formation and this effect was blocked in the presence of the VEGF-A neutralizing 
antibody (Figure 34C and 34D). A221-induced microvessel formation was decreased 
from 142±6% to 85±7% (p<0.05), while VEGFab inhibited A193a-induced tube 
formation from 134±8% to 95±13% (p<0.05). These results suggest that VEGF-A 
plays a role in the regulation of vasculogenesis by miR-193a and miR-221. 
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Figure 34: miR-221 and miR-193a inhibit vasculogenesis via VEGF-A. Panel A and B: 
Representative Western blots and bar graphs of VEGF-A protein expression after 
transfection of the cells with Control Mimic (MC), miR-221 Mimic (M221) or miR-193a Mimic 
(M193a). β-Actin was used as loading control. Panel C and D: The VEGF-A neutralizing 
antibody (VEGFab, 500 ng/ml) abrogates the inducing effects of the Antimirs on tube 
formation. HUVECs were transfected with Control Antimir (AC), miR-221 Antimir (A221) or 
miR-193a Antimir (A193a) and left in growing media for 24 hr before 30 minutes treatment 
with VEGFab. Cells were plated on matrigel, and tube length was measured after 16-18 hr. 
Photomicrographs show representative images for each treatment. n=3, *p<0.05 compared 
to the respective control, §p<0.05 as indicated. 
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5.3.3 The role of ALK1/ SMAD1/5/8/ Id1 pathway in mediating the 
effects of E2 and miR-193a and miR-221 in vasculogenesis 
E2 is known to induce microvessel formation via the ALK1/ SMAD1/5/8/ Id1 pathway. 
Activation of ALK1 leads to SMAD1/5/8 phosphorylation, which in turn leads to 
increased expression of its downstream target Id1, the protein responsible for 
inducing migration and tube formation in ECs. In HUVECs treated with E2 we found 
increased expression of ALK1 protein (from 100±11% to 137±11%, p<0.05; Figure 
35A) as well as a significant induction of Id1 from 100±13% to 309±11% (Figure 
35B). The role of the ALK1/ SMAD1/5/8/ Id1 pathway was further confirmed by the 
fact that Alk1fc, a specific antagonizing antibody for ALK1, abrogated E2-induced 
microvessel formation (from 176±33% to 115±8%, p<0.05). Stimulation by TGFβ was 
used as a positive control, since it is well documented to activate the ALK1/ 
SMAD1/5/8 pathway. Indeed, Alk1fc repressed TGFβ induced microvessel formation 
from 209±20% to 82±33% (p<0.05: Figure 35C). 
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Figure 35: E2 induces vasculogenesis via the ALK1/ Id1 pathway. Panel A and B: 
Representative Western blots and bar graphs of ALK1 and Id1 protein expression after 45 
minutes treatment with 10 nM E2. β-Actin was used as loading control. Panel C: ALK1 
specific antagonizing antibody (ALK1fc, 100 ng/ml) abrogates the effects of E2 and TGFβ on 
tube formation. HUVECs were pre-treated 30 minutes with ALK1fc before 30 minutes 
treatment with E2 (10 nM) or TGFβ1 (1 ng/ml) and plated on matrigel. Tube length was 
measured after 16-18 hr. Photomicrographs show representative images for each treatment. 
n=3, *p<0.05 compared to the respective control, §p<0.05 as indicated. 
Since we were interested in assessing whether miR-221 and miR-193a mediate the 
effects of E2 in ECs, we examined their effect on the ALK1/ SMAD1/5/8/ Id1 
pathway. We found that overexpression of miR-221 by its Mimic M221 repressed 
ALK1 expression (from 100±4% to 51±9%, p<0.05) as well as the downstream target 
Id1 (from 100±11% to 64±9%, p<0.05; Figure 36A and 36B). Similar to miR-221, 
treatment with miR-193a Mimic (M193a) down-regulated ALK1 and Id1 expression 
from 100±10% to 59±8% and to 67±13%, respectively (p<0.05; Figure 36C and 
36D). 
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Figure 36: miR-221 and miR-193a inhibit the ALK1/ Id1 pathway. The representative 
Western blots and bar graphs of ALK1 (Panel A and C) and Id1 (Panel B and D) protein 
expression after transfection of the cells with Control Mimic (MC), miR-221 Mimic (M221) or 
miR-193a Mimic (M193a). β-Actin was used as loading control. n=3, *p<0.05 compared to 
control. 
To further confirm the involvement of the ALK1/ SMAD1/5/8/ Id1 pathway in the effect 
of the miRNAs on E2-induced vasculogenesis, we assessed microvessel formation 
following simultaneous treatment of the cells with the ALK1 inhibitor Alk1fc and 
transfection with the Antimirs (Figure 37A and 37B). The stimulatory effects of A221 
(from 100±6% to 135±12%, p<0.05) and A193a (from 100±6% to 129±9%, p<0.05) 
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were significantly abrogated in both cases by ALk1fc by 57±10% and 42±8%, 
respectively, suggesting that this pathway actively contributes to the regulation of 
microvessel formation by the two miRNAs.  
 
Figure 37: miR-221 and miR-193a inhibit vasculogenesis via the ALK1/ Id1 pathway. 
The ALK1 antagonizing antibody (ALK1fc, 100 ng/ml) abrogates the inducing effects of the 
Antimirs on tube formation. HUVECs were transfected with Control Antimir (AC), miR-221 
Antimir (A221; Panel A) or miR-193a  Antimir (A193a; Panel B) and left in growing media for 
24 hr before 30 minutes treatment with ALK1fc. Cells were plated on matrigel and tube 
length was measured after 16-18 hr. Photomicrographs show representative images for each 
treatment. n=3, *p<0.05 compared to the respective control, §p<0.05 as indicated. 
5.3.4 Discussion 
We investigated the effects of miR-193a and miR-221 on PI3K/ Akt signaling, VEGF 
expression and the ALK1/ SMAD1/5/8/ Id1 pathway, which are known to mediate the 
stimulatory actions of E2 on EC proliferation, migration and vasculogenesis.  
In ECs the PI3K/ Akt signaling axis is activated by a variety of stimuli and regulates 
multiple critical steps in angiogenesis, including endothelial cell survival, migration, 
and tube formation. We first investigated whether E2 stimulates PI3K/ Akt signaling in 
HUVECs and observed an increase in Akt phosphorylation at Serine473 after 
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treatment with E2. Our findings are consistent with the results from previous studies, 
which demonstrated that E2 increases phosphorylation of Akt in ECs and that these 
effects are blocked by the PI3K inhibitors LY294002 and Wortmannin [267, 268]. The 
importance of PI3K/ Akt signaling in estrogen-mediated angiogenesis is well 
established [136, 151, 152]. Our findings that E2 induces Akt phosphorylation and 
tube formation in HUVECs and that these effects are blocked by the PI3K inhibitor 
LY294002 further reconfirms this contention.   
The role of miR-221 in ECs has been extensively studied and we confirmed its anti-
angiogenic action in HUVECs. Moreover, we demonstrated that down-regulation of 
miR-221 potentially mediates the stimulatory actions of E2 on vasculogenesis. Since 
PI3K/ Akt signaling is required for the pro-angiogenic actions of E2, we investigated 
whether miR-221 participates in the regulation of this pathway. Here we provide 
evidence that miR-221 overexpression inhibits the phosphorylation of Akt. Moreover, 
treatment with LY294002 abrogated tube formation following miR-221 knock-down, 
suggesting that miR-221 inhibits vasculogenesis by targeting the PI3K/ Akt pathway 
and may importantly contribute to the vascular repair process. 
It has been reported that the anti-angiogenic properties of miR-221 are mediated 
through the regulation of many targets, including c-Kit, the cell cycle regulator p27, 
transcription factors Ets1, Ets2 [215], zinc finger E-box binding homeobox 2 (ZEB2) 
[269], signal activator and transducer 5A (STAT5a) [270] and endothelial NO-
synthase [209]. In addition, direct effects of miR-221 on the PI3K/ Akt signaling axis 
has been demonstrated in embryonic ECs. miR-221 regulates endothelial tip cell 
migration and proliferation by targeting the PI3K regulatory subunit 1 (PIK3R1) [221]. 
PI3KR1 is the p85α regulatory subunit of the PI3K complex and an essential 
component for PI3K signaling in vascular development [271]. In the absence of 
stimuli, PIK3R1 stabilizes the catalytic subunit, such as p110, of the PI3K signaling 
complex and inhibits its kinase activity. However, PIK3R1 is also required for PI3K 
activity following membrane localization of the PIk3r1/p110 complex and activation by 
a receptor tyrosine kinase [272]. By targeting PIK3R1, miR-221 is likely to alter an 
appropriate balance between regulatory and catalytic subunits. Since PI3KR1 both 
inhibits and is required for PI3K/ Akt activity, it is feasible that miR-221 suppresses 
angiogenesis in mature human ECs through targeting PIK3R1. However, this 
assumption needs to be further verified. In contrast to our findings that miR-221 
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inhibits PI3K/ Akt signaling, miR-221 has been demonstrated to target the negative 
regulator of the pathway, Phosphatase and Tensin Homolog (PTEN), in several 
cancer cell types, i.e. osteosarcoma [273], human glioblastoma [274] and gastric 
carcinoma [275]. Since PTEN suppression would result in increased Akt activity, we 
speculate that PTEN is not inhibited by miR-221 in HUVECs. Given the fact that the 
PI3K/ Akt pathway is activated by upstream receptor tyrosine kinases and interacts 
with other signaling cascades such as MAPK signaling pathways [276, 277], further 
research is necessary to elucidate the mechanisms behind miR-221 mediated 
inhibition of Akt activity. In this regard, several studies provide evidence that miR-221 
inhibits EC proliferation, migration and tube formation through inhibition of stem cell 
factor (SCF) receptor c-Kit [223, 230], and that Akt has an essential role downstream 
of SCF/ c-Kit signaling, as the c-Kit inhibitor STI-571 abrogated Akt phosphorylation 
and SCF-driven tube formation [278]. Moreover, Khella et al. [279] have shown that 
expression of VEGF receptor 2 (VEGFR2) is significantly decreased after miR-221 
overexpression in HUVECs, suggesting that miR-221 blocks relevant signaling 
pathways involved in angiogenesis and cell proliferation by targeting KDR (VEFGR2). 
Hence, these findings suggest that miR-221 might inhibit Akt activity indirectly by 
suppressing SCF/ c-Kit or VEGF signaling.  
Here we provide the first evidence for an inhibitory role of miR-193a in regulating EC 
functions. Overexpression of miR-193a decreased vasculogenesis, migration and 
proliferation of ECs and knock-down of the miRNA showed opposite results. 
Moreover, we demonstrated that the stimulatory actions of E2 on vasculogenesis are 
potentially mediated via down-regulation of miR-193a. Since PI3K/ Akt signaling is 
required for the pro-angiogenic actions of E2, we investigated whether miR-193a 
participates in the regulation of this pathway. Indeed, miR-193a overexpression 
inhibits the phosphorylation of Akt. Further, treatment with LY294002 abrogated tube 
formation seen after miR-193a knock-down, suggesting that miR-193a inhibits 
vasculogenesis by targeting the PI3K/ Akt pathway.  
The association of miR-193a and the PI3K/ Akt pathway has been shown in few 
studies. In acute myeloid leukemia, miR-193a indirectly inhibits PTEN, thus activating 
Akt and contributing to leukemogenesis [264]. However, this is in contrast of the 
inhibitory actions we found in HUVECs. Other evidence of miR-193a association with 
PI3K/ Akt has been shown in non-small-cell lung cancer, where it suppresses its 
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metastasis by targeting the receptor tyrosine-protein kinase ERBB4, a member of the 
EGF receptor subfamily, and inhibiting the downstream PI3K/ Akt cascade [280]. 
These findings suggest that miR-193a actions on PI3K/ Akt signaling depend on the 
cell type. Moreover, we speculate that miR-193a targets molecules upstream of PI3K, 
such as ERBB4 or other receptor tyrosine-protein kinases, resulting in the inhibition 
of PI3K activity. Finally, there is evidence that miR-193a targets c-Kit in myeloid 
leukemia [262] similar to miR-221, thus it is feasible that miR-193a might inhibit PI3K 
activity indirectly via suppressing SCF/ c-Kit or VEGF signaling. 
The activation of Akt leads to phosphorylation of eNOS and NO production, which 
contributes to increased vasodilation and stimulation of angiogenesis [141]. NO 
induces VEGF expression [267, 268], which in turn stimulates the PI3K/ Akt pathway. 
Hence NO and VEGF stimulate each other in a feedback circle until PI3K signaling is 
terminated [144-146, 150].  
Treatment with E2 has been shown to increase VEGF expression in vascular ECs 
[154, 281-283]. Moreover, increased VEGF expression has been associated with E2-
mediated endothelial recovery [284]. Indeed, both VEGF and NO are important 
mediators of estrogenic actions in ECs and there is evidence that estrogen induced 
angiogenesis is dependent on VEGF and NO [135]. Here we confirmed that 
treatment with E2 increases VEGF-A expression. In addition, treatment with a VEGF 
specific neutralizing antibody (VEGFab) abrogated E2-induced vasculogenesis in 
HUVECs, suggesting that VEGF plays indeed an important role in mediating the 
stimulatory actions of E2 in ECs.  
In the current study we show that, in contrast to E2, miR-221 and miR-193a up-
regulation inhibits VEGF-A expression. Furthermore, our observations that 
vasculogenesis induced by the Antimirs neutralizing miR-221 and miR-193a is 
abrogated by VEGFab, suggest that VEGF plays a role in the regulation of tube 
formation by miR-221 and miR-193a in HUVECs. Recently, miR-221 has been shown 
to inhibit the release of NO by inhibiting eNOS expression [209]. Since NO up-
regulates VEGF expression, it is possible that the decrease in VEGF expression is 
due to inhibition of eNOS as well as the suppression of PI3K/ Akt/ eNOS axis. With 
regard to miR-193a, Hua et al. found miR-193a binding sites in the VEGF 3’-UTR, 
thus predicting that miR-193 could putatively target VEGF, based on bioinformatics 
algorithms. However, miR-193a was not differentially expressed in hypoxic compared 
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to control nasopharyngeal carcinoma cells, and therefore the association between 
miR-193a and VEGF was not further investigated [285]. Here we demonstrate that 
miR-193a inhibits VEGF; however, whether this occurs via direct binding to its mRNA 
or via down-regulation of PI3K/ Akt signaling pathway remains unclear and needs to 
be further investigated. The fact that PI3K/ Akt induces eNOS, which in turn up-
regulates VEGF via NO, supports that the inhibitory actions of miR-193a and miR-
221 on PI3K/ Akt may contribute to their inhibitory effects on VEGF and thus tube 
formation. Indeed, inhibition of PI3K/ Akt by LY blocks NO release, VEGF expression 
and angiogenesis [286, 287] and this may contribute to its abrogating actions on 
Antimir induced capillary formation.  
Estrogens regulate TGFβ signaling [169], another prominent pathway in the 
regulation of EC growth, migration and angiogenesis [288]. E2 increased the 
expression of ALK1 and Id1, a downstream target of SMAD1/5/8. Moreover, the 
ALK1 specific antagonizing antibody ALK1fc abrogated E2-induced vasculogenesis, 
confirming previous findings from our laboratory demonstrating that E2 mediates 
vasculogenesis and endothelial growth via the stimulation of ALK1/ Id1 signaling 
[170, 171].  
In the current study we provide the first evidence that miR-221 inhibits ALK1 and Id1. 
We demonstrate that neutralization of miR-221 by its Antimir stimulates 
vasculogenesis, suggesting that the pro-angiogenic actions of ALk1/ Id1 are 
suppressed by miR-221. This notion is supported by the sole evidence provided by 
Rao et al., who reported an association between miR-221 and TGFβ signaling in 
breast cancer cells. In this context, overexpression of miR-221/222 was associated 
with increase of TGFBR2, BMPR2, SMAD1/2/3, Id1 and Id3 expression. Based on 
their findings, Rao et al. conclude that, although it is not clear whether the pathway is 
activated or repressed, the growth inhibitory effects of TGFβ are suppressed by miR-
221/222 [92].  
The role miR-193a in association with TGFβ has not been reported. Here we provide 
the first evidence that overexpression of miR-193 inhibits the expression of both 
ALK1 and Id1, the downstream target of SMAD1/5/8. Moreover, our finding that 
neutralization of miR-193a with its Antimir induces vasculogenesis and that these 
pro-angiogenic actions are blocked in the presence of ALK1fc provide evidence that 
ALK1/ Id1 signaling is involved in the inhibitory actions of miR-193a on 
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vasculogenesis. Taken together, these findings suggest that miR-193 decreases 
vasculogenesis via down-regulation of the pro-angiogenic ALK1/ Id1 signaling. 
Although there is no direct evidence for a role of miR-193a in this pathway, our 
findings are supported by the fact that, based on bioinformatics algorithms such as 
TargetScan [46] and miRIAD [289], ALK1 is a putative target of miR-193a.  
Interestingly, miR-221 and miR-193a showed similar inhibitory effects on all the 
tested pathway proteins, though they do not share the same seed sequence, 
required for pairing to complementary sites within target mRNAs. However, this 
evidence does not exclude that the two miRNA could bind to a same target, although 
at different locations. 
In summary, we confirmed that E2 induces vasculogenesis via the PI3K/ Akt 
pathway, through stimulation of VEGF, and via ALK1/ Id1 signaling. Moreover, we 
provide the first evidence that miR-221 and miR-193a inhibit PI3K activity, VEGF 
expression and both ALK1 and Id1 expression in HUVECs. Further, as outlined in 
Figure 38, we demonstrated that all the investigated pathways are involved in miR-
221 and miR-193a mediated inhibition of vasculogenesis, as tube formation after 
miRNA down-regulation was abrogated by the PI3K inhibitor LY294002, the VEGF 
neutralizing antibody VEGFab and the ALK1 specific antagonizing antibody ALK1fc. 
In addition to the role in angiogenic processes, these pathways are also important for 
EC migration and proliferation. Therefore, based on our results, we postulate that the 
stimulatory effects of E2 on the endothelium is in part mediated via the down-
regulation of miR-221 and miR-193a and the suppression of their inhibitory action on 
PI3K/ Akt, VEGF and ALK1/ Id1. However, the mechanism(s) by which miR-221 and 
miR-193a regulate these signaling pathways need to be further elucidated in order to 
provide a better understanding of miRNA mediated E2-induced endothelial 
protection.  
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Figure 38: Summary of our findings in a simplified schematic representation of the 
pro-vasculogenesis pathways PI3K/ Akt/ VEGF (A) and ALK1/ SMAD1/5/8/ Id1 (B) and 
their regulation by E2. PI3K, Phosphoinositide 3 Kinase; Akt, Protein kinase B; VEGF, 
Vascular Rndothelial Growth Factor; eNOS, endothelial Nitric Oxide Dynthase; NO, Nitric 
Oxide; ALK1, Activin Receptor-Like Kinase1; TGFβ, Transforming Growth Factor β; BMP, 
Bone Morphogenetic Protein; TβR, TGFβ Receptor; Id1, Inhibitor of Differentiation. 
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5.4 E2 regulates miRNAs in SMCs 
Objective 
E2 protects the vasculature by promoting endothelial integrity and function as well as 
by inhibiting vascular SMC proliferation and migration. However, the role of miRNAs 
in mediating these anti-mitogenic actions remains unclear. Hence, under this specific 
aim, we screened for E2-regulated miRNAs in SMCs.  
Introduction 
Apart from promoting EC growth, migration and tube formation, E2 protects the 
vasculature by inhibiting vascular SMC proliferation and migration [124-127, 138], 
which contributes to vascular remodeling leading to occlusion [105]. Although 
miRNAs have been shown to mediate the actions of E2 in several tissues and cell 
lines [88], the role of miRNAs in mediating the effects of E2 on SMCs remains largely 
undefined. In section 5.1-5.3, we provided evidence that E2 regulates two miRNAs in 
HUVECs, miR-221 and miR-193a, and that the beneficial effects of E2 on ECs are 
potentially mediated by these miRNAs.  
Based on our findings and the fact that miRNAs play a role in regulating SMC growth, 
we hypothesize that the anti-mitogenic actions of E2 on vascular SMCs are also 
potentially mediated through the regulation of miRNAs. Hence, under this specific 
aim, we screened for miRNAs that were regulated by E2 in SMCs, by searching the 
literature for interesting miRNAs and subsequently validating the candidates by RT-
qPCR in HCASMCs. 
5.4.1 E2 down-regulates miR-193a and miR-221 in HCASMCs 
E2 protects the vascular system by abrogating the mitogenic and motogenic activities 
of growth factors, such as PDGF-BB. Hence, employing HCASMCs we analyzed the 
effect of E2 on miRNAs following stimulation with PDGF-BB. The cells were treated 
24 hr before RNA extraction and miRNA analyzed by RT-qPCR. We found that 
expression of 3 out of 6 miRNAs that we tested was significantly induced by PDGF-
BB: miR-100.5p, miR-193a.3p and miR-221.3p (from 100% to 233±5%, 172±12%, 
and 189±9%, respectively; Figure 39). Importantly, the PDGF-BB-induced 
expression of these 3 miRNAs was abrogated in HCASMCs simultaneously treated 
with E2, and these effects were concentration-dependent and reached significance at 
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100 nM. In fact, comparing the expression of miR-100.5p, miR-193a.3p and miR-
221.3p after PDGF-BB treatment alone and in the presence of 100 nM E2, the 
expression was reduced by 87±6%, 77±5% and 63±3%, respectively (p<0.05).  
From the other tested miRNAs, our results indicate that miR-222.5p follows a similar 
trend in expression level, showing an increase by PDGF-BB and a concentration 
dependent reduction by E2 treatment (n.s.). Finally, miR-203 and miR-638 were 
unaffected by either PDGF-BB or E2. 
 
Figure 39: E2-regulated miRNAs in HCASMCs. Cells were grown to 60% confluency in 
complete media prior to 24 hr treatment with or without PDGF-BB (20 ng/ml) and 0, 10 and 
100 nM E2. Total RNA was extracted and relative miRNA expression levels were determined 
by RT-qPCR using TaqMan miRNA assays. The results were normalized to U48 and U49. 
n=3, *p<0.05 compared to control, §<0.05 compared to PDGF-BB. 
5.4.2 Discussion 
The protective effects of estrogens in the cardiovascular system are well established 
and include the inhibition of vascular SMC growth and migration and the prevention 
of injury-induced intimal hyperplasia; however, the mechanisms involved remain 
unclear. The role of miRNAs in the vasculature has been extensively studied [193-
195]. Recently, estrogens have been associated with miRNA expression [83, 84] and 
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several studies have shown that E2-regulated miRNAs potentially mediate their 
actions in different tissues, including the vascular system [90-93]. Hence, to assess 
the role of miRNAs in mediating the protective effects of E2 in vascular SMCs, we 
searched the literature for relevant miRNAs and investigated their expression upon 
treatment with E2 in HCASMCs.  
We have found that treatment with PDGF-BB significantly induces the expression of 
miR-100, miR-193a and miR-221 and that E2 inhibits PDGF-BB-induced expression 
of these miRNAs in a concentration dependent manner. The expression of miR-222 
showed a similar trend, though the changes are not significant. The other tested 
miRNAs, miR-203 and miR-638 were unaffected.  
From the 6 miRNAs we tested, 5 were associated with vascular SMC growth: miR-
100, miR-203, miR-221, miR-222 and miR-638. Among these, miR-100, miR-203 and 
miR-638 exhibit anti-mitogenic effects in vascular SMC: miR-100 attenuates murine 
vascular SMC proliferation and migration by suppressing the mammalian target of 
rapamycin (mTOR) [237], miR-203 specifically inhibits mouse aortic SMC 
proliferation [94] and miR-638 is highly expressed in quiescent cells and abrogates 
PDGF-BB-induced cyclin D1 expression, cell proliferation and migration in human 
aortic SMCs [290]. In contrast, miR-221 and miR-222 play a prominent role in the 
vascular tissue by supporting de-differentiation, proliferation and migration of 
vascular SMCs [221-223, 230]. Association with estrogens has been demonstrated 
for miR-203, miR-221, miR-222 and miR-193a. The anti-mitogenic actions of E2 in 
vascular SMCs are mediated by miR-203 [94]. Moreover, there is evidence that E2 
down-regulates miR-193a, miR-221 and miR-222 expression in MCF-7 cells [87, 92, 
93, 291].  
In contrast to the results from Zhao et al. [94] showing that miR-203 mediates the 
effects of E2 in vascular SMCs; we did not observe any change in miR-203 in 
HCASMCs treated with E2. Similarly, we could not confirm the findings from Li et al. 
[290] showing PDGF-BB dependent down-regulation of miR-638. A potential reason 
for the discordant findings might be the difference in cell type and the species of 
origin. Indeed, miR-638 was studied in human aortic SMC, whereas miR-203 was 
analyzed in murine cells.  
The miR-222 gene is part of a gene cluster with the miR-221 gene on the X 
chromosome, and the expression of these miRNAs seems to be co-regulated in 
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some tissues as they share similar nucleotide sequences and are transcribed 
together as a single long non-coding RNA precursor [221, 222]. However, in support 
of our findings, there is evidence for differential regulation of miR-221 and miR-222. 
For instance, Davis et al. [223] showed that miR-221 is strongly induced by PDGF-
BB treatment in PASMCs, while expression of miR-222 was rather decreased. It is 
therefore feasible that correlation of miR-221 and miR-222 expression depends on 
particular cellular/ experimental conditions, cell type and stimuli. 
Among the regulated miRNAs, we found that PDGF-BB up-regulated miR-100, 
suggesting a positive role for this miRNA in proliferation processes. This is in contrast 
to the findings of Grundmann et al. [237], who demonstrated reduced vascular SMCs 
proliferation after transfection of human arotic SMC with pre-miR-100.  
In the studies described in the previous chapters we showed that E2 down-regulates 
miR-193a and miR-221 in HUVECs. Moreover, we discovered that miR-193a inhibits 
HUVEC proliferation, migration and vasculogenesis, similar to miR-221, and that both 
miRNAs potentially mediate the actions of E2 in ECs. Several studies report, that the 
effects of the cell specific miR-221 on proliferation and migration are opposite 
between ECs and vascular SMCs, inasmuch that it inhibits EC functions while it 
stimulates vascular SMCs. Based on our observations that E2 down-regulates 
PDGF-BB-induced miR-221 in HCASMCs, it is feasible that E2 mediates its anti-
mitogenic action on vascular SMCs via inhibition/ down-regulation of the proliferation- 
and migration-inducing miR-221. Although the role of miR-193a in vascular cells has 
not yet been elucidated, we provide evidence for inhibition of HUVEC function. There 
is also evidence for an anti-mitogenic role for miR-193a in different cancer cells [238-
245]; however, we found that miR-193a is up-regulated by PGDF-BB, suggesting that 
it might be involved in the promotion of cell growth. In agreement with this 
hypothesis, Wang et al. supports a pro-proliferative role for miR-193a in bone 
mesenchymal stem cells [292], indicating that it may play contrasting dual functions 
depending on the tissue or cell type where it is expressed. Therefore, it is feasible 
that, similar to miR-221, miR-193a positively contributes to vascular SMC 
proliferation and migration and exhibits differential effects in vascular cells.  
In summary, we discovered that the expression of miR-100, miR-193a and miR-221 
is induced by PDGF-BB, suggesting a growth promoting role in vascular SMC. 
Moreover, these miRNAs are down-regulated by E2, indicating that they could be 
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potential mediators of the inhibitory actions of E2 in HCASMCs. For in-depth 
assessment we further investigated the impact of miR-193a and miR-221 on 
HCASMCs, since miR-100 was not regulated by E2 in HUVECs.   
Results and Discussion 
 
113 
 
5.5 The role of miR-193a and miR-221 in SMCs 
Objective 
Our findings revealed that E2 down-regulates miR-193a and miR-221 in HCASMCs. 
Since E2-dependent vaso-protection is largely due to inhibition of SMC proliferation 
and migration, we investigated the role of miR-193a and miR-221 in these processes. 
Moreover, we examined whether these miRNAs mediate the beneficial actions of E2.  
Introduction 
The function of miR-221 in vascular SMCs has been elucidated by several studies. It 
stimulates proliferation and migration and inhibits apoptosis [230]. Moreover, knock-
down of miR-221 inhibits intimal thickening after vascular injury [222]. Compared to 
miR-221, the impact of miR-193a on vascular SMCs remains unknown. In our 
experiments we observed a significant increase in miR-193a expression in 
HCASMCs stimulated with PDGF-BB, suggesting that it may be positively correlated 
with vascular SMC proliferation. Although we found that miR-193a inhibits EC growth 
and function (section 5.2), Wang et al. demonstrated that miR-193a induces 
proliferation in bone mesenchymal stem cells [292], indicating that miR-193a may 
have cell specific effects. Indeed, differential effects of miRNAs on growth of vascular 
SMCs and ECs are well documented. 
Based on the above findings, we hypothesize that miR-193a may have similar growth 
modulatory effects as miR-221 in vascular SMCs. Moreover, we postulate that the 
effects of miR-193a and miR-221 are opposite to the anti-mitogenic actions of E2.  
Furthermore, we hypothesize that the inhibitory effects of E2 on vascular SMCs are, 
at least in part, due to the down-regulation of miR-193a and miR-221. To explore this 
hypothesis, we first confirmed the role of miR-221 and examined the effects of miR-
193a on HCASMC proliferation and migration using synthetic Mimics and Antimirs to 
specifically modulate the expression of miRNAs. Second, we compared the effects of 
miRNA inhibition with the action of E2. Finally we investigated the role of the two 
miRNAs in mediating the beneficial effects of E2 by restoring the expression of miR-
193a and miR-221 after treatment with E2.  
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5.5.1 Mimics and Antimirs dysregulate the expression of miRNAs 
To determine the biological effects of miR-193a and miR-221 in HCASMCs, the 
levels of these miRNAs were increased by transfection of the cells with miRNA 
Mimics, while down-regulation was achieved using the respective miRNA Antimirs. 
Similar to HUVECs, the transfection success of HCASMCs was assessed using the 
fluorescent Dy547-labelled controls and quantified by flow cytometry. Transfection 
efficiency was 67±6.2% for the Dy547-labelled Control Mimic and 70±4.9% for the 
Dy547-labelled Control Antimir (Figure 40A). Representative images were taken with 
a fluorescence microscope to visualize the transfection efficiency (Figure 40B).  
 
Figure 40: Transfection efficiency of miRNA Mimic and Antimir. Cells were transfected 
with 25 nM of Dy547-labelled Control Mimic (MC-Dy547) or 25 nM of Dy547-labelled Control 
Antimir (AC-Dy547) using Lipofectamine 2000 for 6 hr in the absence of antibiotics and 
serum. Panel A: The percentage of Dy547-positive cells was measured using flow 
cytometry. Panel B: Representative images were taken using bright field and fluorescence 
microscopy (Red = Dy547-labeled Mimic or Antimir; blue = Hoechst33342 stain). n=3. 
Moreover, we confirmed that the experimental set up for the transfection is working 
optimally by means of a positive Control Mimic specifically targeting GAPDH. Protein 
expression of GAPDH was significantly inhibited at each tested time point post-
transfection by 43±5% after 24 hr, 60±8% after 48 hr and 62±10% after 72 hr (Figure 
41). 
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Figure 41: Confirmation of optimal Mimic transfection conditions. HCASMCs 
transfected with 25 nM GAPDH-targeting Positive Control Mimic (MC+), Negative Control 
(MC-) or mock transfected (C) were cultured in growing media for 24 hr, 48 hr and 72 hr prior 
to cell lysis and analysis of GAPDH protein expression by Western Blot. β-Actin was used as 
a loading control. n=3, *p<0.05 compared to MC-. 
In order to confirm the alterations in miRNA levels by the Mimics and Antimirs, we 
isolated RNA from transfected cells and determined miR-193a as well as miR-221 
levels by RT-qPCR (Figure 42A and 42B). Both miR-193a and miR-221 Mimics 
(M193a and M221, respectively) substantially up-regulated the respective miRNA 
levels after 24 hr, 48 hr and 72 hr. Transfection with the Antimir for miR-193a 
reduced miR-193a levels after 48 hr (by 20±34%, n.s.) and 72 hr (by 56±14%, 
p<0.05), whereas miR-221 level was significantly inhibited by ~90% at each tested 
time point by its Antimir.  
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Figure 42: Transfection with Mimics and Antimirs changes the levels of the respective 
miRNAs. HCASMCs were transfected either with 25 nM miR-193a Mimic or Antimir (M193a, 
A193a; Panel A) or 25 nM miR-221 Mimic or Antimir (M221, A221; Panel B) or the 
respective negative Controls (MC, Mimic Control; AC, Antimir Control). The cells were kept in 
growing media 24 hr, 48 hr and 72hr post-transfection before RNA was extracted and the 
miRNA level determined by RT-qPCR. n=3, *p<0.05 compared to the respective control. 
5.5.2 miR-193a and miR-221 induce HCASMC proliferation and 
migration 
We first confirmed the growth promoting role of miR-221 in vascular SMCs and 
compared it with the effects of PDGF-BB. Similar to PDGF-BB, transfection of 
HCASMCs with miR-221 Mimic induced proliferation, as assessed by cell counting 
and analysis of DNA synthesis using BrdU incorporation assay. Both PDGF-BB and 
M221 induced cell number by 194±39% and 93±13%, respectively (p<0.05; Figure 
43A). DNA synthesis was significantly increased from 100±8% to 237±30% by 
PDGF-BB and from 100±4% to 171±17% by miR-221 Mimic (Figure 43B).  
Moreover, we investigated the role of miR-221 on HCASMC migration by means of a 
scratch wound assay. Both PDGF-BB and M221 accelerated wound closure (Figure 
43C) by 72±10% and 69±11%, respectively, (p<0.05) thus confirming the stimulatory 
role of miR-221.   
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Figure 43: miR-221 overexpression induces HCASMC proliferation and migration 
similar to PDGF-BB. HCASMCs were either treated with or without PDGF-BB (PDGF, 20 
ng/ml) or transfected with miR-221 Mimic (M221) or Control Mimic (MC). All the assays were 
conducted in serum free media. Panel A: Cell number was assessed 3 days after 
transfection. Panel B: BrdU incorporation was determined using a BrdU ELISA kit. Panel C: 
Cell migration was determined using a wound closure assay. The cells were grown in 
complete medium for 48 hr after transfection and prior to making the wound. Representative 
images for each condition were taken at time 0 (T0) and 24 hr later (T24) as indicated. n=3, 
*p<0.05 compared to the respective control (C for PDGF-BB, MC for M221). 
In parallel experiments we studied the effect of miR-193a up-regulation on both 
proliferation and migration of HCASMCs. Analogous to M221, miR-193a Mimic 
M193a induced cell number and DNA synthesis (by 79.±8% and 68±15%, 
respectively, p<0.05; Figure 44A and 44B). Similarly, transfection of the cells with 
M193a significantly accelerated wound closure by 91±12% (Figure 44C).  
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Figure 44: miR-193a overexpression induces HCASMC proliferation and migration. 
Cells were transfected with miR-193a Mimic (M193a) or Control Mimic (MC). All the assays 
were made in serum free media. Panel A: Cell number was assessed 3 days after 
transfection. Panel B: BrdU incorporation was determined using a BrdU ELISA kit. Panel C: 
Cell migration was determined using a wound closure assay. Cells were grown in complete 
media for 48 hr after transfection, before the wound was made. Representative images for 
each condition at time 0 (T0) and 24 hr later (T24) are shown. n=3, *p<0.05 compared to 
control. 
The effects of the two miRNAs on proliferation and migration might be due to 
changes in cell viability. To rule out this possibility we investigated whether 
overexpression of miR-221 or miR-193a affects cell viability. As shown in Figure 45, 
neither of the two miRNAs had an effect on cell viability, as assessed by MTT test 
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and PI staining followed by flow cytometric analysis. Compared to the MC, M221 and 
M193a increased MTT absorbance only by 7±4% and 3±2%, respectively (n.s.; 
Figure 45A).  These results were also confirmed by the PI staining, which showed no 
significant change in Control and Mimic treated cells. The MC displayed 10.3±0.9%, 
M221 had 9.2±0.6% and M193a showed 9.6±0.8% PI positives (Figure 45B). 
 
Figure 45: miR-221 and miR-193a overexpression does not affect cell viability. 
HCASMCs were transfected with miR-221 Mimic (M221), miR-193a Mimic (M193a) or the 
Control Mimic (MC) and kept in growing media 24 hr after transfection. Panel A: For the MTT 
assay the cells were incubated 1 hr with 0.5 mg/ml MTT before measuring the absorbance 
was measured. Panel B: For the PI staining cells were trypsinized, incubated for 5 minutes 
with 0.2 g/ml PI and analyzed with a flow cytometer. The percentage of dead cells is 
indicated. n=3, *p<0.05 compared to the respective control. 
5.5.3 miR-193a and miR-221 Antimirs mimic the effects of E2  
In contrast to the Mimics, we expected down-regulation of miR-193a and miR-221 by 
the Antimirs to have an inhibitory action on PDGF-BB-induced HCASMC proliferation. 
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Unfortunately, A193a and A221 only slightly reduced cell number by 7±10% and 
15±9%, respectively (Figure 46A and 46B). However, the more sensitive BrdU 
incorporation assay showed that both A193a and A221 are able to inhibit BrdU 
incorporation from 100±5% to 72±6% and 64±7%, respectively (p<0.05; Figure 46C 
and 46D).  
 
Figure 46: miR-221 and miR-193a down-regulation inhibits HCASMC proliferation. Cells 
were transfected with miR-221 Antimir (A221), miR-193a Antimir (A193a) or Antimir Control 
(AC) prior to treatment with 20 ng/ml PDGF-BB. Panel A and B: Cell number was assessed 
by counting of the cells 3 days after transfection. Panel C and D: DNA synthesis was 
measured using a BrdU incorporation ELISA kit. n=3, *p<0.05 compared to control, §p<0.05 
as indicated. 
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Moreover, down-regulation of miR-193a and miR-221 significantly inhibited PDGF-
BB-induced wound closure. The Antimir A193a reduced the scratch induced wound 
by 15±3%, while A221 showed a stronger effect on cell migration by reducing it from 
100±4% to 76±4% (Figure 47A and 47B). 
 
Figure 47: miR-221 and miR-193a down-regulation inhibits HCASMC migration. Cells 
were transfected with miR-193a Antimir (A193a; Panel A), miR-221 (A221; Panel B) or 
Antimir Control (AC) prior to treatment with 20 ng/ml PDGF-BB. Migration was determined 
using a wound closure scratch assay. Cells were grown in complete media for 48 hr after 
transfection and before making the wound. Photomicrographs depict representative images 
of each condition after scratch at time 0 (T0) and 24 hr later. n=3, *p<0.05 compared to 
control, §p<0.05 as indicated. 
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As for the Mimics, we assessed the role of the Antimirs on cell viability by MTT test 
and PI staining followed by flow cytometric analysis (Figure 48A and 48B). We found 
that silencing of both miRNAs neither led to changes in MTT absorbance nor in the 
profile of the PI-stained cells, (12.6±0.7 %, 11.9±0.6% and 11.5±0.4%). 
 
Figure 48: miR-221 and miR-193a down-regulation does not affect cell viability. 
HCASMCs were transfected with miR-221 Antimir (A221), miR-193a Antimir (A193a) or the 
Control Antimir (AC) and kept in growing media for 24 hr after transfection. Panel A: For the 
MTT assay the cells were incubated for 1 hr with 0.5 mg/ml MTT before measuring the 
absorbance. Panel B: For the PI staining the cells were trypsinized, incubated 5 minutes with 
0.2 g/ml PI and analyzed with a flow cytometer. The percentage of dead cells is indicated. 
n=3, *p<0.05 compared to control. 
The effects of the two Antimirs on HCASMC growth were similar to that of E2. In fact, 
E2 inhibited PDGF-BB-induced proliferation concentration dependently, as assessed 
by cell counting (Figure 49A) and BrdU incorporation (Figure 49B). At a 
concentration of 100 nM E2 significantly inhibited cell number and DNA synthesis (by 
Results and Discussion 
 
123 
 
30±44% and 33±11%, respectively). Furthermore the effects of E2 on HCASMC 
migration were comparable to those following miR-193a and miR-221 down-
regulation. E2 reduced the PDGF-BB-induced wound closure concentration 
dependently and 100 nM E2 significantly decreased it from 100±5% to 73±4% 
(Figure 48C). 
 
Figure 49: E2 inhibits HCASMC proliferation and migration. Cells were treated with 20 
ng/ml PDGF-BB (PDGF) and 0, 10 and 100 nM E2. All the assays were made in serum free 
media. Panel A: Cell number was assessed 3 days after transfection. Panel B: BrdU 
incorporation was determined using a BrdU ELISA kit. Panel C: Cell migration was 
determined using a wound closure assay. The cells were grown in complete media for 48 hr 
after transfection, before the wound was made. Representative images for each condition at 
time 0 (T0) and 24 hr later (T24) are shown. n=3, *p<0.05 compared to control, §p<0.05 as 
indicated. 
5.5.4 miR-193a and miR-221 abrogate the protective actions of E2 
Since we previously found that E2 inhibits miR-193a and miR-221 expression in 
HCASMCs and that down-regulation of both miRNAs had comparable effects to E2 
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on HCASMCs growth, we hypothesized that the protective effects of E2 are, at least 
in part, due to its modulation of miR-193a and miR-221. In order to verify this 
hypothesis, overexpression of miR-193a and miR-221 was combined with E2 
treatment. Indeed, transfection of the cells with either M193a or M221 significantly 
reversed the inhibitory effects of E2 on cell proliferation at both 10 and 100 nM. 
M193a increased cell number from 131±6% to 159±18% (10 nM E2) and from 
110±7% to 170±17% (100 nM E2; Figure 50A), while M221 increased the counts 
from 131±6% to 185±23 (10 nM E2) and from 110±7% to 199±20% (100 nM E2; 
Figure 50B).  
 
Figure 50: miR-193a and miR-221 overexpression reverses the inhibitory effects of E2 
on HCASMC proliferation. Cells were transfected with the Control Mimic (MC), miR-193a 
Mimic (M193a; Panel A) or miR-221 Mimic (M221; Panel B) and immediately treated with or 
without E2 (10-100 nM) and 20 ng/ml PDGF-BB (PDGF). Proliferation was determined by 
counting the cells 3 days after transfection /treatment. n=3, *p<0.05 compared to control, 
§p<0.05 as indicated. 
Furthermore, the wound closure scratch assay revealed similar results with regard to 
HCASMC migration. The inhibitory effects of 10 and 100 nM of E2 on PDGF-BB-
induced migration was reversed by M193a from 179±13% to 258±27% and from 
148±9% to 229±13%, respectively (p<0.05; Figure 51A). Likewise, M221 significantly 
opposed E2 action at both 10 and 100 nM, from 180±13% to 257±13% and from 
152±8% to 248±13%, respectively (Figure 51B). 
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Figure 51: miR-193a and miR-221 overexpression reverses the inhibitory effects of E2 
on HCASMC migration. Cell migration was determined using a wound closure scratch 
assay. The cells were transfected with the Control Mimic (MC), miR-193a Mimic (M193a; 
Panel A) or miR-221 Mimic (M221; Panel B). Treatment with or without E2 (10-100 nM) and 
20 ng/ml PDGF-BB (PDGF) was added after the scratch was made. Photomicrographs were 
taken immediately after the scratch / treatment at time 0 (T0) and 24 hr later (T24). n=3, 
*p<0.05 compared to control, §p<0.05 as indicated. 
5.5.5 miR-193a and miR-221 do not have additive effects 
Since both miRNAs have a similar role in inducing HCASMC growth, we examined 
the combined effect of the two miRNAs on DNA synthesis, using BrdU incorporation 
assay (Figure 52). Interestingly, we found that the combination of the Mimics 
significantly induced BrdU incorporation from 100±3% to 122±3%. However, 
combined treatment did not further increase the effects compared to the individual 
Mimics M193a and M221, which showed an induction of 23±4% and 20±3%, 
respectively (p<0.05). Hence our results demonstrate no additive effect of miR-193a 
and miR-221 on HCASMCs growth.  
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Figure 52: Combined treatment with miR-193a and miR-221 has no additive effect. 
HCASMCs were transfected with 25 nM Control Mimic (MC), miR-221 Mimic (M221) or miR-
193a Mimic (M193a) alone or with a combination of the two Mimics (12.5 nM each). BrdU 
incorporation was determined using a BrdU ELISA kit. n=3, *p<0.05 compared to control. 
5.5.6 Discussion 
The first aim of this part of the study was to confirm the proliferation and migration 
inducing effects of miR-221 in HCASMCs and investigate the effect of miR-193a on 
HCASMC function. Since PDGF-BB stimulates miR-193a and miR-221 expression in 
HCASMCs, we speculated that miR-193a may have stimulatory effects on HCASMCs 
growth similar to miR-221. Since these actions are opposite to the anti-mitogenic 
actions of E2, we hypothesized that down-regulation of miR-193a and miR-221 by E2 
mediates its inhibitory effects on vascular SMC proliferation and migration.  
Indeed, similar to PDGF-BB, miR-221 induced HCASMCs proliferation and migration, 
as assessed by the increase in cell number and DNA synthesis and acceleration of 
wound closure. Similar to PDGF-BB and miR-221 overexpression, the up-regulation 
of miR-193a also induced HCASMC proliferation and migration. The stimulatory role 
of miR-193a and miR-221 in vascular SMCs is further confirmed by our observation 
that neutralization of miRNA with Antimirs inhibited DNA synthesis and wound 
closure. Moreover, down-regulation of both miRNAs inhibited HCASMCs function 
comparable to treatment with E2. Finally, we demonstrate that overexpression of 
miR-193a or miR-221 abrogated E2-mediated inhibition of HCASMC proliferation and 
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migration, suggesting that down-regulation of these miRNAs contributes to the 
protective effects of E2 in vascular SMCs.  
In order to study the physiological role of the miRNAs, we transfected the cells with 
miRNA Mimics or Antimirs using lipofection. The transfection efficiency was relatively 
good (70%), as confirmed using fluorescently labeled controls. Transfection success 
was further verified using a GAPDH-targeting Positive Control miRNA, which 
inhibited GAPDH significantly at each tested time point, suggesting that the Mimics 
are potentially incorporated into the RISC complex and functionally active. Moreover, 
the uptake of miR-193a and miR-221 Mimics and Antimirs was confirmed by RT-
qPCR. The levels of both miRNAs were greatly induced after transfection with the 
respective Mimics. After transfection with the Antimirs, miR-221 levels were 
completely inhibited throughout the tested time points, while miR-193a levels were 
significantly reduced only after 72 hr. It is feasible that the lack of down-regulation of 
miR-193a is due to inhibition of miRNA activity even in absence of its degradation, as 
reported earlier [252, 253]. The use of Antimirs in the functional assays provides 
evidence that miRNA activity is inhibited, independently of the miRNA levels 
observed by RT-qPCR. However, off-target effects of the miRNAs cannot be 
excluded. 
In the current study, we found that miR-221 and miR-193a are up-regulated by 
PDGF-BB and mimic its effects on inducing vascular SMC proliferation, suggesting 
that they might mediate the growth stimulatory actions of PDGF-BB. Indeed, Davis et 
al. demonstrated that miR-221 up-regulation by PDGF-BB mediates its pro-
proliferative actions in pulmonary aortic SMCs through inhibition of c-Kit and p27 
[223]. Here we provide the first evidence that miR-193a participates in the regulation 
of vascular SMC proliferation. These findings, together with the fact that miR-193a 
expression is stimulated by PDGF-BB and that PDGF-BB-induced DNA synthesis 
and wound closure are significantly inhibited by miR-193a down-regulation, suggests 
that miR-193a also mediates the mitogenic effects of PDGF-BB on HCASMCs. 
However, this assumption needs to be verified, for instance by observing whether 
PDGF-BB is able to further simulate vascular SMC activity in cells transfected with 
miR-193a Mimic.  
Interestingly, we observed that the PDGF-BB-induced increase in cell number is only 
slightly reduced by miR-221 or miR-193a inhibition, while the BrdU incorporation 
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assay showed 30-40% decrease in DNA synthesis. An explanation for this differential 
effect might be the higher sensitivity of the BrdU assay as compared to cell counts or 
the short incubation time employed to observe a proper reduction in cell number. 
Since miR-221 or miR-193a down-regulation did not completely abrogate PDGF-BB-
induced HCASMC growth and migration, it is likely that other molecules also 
participate in regulating PDGF-BB actions and inhibition of one miRNA is not enough 
to neutralize its actions.  
Although changes in cell proliferation and migration are influenced by cell survival, 
we could not detect any changes in cell viability by miR-221 and miR-193a 
modulation. There is only one report about the effects of miR-221 on cell viability in 
vascular SMCs. Liu et al. showed that knock-down of miR-221/222 increased 
apoptosis, while overexpression had the opposite effect [230]. However, these results 
were obtained in rat aortic SMCs and under serum-free conditions, while we used 
HCASMCs and kept them in growing medium before measuring cell viability. Hence, 
differences in experimental conditions and cell type may account for the dissimilar 
results. The role of miR-193a on vascular SMC survival has not been investigated; 
nevertheless, its pro-apoptotic functions are reported in several tumors, including 
melanoma, hepatocellular carcinoma, acute myeloid leukemia, breast and prostate 
cancer [245]. Yet in this study we have observed that miR-193a modulation does not 
alter HUVEC viability, which supports our finding that HCASMC survival is also not 
regulated by miR-193a. Finally, we used indirect methods to study the effect of the 
miRNAs on cell viability and did not specifically measure apoptosis. Therefore, the 
analysis of apoptosis using a specific marker, such as Annexin V or TUNEL staining, 
might give a divergent answer about the role of miR-193a and miR-221 in vascular 
SMC survival. 
Davis et al. additionally demonstrated that miR-221 is critical for the modulation of 
vascular SMC phenotype, as up-regulation of miR-221 abrogated the expression of 
SMC genes such as α-smooth muscle action (SMA), smooth muscle calponin (CNN) 
and SM22α [223, 293]. These findings support the pro-proliferative role of miR-221, 
as only de-differentiated SMCs are able to reenter the cell cycle and proliferate. 
Unfortunately, we did not investigate the role of miR-193a in the regulation of SMC 
differentiation, though it could also be a potential mechanism of increased cell 
proliferation.  
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The protective actions of E2 on the vascular system include its inhibitory effects on 
vascular SMC proliferation and migration and the prevention of neointimal formation 
after injury [222]. Here we confirm the anti-mitogenic and anti-migratory actions of E2 
on PDGF-BB-induced HCASMC growth. Moreover, we provide evidence that down-
regulation of miR-221 and miR-193a mimics the effects of E2 on HCASMC 
stimulated by PDGF-BB. These findings suggest that miRNA down-regulation by E2 
might mediate the inhibitory effects of E2 on HCASMCs. Indeed, re-expression of the 
miRNA after its down-regulation by E2 treatment reversed its inhibitory effects on 
proliferation and wound closure. Taken together, our findings demonstrate that 
knock-down of miR-221 and miR-193a abolishes E2-mediated inhibition of HCASMC 
proliferation and migration. Our findings identify that miR-221 and miR-193a actively 
contribute to the growth inhibitory effects of E2 in HCASMCs. These findings are 
further supported by the fact that the same miRNAs potentially mediate estrogenic 
and growth stimulatory actions in ECs, as we demonstrate in the previous chapters.  
The mechanisms by which miRNAs modulate vascular SMCs may include the 
regulation of several intracellular pathways. To test whether miR-193a and miR-221 
affect common or different pathways in stimulating vascular SMC proliferation, we 
tested and compared the individual and combined actions of both miRNAs on 
HCASMCs growth using BrdU incorporation assay. Since we did not observe any 
additive effects compared to overexpression of individual miRNAs, we speculate that 
miR-193a and miR-221 potentially target the same genes or different genes within 
the same pathway. In support of our hypothesis, other studies explain additive effects 
after miRNA combination by the fact that these miRNA target distinct pathways. For 
instance, Stahlhut et al. showed that let-7b and miR-34a synergize to inhibit cell 
proliferation and tumor growth by targeting different sets of oncogenes [294]. 
However, as already discussed in section 5.2.6, our results of the simultaneous 
transfection of miR-193a and mIR-221 Mimics should be interpreted with caution, as 
we did not control whether both Mimics are taken up by the cells and are functionally 
active. First, the possibility that only one miRNA is efficiently transfected into the cells 
should be tested by RT-qPCR analysis. Second, it is necessary to examine 
concentration dependent effects of the Mimic, since we employed only 12.5 nM of 
each miRNA for the co-transfection compared to the 25 nM used for each miRNA 
alone. Third, since co-administered Mimics may compete for the binding of AGO2 
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[265], the functional activaty of both miR-193a and miR-221 Mimics should be 
verified using a reporter assay or through AGO2 pull-down followed by RT-qPCR. 
In conclusion, we hypothesize that down-regulation of miR-193a and miR-221 by E2 
suppresses the stimulatory actions of miR-193a and miR-221 on proliferation, and 
migration of HCASMCs, thereby contributing to the inhibitory effect of E2 on these 
processes. Moreover, we speculate that miR-193a and miR-221 modulate mRNAs of 
genes within the same pathways, which are regulated by E2 and important for E2-
mediated inhibition of SMC growth.   
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5.6 Intracellular mechanisms of E2-regulated miRNAs in SMCs  
Objective 
Our results provide evidence that miR-193a and miR-221 mediate the anti-mitogenic 
actions of E2 in HCASMCs. Hence, we further investigated the potential underlying 
mechanisms. Since E2 inhibits SMC proliferation, in part by blocking cell cycle 
progression from G1 to S phase, we assessed the role of the two miRNAs on the 
regulation of several early cell cycle proteins.  
Introduction 
In section 5.5 we demonstrated that miR-193a and miR-221 mediate the inhibitory 
effects of E2 on proliferation and migration of vascular SMCs. Although the molecular 
mechanisms underlying the anti-mitogenic actions of E2 in SMCs are far from clear, 
current evidence indicates that E2 inhibits SMC proliferation in part by blocking cell 
cycle progression from G1 to S phase by regulating several early cell cycle proteins 
required for S phase entry, such as cyclin D1 and RB [178-180]. 
Since we have found that miR-193a and miR-221 induce DNA synthesis and down-
regulation of miR-193a and miR-221 by E2 potentially mediates its anti-mitogenic 
actions in SMCs, we postulate that they may regulate G1/S transition of the cell cycle. 
Therefore, we further investigated whether miR-193a and miR-221 modulate the 
expression of genes required for S phase initiation and known to be regulated by E2. 
5.6.1 miR-221 and miR-193a stimulate G1-S phase progression  
Cyclin Ds are the first cyclins produced in the cell cycle in response to extracellular 
signals such as growth factors. In fact, cyclin D1 protein expression was strongly 
induced in cells treated with PDGF-BB (from 100±7% to 261±21%, p<0.05; Figure 
53A). Treatment with E2 inhibited PDGF-BB-induced cyclin D1 expression in a 
concentration dependent manner from 176±28% to 135±22% (10 nM) and to 
102±21% (100 nM, p<0.05; Figure 53B). 
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Figure 53: E2 inhibits PDGF-BB-induced cyclin D1. Representative Western blot and bar 
graph of cyclin D1 expression after 48 hr stimulation of HCASMCs with 20 ng/ml PDGF-BB 
(Panel A) and after 1 hr pre-treatment with or without 10 and 100 nM E2 (Panel B). β-Actin 
was used as a loading control. n=3, *p<0.05 compared to control (C), §p<0.05 as indicated. 
Similar to PDGF-BB, up-regulation of miR-221 induced cyclin D1 expression in 
HCASMCs from 100±9% to 174±26% (p<0.05; Figure 54A). Similarly, transfection of 
the cells with the miR-193a Mimic induced cyclin D1 expression from 100±9% to 
170±21% (p<0.05; Figure 54B). Moreover, silencing of both miR-221 and miR-193a 
using the specific Antimirs significantly abrogated the stimulatory effects of PDGF-BB 
on cyclin D1, and this effect was analogous to the observed effects of E2. The 
expression of cyclin D1 was decreased by A221 and A193a by 19±5% and by 
21±8%, respectively (p<0.05; Figure 53C and 53D).  
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Figure 54: miR-221 and miR-193a regulate cyclin D1 expression. Representative 
Western blot and bar graph of cyclin D1 expression after transfection of the HCASMCs either 
with Control Mimics (MC), miR-221 Mimic (M221; Panel A) or miR-193a Mimic (M193a; 
Panel B) or transfection with the Control Antimir (AC), miR-221 Antimir (A221; Panel C) or 
miR-193a Antimir (A193a; Panel D). After transfection, the cells overexpressing miRNAs 
were kept in starving media for 48 hr prior to lysis, while the cells with down-regulated 
miRNA were treated 48 hr with 20 ng/ml PDGF-BB. β-Actin was used as a loading control. 
n=3, *p<0.05 compared to starved control (C), §p<0.05 as indicated. 
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Even though cyclin D1 levels in proliferating cells are sustained as long as the growth 
factors are present, cyclin D1 has no effect on G1/S transition unless it forms a 
complex with CDK4 or CDK6. Our findings show that PDGF-BB induced CDK4 
protein expression (from 100±4% to 131±4%, p<0.05; Figure 55A) and that up-
regulation of both miR-221 and miR-193a by the specific Mimics had similar 
significant stimulatory effects (Figure 55B and 55C): M221 increased CDK4 from 
100±4% to 145±9% and M193a from 100±4% to 152±9%.  
 
Figure 55: miR-221 and miR-193a overexpression increases CDK4 expression. 
Representative Western blot and bar graph of CDK4 expression after 48 hr treatment with 20 
ng/ml PDGF-BB (Panel A) or transfection of the HCASMCs with Control Mimics (MC), miR-
221 Mimic (M221; Panel B) or miR-193a Mimic (M193a; Panel C). After transfection the cells 
overexpressing miRNAs were kept in starving media for 48 hr prior to lysis. β-Actin was used 
as a loading control. n=3, *p<0.05 compared to the respective control. 
The cyclin-dependent kinase inhibitor 1B (p27) is a negative regulator of the cell 
cycle progression at G1, as it prevents the activation of cyclin D1-CDK4 complexes. 
PDGF-BB also promotes proliferation by inhibiting p27 (from 100% to 3.6%, p<0.05) 
while E2, consistent with its anti-mitogenic role, reverses its actions (back to 58%, 
p<0.05 compared to PDGF-BB alone; Figure 56A). Surprisingly, both miR-221 and 
miR-193a Mimics increased the expression of p27 (Figure 56B and 56C) from 
100±4% to 140±11% and from 100±5% to 161±21%, respectively (p<0.05), which is 
associated with cell quiescence.  
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Figure 56: miR-221 and miR-193a overexpression increases p27 expression. 
Representative Western blot and bar graph of p27 expression after 48 hr treatment with 20 
ng/ml PDGF-BB with or without 100 nM E2 (Panel A) or transfection of the HCASMCs with 
Control Mimics (MC), miR-221 Mimic (M221; Panel B) or miR-193a Mimic (M193a; Panel C). 
After transfection the cells overexpressing miRNAs were kept in starving media for 48 hr 
prior to lysis. β-Actin was used as a loading control. n=3, *p<0.05 compared to the respective 
control. 
Given the incongruity of the results, increased cyclin D1-CDK4 and p27, we 
examined the phosphorylation of the retinoblastoma tumor suppressor protein (RB), 
the principal substrate of CDK4. As a growth factor, PDGF-BB induced 
hyperphosphorylation of RB from 100±5% to 130±14%, (p<0.05; Figure 57A). 
Similarly, up-regulation of miR-221 and miR-193a also increased pRB levels from 
100±3% to 131±15% and from 100±4% to 165±18%, respectively (p<0.05; Figure 
57B and 57C), suggesting a growth promoting role in cell cycle progression despite 
p27 up-regulation.   
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Figure 57: miR-221 and miR-193a overexpression increases RB phosphorylation. 
Representative Western blot and bar graph of phosphorylated RB (pRB) after 48 hr 
treatment with 20 ng/ml PDGF-BB (Panel A) or transfection of the HCASMCs with the 
Control Mimic (MC), miR-221 Mimic (M221; Panel B) or miR-193a Mimic (M193a; Panel C). 
After transfection the cells overexpressing miRNAs were kept in starving media for 48 hr 
prior to lysis. n=3, *p<0.05 compared to the respective control. 
Phosphorylation of RB (pRB) by CDK4 allows E2F to dissociate from pRB-E2F 
complexes, allowing E2F-mediated transcription of cyclins, such as cyclin E and 
cyclin A, and PCNA, which is essential for DNA replication and S-phase progression. 
To further test the pro-proliferative role of miR-221 and miR-193a in HCASMCs, we 
investigated their effect on cyclin E and PCNA expression. We found that, similar to 
stimulation with PDGF-BB, the transfection of the cells with the Mimics for the two 
miRNAs did induce both cyclin E and PCNA protein expression. Indeed PDGF-BB 
stimulated cyclin E and PCNA from 100±3% to 132±3% and 100±29% to 219±40%, 
respectively (p<0.05; Figure 58A and 58B).  
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Figure 58: PDGF-BB promotes S-phase progression through induction of cyclin E and 
PCNA expression. Representative Western blot and bar graph of cyclin E (Panel A) and 
PCNA (Panel B) expression after 48 hr treatment with 20 ng/ml PDGF-BB. β-Actin was used 
as a loading control. n=3, *p<0.05 compared to the respective control. 
Up-regulation of miR-221 induced cyclin E expression significantly from 100±3% to 
136±7%, whereas miR-193a Mimic showed a smaller induction (from 100±3% to 
117±3%, p<0.05; Figure 59A and 59B). Similarly, PCNA was significantly up-
regulated from 100±29% to 300±46% after transfection with the miR-221 Mimic and 
from 100±29% to 326±30% with the Mimic for miR-193a (Figure 59C and 59D).  
These results confirm the pro-proliferative function of the two miRNAs and their role 
in G1-S phase progression. Moreover, they suggest that indeed down-regulation of 
miR-221 and miR-193a by E2 might mediate its anti-mitogenic actions in SMCs and 
that this may be mediated via regulation of cell cycle proteins.  
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Figure 59: miR-221 and miR-193a overexpression increases cyclin E and PCNA 
expression. Representative Western blot and bar graph of cyclin E and PCNA expression 
after transfection of the HCASMCs with the Control Mimic (MC), miR-221 Mimic (M221; 
Panel A and Panel C) or miR-193a Mimic (M193a; Panel B and Panel D). After 
transfection, the cells overexpressing miRNAs were kept in starving media for 48 hr prior to 
lysis. β-Actin was used as a loading control. n=3, *p<0.05 compared to the respective 
control. 
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5.6.2 miR-221 and miR-193a activate the PI3K/ Akt signaling pathway 
Cell cycle progression is initiated by the binding of growth factors, such as PDGF-BB, 
to mitogen receptors, which activate the Ras/ Raf/ ERK and PI3K/ Akt signaling 
pathways. Subsequently, this leads to the activation of transcription factors, such as 
Myc and AP-1 family members, which in turn alter transcription of genes important in 
cell cycle, such as CDK4, CDK6 and cyclin D1 genes.  
Since treatment of HCASMCs with PDGF-BB up-regulates miR-193a and miR-221 
expression, together with the fact that overexpression of both miRNAs imitates most 
of the effects of PDGF-BB on the cell cycle, we questioned if they similarly influence 
the transduction pathways upstream from cell cycle. Indeed, PDGF-BB strongly 
induced Akt phosphorylation (from 100±3% to 8478±2585%, p<0.05; Figure 60A). 
Moreover, transfection of the cells with the miR-221 and miR-193a Mimic increased 
Akt phosphorylation from 100±4% to 215±50% and 100±3% to 229±58%, 
respectively (p<0.05; Figure 60B and 60C). 
 
Figure 60: miR-221 and miR-193a promote cell proliferation via the PI3K/ Akt pathway. 
Representative Western blot and bar graph of Akt phosphorylation (pAkt, Ser473) after 48 hr 
treatment with 20 ng/ml PDGF-BB (Panel A) or transfection of the HCASMCs with the 
Control Mimic (MC), miR-221 Mimic (M221; Panel B) or miR-193a Mimic (M193a; Panel C). 
After transfection, the cells overexpressing miRNAs were kept in starving media for 48 hr 
prior to lysis. Total Akt and β-actin were used as loading controls. n=3, *p<0.05 compared to 
the respective control. 
Results and Discussion 
 
140 
 
5.6.3 Discussion 
E2 inhibits SMC proliferation, at least in part, by targeting and down-regulating cell 
cycle progression from G1 to S phase; hence, here we assessed the effects of miR-
193a and miR-221 on the regulation of several early cell cycle proteins. 
In the previous chapter (chapter 5.5) we demonstrated that E2 inhibits PDGF-BB-
induced DNA synthesis using BrdU incorporation assay. Our findings are consistent 
with other studies, which showed that PDGF-BB-induced [3H]-thymidine 
incorporation is significantly decreased after treatment with E2 [174, 175], indicating 
that E2 might regulate several key molecules required for S phase entry. Indeed, 
here we provide evidence that E2 inhibits PDGF-BB-induced cyclin D1 expression. 
Moreover, the suppression of the cyclin-dependent kinase inhibitor p27 by PDGF-BB 
is reversed by E2, suggesting that E2 causes G1 arrest of vascular SMCs through 
inhibition of cyclin D1 and stimulation of p27. In support of our findings, Takahashi et 
al. has shown that E2 inhibits PDGF-BB-stimulated vascular SMC proliferation by 
decreasing PDGF-BB-induced cyclin D1 expression and reducing the 
phosphorylation of RB. However, in contrast to our findings, Takahashi did not 
observe any changes in the expression of p27 after treatment with E2. Moreover, 
PDGF-BB-induced CDK4 and CDK2 were also not affected [176]. Although 
estrogens inhibit proliferation of vascular SMCs, we and other researchers have 
demonstrated their growth stimulatory effects in ECs [295]. Moreover, estrogens 
enhance the proliferation of breast and uterine cells [296], indicating that E2 
modulates diverse cell functions in a cell and tissue specific way. Nevertheless, 
modulation of key G1 phase cell-cycle regulators is an important mechanism by which 
E2 affects proliferation. In fact, several studies have shown that E2 controls cyclin 
D1, c-Myc, CDK2, CDK4 and CDK inhibitors in MCF-7 breast cancer cells, thus 
promoting progression from G1 to S phase of the cell cycle [297, 298].  
We already demonstrated (chapter 5.5) that miR-193a and miR-221 induce DNA 
synthesis, indicating that these two miRNAs may regulate G1/S transition. Moreover, 
we propose that E2-dependent down-regulation of miR-193a and miR-221 mediates 
the anti-mitogenic effects of E2. Since E2 arrests vascular SMCs in G1 phase of the 
cell cycle, we postulated that miR-193a and miR-221 stimulate cell cycle progression 
similar to PDGF-BB. Indeed, cyclin D1 expression is stimulated after up-regulation of 
both miRNAs and down-regulation of both miR-193a and miR-221 decreased PDGF-
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BB-induced cyclin D1 expression. Moreover, these miRNAs increased CDK4 
expression as well as RB phosphorylation, which is a result of active cyclin D1-CDK4 
complexes. Further, we confirmed that E2F is released after miR-193a or miR-221 
up-regulation, since both miRNAs induce the expression of E2F targets cyclin E and 
PCNA. Taken together, our findings reinforce the hypothesis that both miRNAs 
stimulate cell cycle progression from G1 to S phase. 
There is numerous evidence that miR-221 induces proliferation of vascular SMCs via 
inhibition of several cell cycle regulators such as p27, p57 and c-Kit [223, 230]; 
however, our findings provide the first evidence that the mitogenic effects of miR-221 
are associated with increased cyclin D1, CDK4, pRB, cyclin E and PCNA in vascular 
SMCs. Analogously, our findings that miR-193a regulates SMC growth are novel and 
provide the first evidence of a role for miR-193a in vascular SMCs. Various studies 
demonstrate that miR-193a inhibits G1/S transition and proliferation of melanoma and 
breast cancer cells by targeting cell cycle proteins, including CDKs, cyclins and p27 
[238, 299, 300]. However, we found that miR-193a induces growth of HCASMCs by 
upregulating cyclin D1, CDK4, pRB, cyclin E and PCNA. These findings indicate that 
miR-193 modulates the cell cycle progression. Moreover, our assumption that miR-
193a positively regulates cell cycle progression is supported by the findings of Wang 
et al. that up-regulation of miR-193 promotes proliferation of bone mesenchymal 
stem cells by inducing CDK2 expression by directly targeting its negative regulator, 
the Inhibitor of Growth Family, Member 5 (ING5) [292].  
Although we provide abundant evidence for a pro-proliferative role of miR-193a and 
miR-221, their up-regulation increased the expression of the cell cycle inhibitor p27. 
These findings are also in contrast to the results from several studies demonstrating 
that miR-221 directly targets p27 to inhibit vascular SMC proliferation [222, 223, 230]. 
Moreover, there is evidence that miR-221 positively regulates the proliferation of 
several cancer cell types by targeting p27. Gillies et al. have shown that suppression 
of miR-221 arrested growth of U87 glioblastoma cells via up-regulation of p27 [301]. 
Galardi et al. observed that knock-down of endogenous miR-221 in PC3 prostate 
cancer cells blocked proliferation and increased p27 protein, while exogenous 
expression of miR-221 in LNCaP prostate cancer cells coincided with increased 
proliferation rates and decreased p27 levels. Moreover, knock-down of p27 after miR-
221 suppression rescued the growth arrest in G1 [302]. The effect of miR-193a on 
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p27 has solely been studied by Uhlmann et al. His group investigated the impact of 
different miRNAs, including miR-193a, in EGFR-driven cell cycle pathway and 
showed that miR-193a up-regulates p27 expression in breast cancer cells [299]. In 
contrast to vascular SMCs, miR-193a exhibits anti-proliferative actions in breast 
cancers cells. Moreover, it also inhibits CDK4 and cyclin D1. Therefore we cannot 
compare our findings on increases in p27 levels with the findings in breast cancer 
cells, as the growth outcome was different.  
Phosphorylation of RB is one of the most crucial steps regulating the progression of 
the cell cycle as it allows the release of E2F and the subsequent induction of genes 
required for DNA synthesis. Here we demonstrate that, in spite of high p27 
expression, RB is phosphorylated and E2F is probably released, since we observed 
induction of cyclin E and PCNA expression. These findings support the pro-
proliferative role of miR-221 and miR-193a in HCASMCs and suggest that, though 
p27 levels are high, the molecule may not be functionally active. Since p27 
concentration is regulated at different levels, including transcription, translation, 
protein stability and subcellular localization [303-305], we postulate that one or more 
of these mechanisms is disrupted by miR-221 and miR-193a overexpression. The 
regulation of p27 has been shown to differ slightly from one cell type to another [306]. 
Depending on its phosphorylation, p27 is degraded in the nucleus or exported to the 
cytoplasm where it is either degraded or retained. In quiescent cells, p27 levels are 
high and bound to CDK2 to ensure complete inhibition of kinase activity. In 
proliferating cells, p27 needs to be inactivated in order to allow cyclin E-CDK2 
complexes to actively phosphorylate RB and release E2F, thus allowing the 
transcription of genes important for DNA synthesis in S-phase. Upon mitogenic 
stimulation, Ras and/or PI3K pathways are activated and trigger c-Myc and Akt to 
negatively influence p27. c-Myc directly represses p27 expression [307]. Moreover, it 
induces expression of cyclin Ds and CDK4 so that the cyclin D-CDK4 complexes 
sequester p27 and CDK2 repression is relieved [307]. This allows CDK2 to 
phosphorylate p27 at Thr187, making it a target for ubiquitination by the Skp/ Cullin/ 
F-box complex (SCFSkp2) and enhancing p27 degradation in the nucleus [308-310]. 
Akt directly regulates the expression of p27 through phosphorylation, which results in 
p27 redistribution and retention in the cytoplasm. Furthermore, Akt indirectly inhibits 
p27 transcription through inhibition of FoxO transcription factors and maintains cyclin 
D-CDK complex stability for p27 sequestering [311, 312]. Since c-Myc and Akt are 
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key molecules in the signaling pathways activating cell proliferation and are required 
for the transcription of other important cell cycle regulators, it is unlikely that they are 
inhibited by the pro-proliferative miR-221 and miR-193, thus preventing repression of 
p27 transcription. Phosphorylation of p27 and its subcellular localization define p27 
activity. Therefore it is feasible that miR-221 and miR-193a increase p27 by 
preventing its suppression, either by enhancing its cytoplasmatic retention or 
inhibiting its proteosomal degradation. However, this remains speculative and needs 
to be tested in the future. 
In support of our findings, Sherr at al. demonstrate a positive role of p27 in G1-phase 
progression [313]. He discusses the research of different groups demonstrating that 
the Cip/Kip proteins (p21, p27 and p57) are potent inhibitors of cyclin E- and cyclin A-
dependent CDK2, yet they act as positive regulators of cyclin D-dependent kinases 
[314]. Moreover, Donjerkovic et al. states that p27 and p21 have been shown to 
associate with CDK/ cyclin complexes both inhibiting or inducing the kinase activity 
and the stoichiometry is thought to determine which of these final effects are induced 
[306]. 
In the current study we observe that miR-221 and miR-193a positively regulate cell 
cycle progression through up-regulation of cyclin D1, CDK4, pRB, cyclin E and 
PCNA. However, the direct targets for the two miRNAs remain unclear. Increasing 
evidence indicates that miRNAs not only repress their targets, but also induce their 
expression depending on particular cellular conditions, cell type and context [68, 69]. 
We speculate that miR-193a and miR-221 may target negative regulators of the cell 
cycle or the mitogenic signal transduction mechanism(s) upstream of cyclin Ds.  
The major function of D cyclins is to provide a link between mitogenic stimulus and 
the cell cycle machinery. Therefore, it is feasible that increased cyclin D1 levels and 
the downstream cell cycle effectors are merely due to the induction of upstream 
signaling cascades regulating proliferation processes, such as the Ras/ Raf/ ERK 
and PI3K/ Akt signaling pathways. Akt promotes G1-S phase cell cycle progression 
by preventing the phosphorylation and degradation of cyclin D1 and -catenin, which 
up-regulates the expression of genes important for cell cycle transition, including 
cyclin D1 [315].  
In the current study we investigated the effects of miR-193a and miR-221 on the 
PI3K/ Akt pathway and demonstrated that both miRNAs activate it in HCASMCs, as 
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shown by the increase in Akt phosphorylation after miRNA overexpression. However, 
stimulation of Akt phosphorylation is slight in comparison to the considerable 
increase after treatment with PDGF-BB, suggesting that this is not the main 
mechanism by which miR-193a and miR-221 induce vascular SMC proliferation. 
Alternatively, the potent effects of PDGF-BB may be due to a combination of factors 
beside miR-221 and miR-193a.  
Besides regulation of PI3K/ Akt, the anti-mitogenic actions of E2 include inhibition of 
Raf/ Mek/ Erk MAPK signaling, which plays a prominent role in proliferation. Thus, 
based on the fact that E2 inhibits SMC growth by abrogating MAPK phosphorylation 
[178], we speculate that miR-193a and miR-221 may contribute to vascular SMC 
growth also through induction of this MAPK pathway. 
We already discussed the role of miR-221 and miR-193a on the PI3K/ Akt pathway in 
a previous chapter (chapter 5.3). In contrast to HUVECs, where both miRNAs inhibit 
PI3K/ Akt signaling, in HCASMCs they activate it. In support of these findings, miR-
221 is shown to induce PI3K/ Akt signaling by suppressing the negative regulator 
PTEN in several cancer cell lines [273-275]. Further, miR-193a indirectly inhibits 
PTEN, thus activating Akt and contributing to leukemogenesis [257] and suppresses 
the metastasis of human non-small-cell by indirect inhibition of PI3K/ Akt cascade 
[271]. Therefore it is possible that miR-193a and miR-221 increase PI3K/ Akt 
signaling in HCASMCs through targeting its negative regulator PTEN. Taken 
together, these findings strongly suggest that miR-193a and miR-221 differentially 
regulate the PI3K/ Akt signaling pathway depending on the cell type and context.  
In summary, in this chapter we first demonstrate that E2 inhibits PDGF-BB-induced 
vascular SMC proliferation via inhibition of cell cycle progression from G1 to S phase. 
Specifically, E2 decreased PDGF-BB-induced cyclin D1 expression and up-regulated 
the cell cycle inhibitor p27. Moreover, we provide insight into the molecular 
mechanisms by which miR-193a and miR-221 influence vascular SMC proliferation 
(Figure 61). Overexpression of both miRNAs induces Akt phosphorylation, indicating 
that they activate the PI3K/ Akt pathway. Similar to PDGF-BB, up-regulation of both 
miRNAs induced cyclin D1, CDK4, cyclin E and PCNA expression and increased RB 
phosphorylation. However, in contrast to our expectations and to the results from 
other researchers, both miRNAs also induced p27. Nevertheless, we found that both 
miRNAs induced PCNA expression and promoted DNA synthesis (results from the 
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previous chapter), thus it is likely that p27 up-regulation is not associated with 
increased p27 activity. In conclusion, the mechanisms by which miR-221 and miR-
193a regulate cell cycle progression still need to be elucidated to provide a better 
understanding of how down-regulation of these miRNAs by E2 mediates the anti-
mitogenic actions of E2 in vascular SMCs.  
 
Figure 61: Summary of our findings in a simplified schematic representation of the cell 
cycle in vascular SMCs and its regulation by E2. G0, quiescence; G1, Gap 1; S, 
Synthesis; G2, Gap 2; M, Mitosis; PDGF-BB, Platelet-Derived Growth Factor BB; MAPK, 
Mitogen Activated Protein Kinase; PI3K, Phosphoinositide 3-Kinase; CDK, Cyclin-Dependent 
Kinase; RB, Retinoblastoma protein; PCNA, Proliferating Cell Nuclear Antigen; MPF, Mitosis 
Promoting Factor.  
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5.7 ERα mediates miR-221 and miR-193a down-regulation 
Objective 
The role of ERs in mediating the beneficial effects of E2 in vascular cells is well 
established. Therefore, under this specific aim, we examined whether down-
regulation of miR-193a and miR-221 by E2 is mediated via ERα, ERβ or GPER. 
Introduction 
The biologic actions of E2 are mediated via genomic pathways, which involve 
changes in gene expression either through direct activation of the ERs as 
transcription factors, via association with other transcription factors or without the 
involvement of estrogens [44]. Additionally, E2 can also induce its biological effects 
via rapid non-genomic mechanisms [35], most likely initiated at the membrane level, 
which include the activation of intracellular signaling cascades. The genomic 
pathways are mediated via the classic ERs, ERα and ERβ, whereas the rapid non-
genomic mechanisms presumably involve ERα [40] and GPER [29, 32] at the 
membrane level.  
E2-dependent modulation of miR-193a and miR-221 is potentially mediated via 
genomic or non-genomic mechanisms and might involve one or more ERs. Indeed, 
all three ERs have been shown to directly or indirectly regulate miRNAs in tumors 
and normal cells. For example, ERα mediates the down-regulation of miR-21, miR-
26a, miR-143, miR-145, miR-195 and miR-221, while it stimulates the expression of 
miR-19, miR-101, miR-203 and miR-425. ERβ is associated with inhibition of miR-17, 
miR-24, miR-183 and miR-301a, and up-regulation of miR-23b, miR-27b and miR-
205. GPER was shown to mediate repression of miR-338 [316]. 
Therefore, we investigated the role of ERs in mediating the down-regulation of miR-
193a and miR-221 in HUVECs and HCASMCs. To achieve this, we used 
pharmacologically specific and unspecific ER agonists and antagonists. The specific 
agonists include PPT (ERα), DPN (ERβ) and G1 (GPER). The antagonists include 
ICI 182,780 (ICI, unspecific ER inhibitor), MPP (specific for ERα), PHTPP (specific 
for ERβ) and G15 (GPER inhibitor).  
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5.7.1 ERα mediates miRNA down-regulation in HUVECs 
Treatment of HUVECs with E2 and the Estrogen Receptor (ER) specific agonists 
revealed a role for ERα in mediating the suppressive effects of E2 on miR-221 and 
miR-193a expression. In fact, E2 and the ERα agonist PPT decreased miR-221 
expression by 20±3% and 15±3% respectively (p<0.05) and miR-193a expression by 
17±4% and 21±6% respectively (p<0.05). Besides, ERβ and GPER agonists DPN 
and G1 did not significantly alter the expression of the two miRNAs, which changed 
from 100±2% to 102±16% and 92±4%, respectively, for miR-221 and from 100±3% to 
110±6% and 103±8%, respectively, for miR-193a (Figure 62A and 62B).  
 
Figure 62: ERα agonist PPT down-regulates miR-193a and miR-221 expression in 
HUVECs. Cells were grown to 60% confluency in complete media prior to 24 hr treatment 
with E2 (10 nM) and the ER agonist: PPT (100 nM, ERα agonist), DPN (100 nM, ERβ 
agonist), G1 (100 nM, GPER agonist). Total RNA was extracted and relative miRNA 
expression levels were determined by RT-qPCR using TaqMan miRNA assays for miR-
221.3p (Panel A) and miR-193a.3p (Panel B). The results were normalized to U48 and U49. 
n=3, *p<0.05 compared to control. 
The importance of ERα is further confirmed by addition of the ERα antagonist MPP, 
which reversed the inhibitory effect of E2 and PPT on both miR-221 and miR-193a 
(Figure 63A and 63B). As a positive control, the down-regulation of the two miRNAs 
by E2 is reversed by the unspecific ER antagonist ICI 182780 (Figure 63C and 63D). 
These observations indicate that ERα is necessary for E2-mediated down-regulation 
of miR-221 and miR-193a.  
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Figure 63: ERα mediates down-regulation of miR-193a and miR-221 expression in 
HUVECs. Cells were grown to 60% confluency in complete media prior to 24 hr treatment 
with E2 (10 nM), PPT (100 nM, ERα agonist) and the ER antagonist MPP (500 nM, ERα 
antagonist) and ICI (1 μM, ERα and ERβ antagonist). Total RNA was extracted and relative 
miRNA expression levels were determined by RT-qPCR using TaqMan miRNA assays for 
miR-221.3p (Panel A and C) and miR-193a.3p (Panel B and D). The results were 
normalized to U48 and U49. n=3, *p<0.05 compared to control, §p<0.05 as indicated. 
5.7.2 ERα mediates miRNA down-regulation in HCASMCs 
The inhibitory effects of E2 on PDGF-BB-induced miR-221 production in HCASMCs 
were mimicked by the ERα agonist PPT, but not by ERβ and GPER agonists (Figure 
64A). E2 and PPT decreased miR-221 expression by 29±3% and by 20±7% 
respectively (p<0.05). Similar results were seen for PDGF-BB-induced miR-193a. 
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Both E2 and the ERα agonist PPT down-regulated miR-193a expression by 34±6% 
and 31±6%, respectively (p<0.05), while ERβ and GPER agonists hat no statistically 
significant effect (Figure 64B).  
 
Figure 64: ERα agonist PPT down-regulates miR-193a and miR-221 expression in 
HCASMCs. Cells were grown to 60% confluency in complete media prior to 24 hr treatment 
with PDGF-BB (20 ng/ml), E2 (10 nM) or the ER agonist: PPT (100 nM, ERα agonist), DPN 
(100 nM, ERβ agonist), G1 (100 nM, GPER agonist). Total RNA was extracted and relative 
miRNA expression levels were determined by RT-qPCR using TaqMan miRNA assays for 
miR-221.3p (Panel A) and miR-193a.3p (Panel B). The results were normalized to U48 and 
U49. n=3, *p<0.05 compared to control.  
Furthermore, 500 nM of the ERα antagonist MPP significantly blocked the effects of 
both E2 and PPT, thus inhibiting down-regulation of both miR-221 and miR-193a 
(Figure 65A and 65B). The unspecific ER antagonist ICI 182780 (1 μM) was used as 
a positive control and also blocked miR-221 and miR-193a down-regulation by E2 
(Figure 65C and 65D). These results suggest a role for ERα in mediating the 
modulation of miR-221 and miR-193a. 
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Figure 65: ERα mediates down-regulation of miR-193a and miR-221 expression in 
HCASMCs. Cells were grown to 60% confluency in complete media prior to 24 hr treatment 
with PDGF-BB (20 ng/ml), E2 (10 nM), PPT (100 nM, ERα agonist) and the ER antagonist 
MPP (500 nM, ERα antagonist) and ICI (1 μM, ERα and ERβ antagonist). Total RNA was 
extracted and relative miRNA expression levels were determined by RT-qPCR using 
TaqMan miRNA assays for miR-221.3p (Panel A and C) and miR-193a.3p (Panel B and D). 
The results were normalized to U48 and U49. n=3, *p<0.05 compared to control. 
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5.7.3 Discussion 
The role of ERs in mediating the beneficial effects of E2 in vascular cells is well 
established. Therefore, we investigated whether they are also involved in the down-
regulation of miR-193a and miR-221 by E2 in HUVECs and HCASMCs. 
Here we show that down-regulation of the two miRNAs is mimicked by the ERα 
agonist PPT and not by ERβ or GPER agonists. Moreover, the broad spectrum ER 
antagonist ICI and the ERα specific antagonist MPP blocked E2- and PPT-dependent 
miRNA inhibition, suggesting that ERα is required for E2-mediated miRNA down-
regulation. 
Numerous studies report that ERα mediates the cardiovascular protective effects of 
estrogen. In ERβ knock-out mice, estrogen was still protective against vascular injury 
[317], whereas in ERα knock-out mice estrogen treatment showed no protective 
effect on vascular SMC proliferation after vascular injury [318], supporting that ERα is 
necessary for the anti-mitogenic actions of estrogen in vascular SMC. Moreover, 
Takahashi et al. reported that the inhibitory effects of E2 on RB phosphorylation are 
lost in the presence of the unspecific antagonist ICI. Moreover, E2 could not inhibit 
PDGF-BB-induced proliferation in A10 cells (a primary rat embryonic thoracic aorta 
cell line) lacking ERα expression, but significantly inhibited the PDGF-BB-induced 
cyclin D1 in A10 cells transfected with ERα, suggesting that ERα is required for E2-
induced G1 arrest of vascular SMCs [180]. Finally, ERα mediates the rapid E2 effects 
leading to increased Akt phosphorylation in vascular SMCs and ECs [191] and is 
required for the activation of eNOS and E2-dependent vascular relaxation in ECs [41, 
319]. 
Although there is ample evidence for a role of ERα in mediating the vaso-protective 
actions of E2, which ER is responsible for the beneficial effect of E2 in the vascular 
system is still intensely debated. The results from Watanabe et al. indicate that ERβ 
is more potent than ERα in the inhibitory effect on vascular SMC proliferation [320]. 
Hodge et al. reported that ERβ is the predominantly expressed form of ER in 
vascular SMCs, suggesting that the protective effects of estrogens in the 
cardiovascular system may be due to the genomic effects of ERβ in vascular tissue 
[321]. In addition, there is evidence that estrogen inhibits vascular SMC proliferation 
in response to vascular injury in knock-out mice lacking ERα [322]. However, ERα 
may be involved in the protective effects because this knock-out mouse expressed a 
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variant ERα [323]. Finally, studies with ERα/ ERβ double knock-out mice 
demonstrated decreased proliferation of vascular SMCs upon estrogen treatment, 
suggesting a role also for GPER in mediating the beneficial actions of estrogen on 
the vascular system [324].  
In support of our findings that ERα is required for down-regulation of miR-193a and 
miR-221, E2 and the ERα-selective agonist PPT decreased miR-206 expression in 
MCF-7 cells [325]. Moreover, Di Leva et al. reported that E2-ERα mediate the 
repression of miR-221/222 in MCF-7 cells [291] and Zhao et al. demonstrated that 
ERα mediates miR-203 up-regulation by E2 in vascular SMCs and that miR-203 
participates in the anti-mitogenic actions of E2 in these cells [94]. 
Interestingly, miRNAs have also been reported to influence E2-regulated gene 
expression by directly reducing ERα mRNA stability or translation [84, 86, 316, 326]. 
The role of miR-221/222 in breast cancer resistance has been extensively studied. 
Indeed, these miRNA are both down-regulated by E2-ERα and in turn target ERα, 
pointing to a regulatory loop between ERα and miRNA expression [291, 327-329].  
In summary, here we provide evidence that ERα is involved in miR-193a and miR-
221 regulation; however, we did not investigate whether these miRNAs influence 
ERα expression in vascular cells. Furthermore, the molecular mechanisms by which 
E2-ERα inhibit miR-193a and miR-221 expression remain unknown. 
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5.8 E2 modulates miR-221 and miR-193a processing 
Objective 
We demonstrated that ERα is required for the down-regulation of miR-193a and miR-
221 in HUVECs and HCASMCs. Since E2-ERα regulates gene expression including 
miRNA expression, we hypothesize that E2 inhibits miR-193a and miR-221 at the 
transcriptional level. Hence, we examined the expression of pri-miRNAs following E2 
treatment.  
Introduction 
Our results from section 5.7 show that down-regulation of miR-193a and miR-221 by 
E2 requires ERα in both HUVECs and HCASMCs. ERα is a ligand-activated 
transcription factor, which mediates the effects of E2 either via alteration of gene 
expression or activation of rapid intracellular transduction pathways. Biogenesis of 
miRNAs is regulated at multiple levels, including modulation of miRNA gene 
transcription and procession to mature miRNAs by Drosha and Dicer in the nucleus 
and cytoplasm, respectively. Moreover, AGO2 loading and RNA decay also modulate 
miRNA activity and expression [59]. Many miRNAs are regulated directly by 
transcription factors, as their promoter region is similar to that of regular protein 
coding genes. E2-ERα has also been shown to alter miRNA expression. Indeed, 
there is evidence for ERα mediated regulation of miRNA at the transcriptional level. 
Zhao et al. demonstrated that E2-ERα induces miR-203 transcription in vascular 
SMC [94]. Di Leva et al provide evidence that E2-ERα directly represses miR-221 
transcription in MCF-7 cells [291]. 
Based on the above evidence, we hypothesize that E2 inhibits miR-193a and miR-
221 at the transcriptional level. To test this hypothesis, using RT-qPCR, we examined 
the expression of the pri-miRNAs in both HUVECs and HCASMCs treated with E2.  
5.8.1 E2 does not influence pri-miR-221 and pri-miR-193a in HUVECs 
Treatment of HUVECs with 10 nM E2 for 24 hr only slightly diminished the 
expression of both pri-miR-221 (from 100±2% to 94±2%, n.s.) and pri-miR-193a 
(from 100±3% to 92±2%, n.s.; Figure 66A and 66B). To exclude the possibility of 
time-dependent down-regulation of the pri-miRNA by E2, we examined their 
expression also after 6 hr of treatment. As shown in Figure 66C, we found that pri-
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miR-221 is not affected by E2 (relative expression of 107±9%, n.s.). Likewise, pri-
miR-193a expression did not change after 6 hr E2 treatment (from 100±6% to 
107±8%) and is only slightly reduced after 24 hr treatment by 8±2% (n.s.; Figure 
66D).  
 
Figure 66: E2 does not inhibit pri-miRNA expression in HUVECs. Cells were grown to 
60% confluency in complete media prior to treatment with or without E2 (10 nM). Panel A 
and B: Pri-miR-221 and pri-miR-193a expression after 24 hr treatment with E2. Panel C and 
Panel D: Comparison of pri-miRNA and mature miRNA expression after 6 and 24 hr 
treatment. Total RNA was extracted and relative pri-miRNA expression levels were 
determined by RT-qPCR using TaqMan assays for pri-miR-221 and pri-miR-193a. The 
results were normalized to GAPDH and hPRT1 mRNA. n=3, *p<0.05 compared to control. 
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5.8.2 E2 abrogates the effects of PDGF-BB on pri-miRNA expression 
in HCASMCs 
In HCASMCs the expression of the pri-miRNAs was strongly affected by 24 hr 
treatment with PDGF-BB and the effect of PDGF-BB was significantly reversed by 
treatment of the cells with 100 nM E2 (Figure 67A and 67B). Indeed, PDGF-BB 
reduced pri-miR-221 (by 43±3%, p<0.05), while E2 increased it in a concentration 
dependent manner from 57±3% to 64±7% and 77±7%, respectively (p<0.05). 
Similarly, pri-miR-193a was inhibited by stimulation of the cells with PDGF-BB (by 
44±2%, p<0.05). Moreover, the inhibitory-effect of PDGF-BB was abrogated in a 
concentration-dependent manner by E2 (from 56±2% to 69±4% and 71±8%, 
respectively (p<0.05). 
 
Figure 67: E2 reversed the PDGF-BB-dependent decrease in pri-miR-221 and pri-miR-
193a in HCASMCs. Cells were grown to 60% confluency in complete media prior to 
treatment with PDGF-BB and E2 (0, 10 and 100 nM). Panel A and B: Pri-miR-221 and pri-
miR-193a expression after 24 hr treatment with E2. Total RNA was extracted and relative pri-
miRNA expression levels were determined by RT-qPCR using TaqMan assays for pri-miR-
221 and pri-miR-193a. The results were normalized to GAPDH and hPRT1 mRNAs. n=3, 
*p<0.05 compared to control, §p<0.05 as indicated. 
Since the observed effect might be due to the conversion of pri-miRNAs into mature 
miRNAs, we additionally looked at the pri-miRNA expression after 3 and 6 hr 
treatment with E2 and compared it with the expression of the mature miRNAs. 
Interestingly, the levels of pri-miR-221 decreased in response to PDGF-BB at each 
tested time point, whereas mature miR-221 was induced. Moreover, E2 lessened the 
effects of PDGF-BB in regard to both the pri- and the mature miRNA (Figure 68A). In 
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regard to miR-193a we observed similar results as for miR-221: the pri-miR-193 is 
decreased by PDGF-BB at each tested time, while the mature miR-193a is strongly 
induced. Again, E2 treatment reversed the effect of PDGF-BB on both pri- and 
mature miRNA, hence showing an increase in pri-miRNA level and inhibiting the 
PDGF-BB-induced mature miR-193a (Figure 68B). 
 
Figure 68: PDGF-BB and E2 differentially affect pri-miRNA and mature miRNA 
expression in HCASMCs. Evidence that E2 attenuates the effects of PDGF-BB on pri- and 
mature miRNA expression. Cells were grown to 60% confluency in complete media prior to 
treatment with PDGF-BB and E2 (100 nM) for 3, 6 and 24 hr. Expression of pri-miRNA and 
mature miRNA of miR-221 (Panel A) and miR-193a (Panel B). Total RNA was extracted and 
relative pri-miRNA and mature miRNA levels were determined by RT-qPCR using TaqMan 
assays for pri-miR-221 and pri-miR-193a or the respective TaqMan miRNA assay. The 
results from pri-miRNAs were normalized to GAPDH and hPRT1 mRNAs. Mature miRNA 
expression was normalized to U48 and U49. n=3, *p<0.05 compared to control. 
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5.8.3 Discussion 
The aim of the experiments described in this chapter was to assess whether E2-ERα 
down-regulates miR-193a and miR-221 by inhibiting them at the transcriptional level. 
Therefore, we examined the expression of the pri-miRNAs after treatment with E2. In 
contrast to our expectations, E2 did not suppress the expression of the pri-miRNAs, 
neither in HUVECs nor in HCASMCs.  
In HUVECs, the level of pri-miRNA after 24 hr treatment with E2 was slightly 
decreased, but there was no significant down-regulation. To exclude time dependent 
regulation of pri-miRNAs, their expression was also analyzed at an earlier time point, 
however, we obtained negative results. Since we observed decreased mature miRNA 
levels after 24 hr without significant alteration in pri-miRNA expression, we postulate 
that E2 inhibits procession of these miRNAs rather than their transcription.  
Surprisingly, we found that PDGF-BB inhibited the expression of the pri-miRNAs in 
HCASMCs at every tested time point, although mature miRNA levels are induced by 
PDGF-BB. Our results are also contrasting with the findings from Davis et al., which 
demonstrated that both pri-miR-221 and mature miR-221 are up-regulated by PDGF-
BB within 0.5 to 24 hr and that PDGF-BB induces this miRNA by increasing its 
transcription [223]. Interestingly, E2 reversed the effects of PDGF-BB on pri-miRNA, 
showing increased expression compared to PDGF-BB, recalling its inhibitory action 
on PDGF-BB-induced mature miRNA levels. Since E2 attenuated both the inhibitory 
effects of PDGF-BB on pri-miRNA expression and stimulatory effects of PDGF-BB on 
mature miRNAs, we postulate that PDGF-BB stimulates the maturation process of 
these miRNAs, depleting the pri-miRNA levels in sustenance for higher mature 
miRNA expression and that E2 restrains it. Some studies demonstrate that E2 
inhibits miR-221 in MCF-7 breast cancer cells expression via negative regulation of 
its transcription [291, 327, 328]. Moreover, E2-ERα induces miR-203 transcription in 
vascular SMCs via ERE-independent mechanisms, providing evidence that ERE in 
the promotor region of the miRNA gene are not a prerequisite for E2 dependent 
regulation of transcription [94]. However, we could not demonstrate that E2 inhibits 
miR-193a and miR-221 transcription in HVUECs and HCASMCs and therefore we 
suggest that it influences miRNA procession. Nevertheless, further research is 
necessary to test our assumption and clarify the mechanisms by which E2 inhibits 
miR-193a and miR-221.  
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In support of our hypothesis, ERα is able to regulate the biogenesis of miRNAs. 
Several components of the Drosha-processing complex interact with transcription 
factors, including SMADs and ERα [86, 193]. It was shown that E2-ERα directly 
inhibits pri-miRNA processing by Drosha, through interaction with p68 and p72, which 
are part of the Drosha microprocessor complex [330] and established ERα 
coregulators [331]. Indeed, Drosha and p68/DDX5 could be co-purified with ERα in 
MCF-7 cells [85]. E2-ERα-p68 interaction was reported to inhibit the formation of 
Drosha complex and thus repress pri-miRNA processing [332], though this work has 
been retracted [333]. Exportin-5, which controls the nuclear export of precursors, is 
induced by E2 [334] and processing of pre-miRNA to mature miRNA might also be 
coupled with ERα. The RNA co-activator steroid receptor RNA activator (SRA) binds 
Dicer complex components in various cell lines and also binds nuclear receptors, 
including ERα. Moreover, Dicer acts as nuclear receptor coactivator in MCF-7 cells 
[335] and its expression was shown to be induced by E2 and is higher in ERα 
positive breast cancers compared to negative ones [336, 337]. Finally, there is 
contrasting evidence that the expression of AGO2, the catalytic component of the 
RISC complex, is regulated by E2 both negatively, through activation of EGFR/ 
MAPK signaling [338], and positively [336].  
In summary, here we provide evidence that E2 does not inhibit miR-193a and miR-
221 transcription in HUVECs and HCASMCs. Moreover, based on the recent findings 
that E2-ERα plays a role for Drosha and Dicer function and that E2 regulates AGO2, 
we postulate that E2 down-regulates miR-193a and miR-221 by inhibiting their 
procession from primary transcript to mature functional miRNAs.  
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5.9 Differential effect of miR-193a and miR-221 in vascular ECs 
and SMCs  
Objectives 
E2 exerts differential effects on ECs and vascular SMCs; however, the mechanisms 
involved are not fully understood. Here we postulate that the differential actions of E2 
are, in part, mediated via the down-regulation of miR-193a and miR-221. Hence, in 
this section we provide a summary of the cell specific effects of these miRNAs in 
HUVECs and HCASMCs and of their role in mediating the vascular actions of E2.  
Introduction 
Impaired endothelial function and abnormal growth of vascular SMCs contribute to 
the vascular remodeling processes associated with CVD. The beneficial effects of 
estrogens are well established and include accelerated endothelial repair and 
regeneration and attenuation of intimal thickening. These effects are largely due to 
the differential effects of E2 in vascular cells, where it stimulates EC activity and 
inhibits vascular SMC growth [129]. However, the mechanisms involved in the 
differential role of E2 in vascular cells remain largely unknown. Recent studies in 
cancer cells provide evidence for cell specific effects of miRNAs [224, 225]. These 
cell specific actions of miRNAs appear to be relevant in the vascular system as well, 
where miRNAs have been demonstrated to differentially regulate EC and SMC 
growth and function [220, 226-230]. 
Since miR-193a and miR-221 are down-regulated by E2 in both HUVECs and 
HCASMCs and exhibit cell specific effects in vascular cells, we hypothesize that they 
mediate the differential actions of E2. Hence, in this section we summarize the cell 
specific differential effects of miR-193a and miR-221 and their role in mediating the 
protective actions of E2 on the vasculature. 
5.9.1 E2 down-regulates miR-193a and miR-221 via ERα  
In this study we found that E2 significantly down-regulates miR-193a and miR-221 in 
both HUVECs and PDGF-BB-induced HCASMCs. Moreover, we demonstrate that 
the inhibitory effects of E2 requires ERα, since the ERα agonist PPT reduced miRNA 
levels similar to E2 and the ERα antagonist PPT abrogated their effects (p<0.05; 
Figure 69A and 69B).  
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Figure 69: E2 down-regulates miR-221 and miR-193 via ERα in HCASMCs and 
HUVECs. Cells were incubated 24 hr with E2 or the ERα agonist PPT (100 nM) with or 
without the ERα antagonist MPP (500 nM). Panel A: HUVECs ere treated with 10 nM E2. 
Panel B: HCASMCs were treated with 100 nM E2 in the presence of PDGF-BB (20 ng/ml). 
RNA was extracted and relative miRNA expression levels were determined by RT-qPCR 
using TaqMan miRNA assays. The results were normalized to U48 and U49. n=3, *p<0.05 
compared to control. 
5.9.2 miR-193a and miR-221 differentially regulate ECs and SMCs  
Since E2 has differential effects on EC and vascular SMC function and inhibits miR-
193a and miR-221 in both HUVECs and HCASMCs, we hypothesized that these 
miRNAs might differentially regulate vascular cells. Indeed, using gain- and loss- of 
function approaches we found that miR-221 significantly inhibits proliferation, wound 
closure and tube formation in HUVECs (Figure 70A, 70B and 70C), while it 
promotes DNA synthesis and migration of HCASMCs (Figure 70D and 70E). 
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Figure 70: Cell specific effects of miR-221 in HUVECs and HCASMCs. HUVECs and 
HCASMCs were transfected with miR-221 Mimic (M221) or Antimir (A221) or their respective 
Controls (MC or AC) before tested in the different functional assays. HUVEC proliferation 
was assessed by cell counting (Panel A), migration by wound closure assay (Panel B) and 
tube formation using a matrigel-based assay (Panel C). HCASMCs proliferation was 
assessed by BrdU incorporation assay (Panel D) and migration by wound closure assay 
(Panel E). n=3, *p<0.05 compared to the respective control. 
Similar to miR-221, miR-193a overexpression significantly inhibited proliferation, 
wound closure and tube formation in HUVECs, while it promotes DNA synthesis and 
migration of HCASMCs. In contrast, inhibition of miR-193a by the Antimir induced 
HUVEC proliferation, migration and vasculogenesis, while it inhibited HCASMC 
proliferation and migration (Figure 71A-E).  
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Figure 71: Cell specific effects of miR-193a in HUVECs and HCASMCs. HUVECs and 
HCASMCs were transfected with miR-193a Mimic (M193a) or Antimir (A193a) or their 
respective Controls (MC or AC) before being tested in the different functional assays. 
HUVEC proliferation was assessed by cell counting (Panel A), migration by wound closure 
assay (Panel B) and tube formation using a matrigel-based assay (Panel C). HCASMCs 
proliferation was assessed by BrdU incorporation assay (Panel D) and migration by wound 
closure assay (Panel E). n=3, *p<0.05 compared to the respective control. 
5.9.3 Down-regulation of miR-193a and miR-221 by E2 mediates its 
differential actions on vascular cells 
Since we demonstrated that E2 inhibits miR-193a and miR-221 and that these 
miRNAs have contrasting effects in HUVECs and HCASMCs, we hypothesized that 
the differential effects of E2 are mediated via the down-regulation of miR-193a and 
miR-221. Therefore, we investigated whether restoring the miRNA level after 
treatment with E2 reverses its stimulatory actions in HUVECs and inhibitory effects in 
HCASMCs. Indeed, we found that miR-221 overexpression abrogates E2-induced 
vasculogenesis and wound closure in HUVECs (p<0.5; Figure 72A and 72B). 
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Moreover, up-regulation of miR-221 significantly reversed the inhibitory action of E2 
on HCASMCs proliferation and migration (Figure 72C and 72D).  
 
Figure 72: miR-221 mediates the differential effects of E2 in HUVECs and HCASMCs. 
HUVECs and HCASMCs were transfected with miR-221 Mimic (M221) or the respective 
Control (MC) in the presence or absence of E2 before being tested in the different functional 
assays. HUVEC tube formation was assessed using a matrigel-based assay (Panel A) and 
migration by wound closure assay (Panel B). HCASMC proliferation was assessed by BrdU 
incorporation assay (Panel C) and migration by wound closure assay (Panel D) .n=3, 
*p<0.05 compared to the respective control, §p<0.05 as indicated. 
We observed similar results when restoring miR-193a levels after E2 treatment. Up-
regulation of miR-193a significantly abrogated E2-induced tube formation and wound 
closure in HUVECs (p<0.5; Figure 73A and 73B). Moreover, overexpression of miR-
193a in HCASMCs significantly reversed the PDGF-BB-induced anti-mitogenic and 
anti-migratory actions of E2 (Figure 73C and 73D). 
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Figure 73: miR-193a mediates the differential effects of E2 in HUVECs and HCASMCs. 
HUVECs and HCASMCs were transfected with miR-193a Mimic (M193a) or the respective 
Control (MC) in the presence or absence of E2 before tested in the different functional 
assays. HUVEC tube formation was assessed using a matrigel-based assay (Panel A) and 
migration by wound closure assay (Panel B). HCASMC proliferation was assessed by BrdU 
incorporation assay (Panel C) and migration by wound closure assay (Panel D). n=3, 
*p<0.05 compared to the respective control, §p<0.05 as indicated. 
5.9.4 Discussion 
In this chapter we summarize the cell specific actions of miR-193a and miR-221 in 
HUVECs and HCASMCs and their role in mediating the effects of E2. First, we 
showed that both miRNAs are inhibited by E2 in HUVECs and HCASMCs and we 
demonstrate that their down-regulation requires ERα. Second, we confirmed the dual 
role of miR-221 in vascular cells, where its up-regulation inhibits HUVEC proliferation, 
migration and tube formation and induces HCASMCs growth and migration. 
Moreover, suppression of miR-221 has opposite effects in both cell types. Third, we 
provide the first evidence that miR-193a plays an active role in the regulation of EC 
and vascular SMC functions and exhibits cell specific effects, similar to miR-221. 
Given the fact that E2 regulates both miRNAs and that their reduction mediates the 
actions of E2 in both HUVECs and HCASMCs, we postulate that the differential 
actions of E2 are due to the opposite effect of miR-193a and miR-221 in vascular 
Results and Discussion 
 
165 
 
cells. Indeed, restoration of miRNA levels by overexpressing them abrogated E2-
induced vasculogenesis and wound closure in HUVECs and reversed the inhibitory 
actions of E2 on HCASMC proliferation and migration. This supports our contention 
that both miR-193a and miR-221 participate in E2-mediated stimulation of ECs and 
inhibition of vascular SMCs.  
Estrogens inhibit proliferation of vascular SMCs [124-127, 178, 180, 191] and have 
growth stimulatory and anti-apoptotic effects in ECs [130-136, 295]. Moreover, they 
enhance the proliferation of breast and uterine cells [296], indicating that E2 
modulates diverse cell functions in a tissue specific manner. The specific actions of 
E2 are mediated via the ERs. Besides the differences in structure and ligand-binding 
specificity, the distribution of the ERs is also dissimilar depending on the tissue and 
more specifically the cell type [4]. Moreover, knock-out studies for ERα and ERβ 
provide evidence of different functions for the two receptors [22], hence indicating 
that the final effect of ER-ligands depends on ER regulation within a cell type, which 
is influenced by extracellular signals. Furthermore, E2 itself has been shown to 
regulate the expression of the ERs in many cell types, such as human breast cancer 
cells [23], retinal pigment epithelium [24], osteoclasts [25] and vascular SMCs [14].  
Recently, estrogen regulated miRNAs have been shown to target ERα mRNA and 
influence its expression [316], suggesting that they may play a role in mediating the 
differential actions of E2. The cell specific effects of miRNAs have been shown in 
many cells [224, 225], including the vascular system, where miRNA such as miR-21, 
miR-26a and miR-221 differentially regulate EC and SMC functions [220, 226-230]. In 
this study we show that miR-221 and miR-193a have inhibitory actions on HUVEC 
proliferation, migration and tube formation while they induce HCASMC growth and 
migration. Moreover, we demonstrate that E2 interaction with ERα down-regulates 
miR-193a and miR-221 and provide evidence that miR-193a and miR-221 down-
regulation by E2-ERα mediates the cell specific actions of E2 in ECs and vascular 
SMCs.  
The molecular mechanisms by which these miRNAs exert their dual role is currently 
unclear and beyond the scope of this study. However, abundance of target mRNAs 
may be dependent on the cell type, as it is well established that gene expression 
profiles vary among different cells and environmental context. Therefore, it is feasible 
that the same miRNA has a great impact on its target in cells where the target is 
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highly expressed, compared to cells where this target is less abundant. Moreover, a 
single miRNA can regulate a whole set of different mRNAs and different miRNAs can 
target the same mRNA [67]. Thus, it is quite possible that target mRNAs compete for 
the binding of one miRNA and that many miRNAs compete for the binding of one 
specific target, given that binding occurs at the same region. Hence, the final effect of 
one miRNA may be strongly dependent on the relative abundance of its targets and 
on the expression levels of other miRNAs competing for the binding of the same 
target. 
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6 Conclusion and Perspectives 
The observation that premenopausal women have lower incidence of CVD in 
comparison to age-matched men and postmenopausal women, suggest that 
estrogens protect against cardiovascular disorders [108-111]. This association is 
further supported by the fact that postmenopausal women taking hormone 
replacement therapy present a reduced risk for CVD and all-cause mortality [112-
115]. Estrogens prevent vascular remodeling processes associated with CVD by 
promoting endothelial recovery and regeneration through induction of EC growth, 
recruitment of EPC and stimulation of angiogenesis [131, 132, 135, 136]. Moreover, 
estrogens inhibit vascular SMC proliferation and migration, thus preventing intimal 
thickening and vascular occlusion [125-127]. However, the underlying mechanisms 
for the vaso-protective actions of estrogens have not been completely elucidated. 
Therefore, the overall goal of this study was to improve our understanding of the 
mechanism(s) by which E2 regulates growth and function of vascular cells. These 
insights may be important for the development of drugs able to exhibit the desired 
beneficial effects of estrogens without inducing its undesired side effects, such as 
feminization and carcinogenicity. Since miRNAs are entailed in the processes of 
vascular remodeling [193-195] and estrogen signaling [316], we hypothesized that 
E2-regulated miRNAs participate in mediating the protective actions of E2 on the 
vascular system. Moreover, they could potentially be responsible for its differential 
effects on EC and vascular SMC growth. 
We demonstrate that E2 down-regulates miR-193a and miR-221 in HUVECs. 
Moreover, suppression of miR-193a and miR-221 improves endothelial function, as it 
stimulates vasculogenesis, migration and proliferation of HUVECs. Further, our 
findings provide evidence that down-regulation of these miRNAs by E2 mediates the 
protective effects of E2. In addition, we show that miR-221 and miR-193a negatively 
influence EC functions by suppressing PI3K/ Akt / VEGF signaling and inhibiting the 
ALK1/ SMAD1/5/8/ Id1 pathway, which are both partly responsible for E2-stimulated 
tube formation in HVUECs.  
We determined that E2 down-regulates PDGF-BB-induced miR-193a and miR-221 in 
HCASMCs and that these miRNAs stimulate HCASMC proliferation and migration 
similar to PDGF-BB, while their suppression inhibits PDGF-BB-induced growth. 
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Moreover, we show that down-regulation of both miRNAs by E2 mediates the 
protective effects of E2 by inhibiting HCASMCs growth and migration. Additionally, 
we provide evidence that miR-193a and miR-221 induce cell cycle progression from 
G1 to S phase, and inhibition of their expression by E2 or their respective Antimirs 
contributes to their anti-mitogenic actions in vascular SMCs.  
Importantly, we provide the first evidence that miR-193a plays a role in differentially 
regulating EC and vascular SMC activity.   
Taken together, we demonstrate that miR-193a and miR-221 actively contribute to 
the protective actions of E2 in the vascular system. Importantly, down-regulation of 
miR-193a and miR-221 by E2 improves endothelial function and inhibits vascular 
SMC proliferation and migration (Figure 74).  
 
Figure 74: Schematic representation of the role of miR-193a and miR-221 in mediating 
the protective actions of E2 and the potentially involved molecular mechanisms. Panel 
A: Down-regulation of miR-221 and miR-193a suppresses their inhibitory effect on HUVEC 
functions. Panel B: Down-regulation of miR-221 and miR-193a by E2 suppresses their 
stimulatory effects on HCASMC proliferation. E2, 17β-estradiol; ER, Estrogen Receptor; 
ALK1, Activin Receptor-Like Kinase 1; Id1, Inhibitor of Differentiation; PI3K, Phosphoinositide 
3 Kinase; Akt, Protein Kinase B; VEGF, Vascular Endothelial Growth Factor; G1, Gap1; S, 
Synthesis; CDK, Cyclin-Dependent Kinase; pRB, hyperphosphorylated Retinoblastoma 
protein; PCNA, Proliferating Cell Nuclear Antigene. 
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Furthermore, our findings suggest that miR-221 and miR-193a may be interesting 
therapeutic targets to protect post-menopausal women against occlusive vascular 
disorders. Since miR-221 and miR-193a are expressed in both genders, they might 
also be usefull to treat CVD in men. However, it is yet unknown whether modulation 
of these miRNAs bypasses the cancerogenic side effects of hormones currently used 
for replacement therapy. The expression of miR-221 is different in ER positive and 
negative breast cancers and high miR-221 levels associate with tamoxifen and 
fulvestrant-resistance. Moreover, there is evidence that miR-221 contributes to breast 
cancer tumorigenesis through promotion of proliferation and metastasis [92, 291, 
327]. In regard to miR-193a, numerous studies revealed that it suppresses tumor 
development and migration in different types of cancers, including breast and ovarian 
cancers [238-247], suggesting that further research is required to fully understand the 
role of both these miRNAs in the human body.  
Compared to the classic molecular therapeutics, miRNA therapeutics is a promising 
field, with the advantage of small size and low molecular weight, conserved 
sequences and stability in the body fluids. Moreover, as miRNAs have multiple 
related targets, entire pathways involved in the pathogenesis of a disease may be 
modulated by the alteration of single miRNAs. The function of miRNAs can be 
restored or inhibited through the delivery of synthetic miRNA Mimics or Antimirs, 
respectively, or using miRNAs encoded in expression vectors. However, several 
obstacles including miRNA stability, inefficient and unspecific delivery, off-target 
effects and the immunogenicity of both the nucleic acids and delivery vehicles still 
have to be resolved.  
The first strategy developed for systemic delivery of miRNAs in vivo is to use 
chemically modified Mimics and Antimirs to improve efficient and safe systemic 
delivery. 2’OH group modifications, such as 2’-O-methyl (2’-OMe), 2’-O-methoxyethyl 
(2’-MOE) and 2’-fluoro (2’-F), and locked nucleic acid (LNA) enhance stability, 
increase binding affinity and improve gene silencing compared to unmodified 
oligonucleotides. Moreover, increased nuclease resistance is achieved using peptide 
nucleic acid (PNA) and by substituting phosphodiester (PO) backbone linkage with 
phosphorothioate (PS) linkage, which additinally enhances the pharmacokinetic 
properties, facilitating delivery into many peripheral tissues. Modifications of the 
passenger strand of the double stranded miRNA Mimics prevents RISC loading and 
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protects against non-specific immune responses, while cellular uptake of the Mimics 
and Antimirs is facilitated by cholesterol conjugation. The second strategy is to 
restore miRNAs levels through viral delivery of expression vectors carried by viruses 
such as lentiviruses, adenoviruses and adeno-associated viruses. The application of 
tissue-specific promoters enables tissue-specific expression of miRNA Mimics or 
Antimirs and therefore to reduce off-target effects. The third strategy consists of 
delivering the miRNAs nanoparticles, designed to increase passive diffusion into 
target tissues. Liposomes and polymer-based nanoparticles protect miRNA Mimics 
and Antimirs from degradation and enhance their cellular uptake. Inorganic 
nanoparticles made of materials such as gold, carbon and silica, offer potential for 
the development of a biocompatible, non-immunogenic and non-toxic delivery 
system. Additionally, surface modifications of the nanoparticles using tissue- or 
tumor- specific antibodies allow specific delivery and may facilitate the internalization 
of the nanoparticle through receptor-mediated endocytosis.  
The successful use of miRNA therapeutics has been demonstrated against several 
cardiovascular and metabolic disorders and tumors. Indeed, a small number of 
miRNA inhibition and replacement strategies to restore the original miRNA 
expression levels have already entered preclinical and clinical trials and may be soon 
available for clinical use, suggesting that the modulation of miRNAs may be a 
promising technology for future therapeutic developments [78, 339-343] .  
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